FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Fernandes, RS
   Freire, MCLC
   Bueno, RV
   Godoy, AS
   Gil, LHVG
   Oliva, G
AF Fernandes, Rafaela S.
   Freire, Marjorie C. L. C.
   Bueno, Renata, V
   Godoy, Andre S.
   Gil, Laura H. V. G.
   Oliva, Glaucius
TI Reporter Replicons for Antiviral Drug Discovery against Positive
   Single-Stranded RNA Viruses
SO VIRUSES-BASEL
LA English
DT Review
DE replicon systems; (+) ssRNA viruses; direct-acting antivirals; drug
   discovery
ID HEPATITIS-C VIRUS; ACUTE RESPIRATORY SYNDROME; GREEN FLUORESCENT
   PROTEIN; SMALL-MOLECULE INHIBITORS; SARS-CORONAVIRUS REPLICON;
   SERINE-TYPE PROTEINASE; CELL-LINE; REPLICATION INHIBITOR; EXPRESSING
   REPLICON; DENGUE VIRUS
AB Single-stranded positive RNA ((+) ssRNA) viruses include several important human pathogens. Some members are responsible for large outbreaks, such as Zika virus, West Nile virus, SARS-CoV, and SARS-CoV-2, while others are endemic, causing an enormous global health burden. Since vaccines or specific treatments are not available for most viral infections, the discovery of direct-acting antivirals (DAA) is an urgent need. Still, the low-throughput nature of and biosafety concerns related to traditional antiviral assays hinders the discovery of new inhibitors. With the advances of reverse genetics, reporter replicon systems have become an alternative tool for the screening of DAAs. Herein, we review decades of the use of (+) ssRNA viruses replicon systems for the discovery of antiviral agents. We summarize different strategies used to develop those systems, as well as highlight some of the most promising inhibitors identified by the method. Despite the genetic alterations introduced, reporter replicons have been shown to be reliable systems for screening and identification of viral replication inhibitors and, therefore, an important tool for the discovery of new DAAs.
C1 [Fernandes, Rafaela S.; Freire, Marjorie C. L. C.; Bueno, Renata, V; Godoy, Andre S.; Oliva, Glaucius] Univ Sao Paulo, Phys Inst Sao Carlos, BR-13566590 Sao Carlos, SP, Brazil.
   [Gil, Laura H. V. G.] IAM FIOCRUZ, Inst Aggeu Magalhaes, BR-50670420 Recife, PE, Brazil.
RP Oliva, G (corresponding author), Univ Sao Paulo, Phys Inst Sao Carlos, BR-13566590 Sao Carlos, SP, Brazil.
EM rafaela.fernandes@usp.br; marjorie_freire_@hotmail.com;
   buenorvieira@gmail.com; andre_godoy@yahoo.com.br; lgilfiocruz@gmail.com;
   oliva@ifsc.usp.br
RI Oliva, Glaucius/J-2382-2015; Godoy, Andre/I-1302-2017
OI Oliva, Glaucius/0000-0003-2719-0302; Godoy, Andre/0000-0002-0613-9164;
   Freire, Marjorie/0000-0001-7734-5144
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP-CEPID)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2013/07600-3, 2018/05130-3, 2018/17095-8, 2016/19712-9];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [400773/2019-8, 151058/2018-0]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP-CEPID grant 2013/07600-3 and grants 2018/05130-3,
   2018/17095-8, and 2016/19712-9) and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq-grants 400773/2019-8 and 151058/2018-0).
CR Adedeji AO, 2014, ANTIMICROB AGENTS CH, V58, P4894, DOI 10.1128/AAC.02994-14
   Adedeji AO, 2012, ANTIMICROB AGENTS CH, V56, P4718, DOI 10.1128/AAC.00957-12
   Albulescu IC, 2015, ANTIVIR RES, V121, P39, DOI 10.1016/j.antiviral.2015.06.013
   Almazan F, 2006, J VIROL, V80, P10900, DOI 10.1128/JVI.00385-06
   Alqahtani S.A., 2009, HCV JOURNEY DISCOVER, P223, DOI [10.1007/7355_2018_59, DOI 10.1007/7355_2018_59]
   Amblard F, 2018, BIOORG MED CHEM LETT, V28, P2165, DOI 10.1016/j.bmcl.2018.05.012
   Appel N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000035
   Aubry F, 2014, J GEN VIROL, V95, P2462, DOI 10.1099/vir.0.068023-0
   Balasubramanian A, 2016, ANTIVIR RES, V134, P6, DOI 10.1016/j.antiviral.2016.08.014
   BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993
   BARTENSCHLAGER R, 1995, J VIROL, V69, P198, DOI 10.1128/JVI.69.1.198-205.1995
   BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995
   BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994
   Belov GA, 2007, J VIROL, V81, P558, DOI 10.1128/JVI.01820-06
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358
   Bok K, 2008, VIROLOGY, V380, P328, DOI 10.1016/j.virol.2008.08.007
   Boonyasuppayakorn S, 2014, ANTIVIR RES, V106, P125, DOI 10.1016/j.antiviral.2014.03.014
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang KO, 2007, J VIROL, V81, P12111, DOI 10.1128/JVI.00560-07
   Chang KO, 2006, VIROLOGY, V353, P463, DOI 10.1016/j.virol.2006.06.006
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   De Palma AM, 2008, MED RES REV, V28, P823, DOI 10.1002/med.20125
   De Palma AM, 2008, J VIROL, V82, P4720, DOI 10.1128/JVI.01338-07
   Delang L, 2013, CURR TOP MICROBIOL, V369, P289, DOI 10.1007/978-3-642-27340-7_12
   Dou D, 2012, BIOORGAN MED CHEM, V20, P2111, DOI 10.1016/j.bmc.2012.01.030
   FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994
   Fros JJ, 2010, J VIROL, V84, P10877, DOI 10.1128/JVI.00949-10
   Gao M, 2010, NATURE, V465, P96, DOI 10.1038/nature08960
   Gao QQ, 2015, ANTIMICROB AGENTS CH, V59, P2654, DOI 10.1128/AAC.05108-14
   Ge F, 2008, ANTIVIR RES, V80, P107, DOI 10.1016/j.antiviral.2008.05.005
   Ge F, 2007, VIROLOGY, V360, P150, DOI 10.1016/j.virol.2006.10.016
   GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993
   Green N, 2008, EXPERT OPIN DRUG DIS, V3, P671, DOI 10.1517/17460441.3.6.671
   Harmalkar DS, 2019, EUR J MED CHEM, V184, DOI 10.1016/j.ejmech.2019.111733
   Hayes EB, 2010, VACCINE, V28, P8073, DOI 10.1016/j.vaccine.2010.10.015
   Hennessy S, 1996, LANCET, V347, P1583, DOI 10.1016/S0140-6736(96)91075-2
   Horscroft Nigel, 2005, Antiviral Chemistry & Chemotherapy, V16, P1
   Hsu YC, 2012, ARCH VIROL, V157, P681, DOI 10.1007/s00705-012-1224-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huber SA, 1999, ADV VIRUS RES, V51, P35
   Johne R, 2014, INFECT GENET EVOL, V27, P212, DOI 10.1016/j.meegid.2014.06.024
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   Kanda T, 2005, BIOCHEM BIOPH RES CO, V331, P621, DOI 10.1016/j.bbrc.2005.03.212
   Kim C, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0557-8
   Kim TK, 2010, ANAL BIOANAL CHEM, V397, P3173, DOI 10.1007/s00216-010-3821-6
   Kummerer BM, 2018, ADV EXP MED BIOL, V1062, P165, DOI 10.1007/978-981-10-8727-1_12
   Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8
   Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099
   Lani R, 2016, ANTIVIR RES, V133, P50, DOI 10.1016/j.antiviral.2016.07.009
   Lani R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11421
   Leardkamolkarn V, 2012, J BIOMOL SCREEN, V17, P283, DOI 10.1177/1087057111426903
   Lemm JA, 2010, J VIROL, V84, P482, DOI 10.1128/JVI.01360-09
   Li JQ, 2018, ANTIVIR RES, V150, P148, DOI 10.1016/j.antiviral.2017.12.017
   Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200
   LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995
   Lin K, 2006, ANTIMICROB AGENTS CH, V50, P1813, DOI 10.1128/AAC.50.5.1813-1822.2006
   Lindenbach B.D., 2007, FIELDS VIROLOGY, P1101, DOI DOI 10.1016/0038-092X(88)90131-4
   Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001
   Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110
   Lohmann V, 2019, MED MICROBIOL IMMUN, V208, P3, DOI 10.1007/s00430-018-0566-x
   Lu LJ, 2004, ANTIMICROB AGENTS CH, V48, P2260, DOI 10.1128/AAC.48.6.2260-2266.2004
   Lucero Y, 2018, VACCINE, V36, P5435, DOI 10.1016/j.vaccine.2017.06.043
   Luna JM, 2019, CURR OPIN VIROL, V35, P27, DOI 10.1016/j.coviro.2019.02.008
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Mandadapu SR, 2013, BIOORG MED CHEM LETT, V23, P5941, DOI 10.1016/j.bmcl.2013.08.073
   McErlean P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001847
   Mello C, 2014, ANTIMICROB AGENTS CH, V58, P1546, DOI 10.1128/AAC.01746-13
   Monath TP, 2012, EXPERT REV VACCINES, V11, P427, DOI [10.1586/ERV.12.6, 10.1586/erv.12.6]
   Morens DM, 2017, J INFECT DIS, V216, pS857, DOI 10.1093/infdis/jix383
   Morrey JD, 2002, ANTIVIR RES, V55, P107, DOI 10.1016/S0166-3542(02)00013-X
   Mueller NH, 2008, ANTIMICROB AGENTS CH, V52, P3385, DOI 10.1128/AAC.01508-07
   Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961
   Netzler NE, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00003-19
   Neufeldt CJ, 2018, NAT REV MICROBIOL, V16, P125, DOI 10.1038/nrmicro.2017.170
   Nimgaonkar I, 2018, NAT REV GASTRO HEPAT, V15, P96, DOI 10.1038/nrgastro.2017.150
   Nishiyama T, 2019, J VIROL METHODS, V270, P1, DOI 10.1016/j.jviromet.2019.04.017
   Norder H, 2011, ANTIVIR RES, V89, P204, DOI 10.1016/j.antiviral.2010.12.007
   O'Boyle DR, 2005, ANTIMICROB AGENTS CH, V49, P1346, DOI 10.1128/AAC.49.4.1346-1353.2005
   Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557
   Patkar CG, 2009, ANTIMICROB AGENTS CH, V53, P4103, DOI 10.1128/AAC.00074-09
   Payne S, 2017, VIRUSES: FROM UNDERSTANDING TO INVESTIGATION, P115, DOI 10.1016/B978-0-12-803109-4.00012-X
   Payne S, 2017, VIRUSES: FROM UNDERSTANDING TO INVESTIGATION, P121, DOI 10.1016/B978-0-12-803109-4.00013-1
   Payne S, 2017, VIRUSES: FROM UNDERSTANDING TO INVESTIGATION, P149, DOI 10.1016/B978-0-12-803109-4.00017-9
   Petruzziello A, 2016, WORLD J GASTROENTERO, V22, P7824, DOI 10.3748/wjg.v22.i34.7824
   Pietla MK, 2017, VIRUS RES, V234, P44, DOI 10.1016/j.virusres.2017.01.007
   Pohjala L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028923
   Puig-Basagoiti F, 2006, ANTIMICROB AGENTS CH, V50, P1320, DOI 10.1128/AAC.50.4.1320-1329.2006
   Puig-Basagoiti F, 2005, ANTIMICROB AGENTS CH, V49, P4980, DOI 10.1128/AAC.49.12.4980-4988.2005
   Reiss S, 2011, CELL HOST MICROBE, V9, P32, DOI 10.1016/j.chom.2010.12.002
   Rocha-Pereira J, 2014, BIOCHEM PHARMACOL, V91, P1, DOI 10.1016/j.bcp.2014.05.021
   Romero-Brey I, 2015, MBIO, V6, DOI 10.1128/mBio.00759-15
   Shan C, 2016, CELL HOST MICROBE, V19, P891, DOI 10.1016/j.chom.2016.05.004
   Shi PY, 2002, VIROLOGY, V296, P219, DOI 10.1006/viro.2002.1453
   Shimizu H, 2014, LANCET INFECT DIS, V14, P262, DOI 10.1016/S1473-3099(13)70330-X
   Siltz LAF, 2014, J VIROL, V88, P11091, DOI 10.1128/JVI.01877-14
   Sofia M.J., 2019, HCV JOURNEY DISCOVER, P223
   Stuyver Lieven J., 2006, Antiviral Chemistry & Chemotherapy, V17, P79
   Suzuki R, 2014, J GEN VIROL, V95, P60, DOI 10.1099/vir.0.058008-0
   Teshale EH, 2010, EMERG INFECT DIS, V16, P126, DOI 10.3201/eid1601.090764
   Tews BA, 2017, METHODS MOL BIOL, V1499, P15, DOI 10.1007/978-1-4939-6481-9_2
   TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993
   Tulloch F, 2014, J VIROL METHODS, V209, P35, DOI 10.1016/j.jviromet.2014.08.020
   van der Linden L, 2010, J VIROL, V84, P7535, DOI 10.1128/JVI.02684-09
   Varghese FS, 2016, ANTIVIR RES, V126, P117, DOI 10.1016/j.antiviral.2015.12.012
   Wada Y, 2017, VIROLOGY, V505, P102, DOI 10.1016/j.virol.2017.02.014
   Wang JM, 2008, BIOCHEM BIOPH RES CO, V374, P138, DOI 10.1016/j.bbrc.2008.06.129
   Wehbe M, 2016, J VIROL METHODS, V230, P1, DOI 10.1016/j.jviromet.2016.01.005
   Wichit S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03316-5
   World Health Organization, 2018, GUID CAR TREATM PERS
   Wu KX, 2017, ANTIVIR RES, V143, P122, DOI 10.1016/j.antiviral.2017.04.008
   Xie XP, 2016, EBIOMEDICINE, V12, P156, DOI 10.1016/j.ebiom.2016.09.013
   Xiong Q, 2017, J VIROL METHODS, V248, P87, DOI 10.1016/j.jviromet.2017.06.009
   Xu L, 2014, VIRUSES-BASEL, V6, P2778, DOI 10.3390/v6072778
   Yang LL, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-212
   Zhang QY, 2017, ARCH VIROL, V162, P3417, DOI 10.1007/s00705-017-3508-9
NR 116
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD JUN
PY 2020
VL 12
IS 6
AR 598
DI 10.3390/v12060598
PG 22
WC Virology
SC Virology
GA MR9NP
UT WOS:000553916300001
PM 32486283
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Simao, EP
   Silva, DBS
   Cordeiro, MT
   Gil, LHV
   Andrade, CAS
   Oliveira, MDL
AF Simao, Estefani P.
   Silva, Dammyres B. S.
   Cordeiro, Marli T.
   Gil, Laura H. V.
   Andrade, Cesar A. S.
   Oliveira, Maria D. L.
TI Nanostructured impedimetric lectin-based biosensor for arboviruses
   detection
SO TALANTA
LA English
DT Article
DE Concanavalin A; Nanoparticles; Arboviruses; Biosensor; Impedance
   spectroscopy
ID ZINC-OXIDE NANOPARTICLES; BORON-NITRIDE NANOSHEETS; GOLD NANOPARTICLES;
   SENSOR; DENGUE; CHIKUNGUNYA; DIAGNOSIS; SEROTYPE
AB Arboviruses have been emerging as a significant global health problem due to the recurrent epidemics. Arboviruses require the development of new diagnostic devices due to the nonspecific clinical manifestations. Herein, we report a biosensor based on cysteine (Cys), zinc oxide nanoparticles (ZnONp), and Concanavalin A (ConA) lectin to differentiate between arboviruses infections. ConA is capable of interacting with the saccharide components of the viral capsid. In this study, we evaluated the reproducibility, sensitivity, and specificity of the sensor for the virus of Dengue type 2 (DENV2), Zika (ZIKV), Chikungunya (CHIKV), and Yellow fever (YFV). Atomic force microscopy measurements confirmed the electrode surface modification and revealed a heterogeneous topography during the biorecognition process. Cyclic voltammetry (CV) and impedance spectroscopy (EIS) were used to characterize the biosensor. The blockage of the oxidation-reduction process is related to the formation of Cys-ZnONp-ConA system on the electroactive area and its subsequent interaction with viral glycoproteins. The sensor exhibited a linear response to different concentrations of the studied arboviruses. Our study demonstrates that ConA lectin recognizes the structural glycoproteins of the DENV2, ZIKV, CHIKV, and YFV. DENV2 is the most structurally similar to ZIKV. Our results have shown that the impedimetric response correlates with the structural glycoproteins, as follow: DENV2 (18.6 k Omega) > ZIKV (14.6 k Omega) > CHIKV (6.86 k Omega) > YFV (5.98 k Omega). The homologous structural regions contribute to ConA-arboviruses recognition. Our results demonstrate the use of the proposed system for the development of biosensors for arboviruses infections.
C1 [Simao, Estefani P.; Oliveira, Maria D. L.] Univ Fed Pernambuco, Programa Posgrad Ciencias Biol, BR-50670901 Recife, PE, Brazil.
   [Silva, Dammyres B. S.; Andrade, Cesar A. S.; Oliveira, Maria D. L.] Univ Fed Pernambuco, Dept Bioquim, BR-50670901 Recife, PE, Brazil.
   [Cordeiro, Marli T.; Gil, Laura H. V.] Inst Aggeu Magalhaes Fiocruz, Dept Virol, BR-50670420 Recife, PE, Brazil.
RP Oliveira, MDL (corresponding author), Univ Fed Pernambuco, Dept Bioquim, BR-50670901 Recife, PE, Brazil.
EM m_danielly@yahoo.com.br
RI Oliveira, Maria/AAM-4055-2020
OI Oliveira, Maria/0000-0002-8572-4846; Souza de Andrade, Cesar
   Augusto/0000-0002-3271-2817
FU Foundation for Science and Technology of the State of Pernambuco
   (FACEPE); FACEPE [APQ-0739-2.12/17]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [314894/2018-7, 314756/2018-3]
FX E.P. Simao would like to thank Foundation for Science and Technology of
   the State of Pernambuco (FACEPE) for a Ph.D. scholarship. L.H.V. Gil
   would like to thank FACEPE (grant APQ-0739-2.12/17). M.D.L. Oliveira and
   C.A.S. Andrade would like to thank CNPq (grant 314894/2018-7 and
   314756/2018-3).
CR Akahata W, 2012, J VIROL, V86, P8879, DOI 10.1128/JVI.00370-12
   Andrade CAS, 2011, J COLLOID INTERF SCI, V362, P517, DOI 10.1016/j.jcis.2011.07.013
   Atar N, 2018, J ELECTROCHEM SOC, V165, pH255, DOI [10.1149/2.1311805jes, 10.1149/2.1311805JES]
   Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144
   CDC (U.S. Centers for Disease Control and Prevention), 2016, TRIOPL REAL TIM RT P
   CDC (U.S. Centers for Disease Control and Prevention), 2016, TYP ZIK VIR TESTS
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   da Silva JSL, 2014, COLLOID SURFACE B, V117, P549, DOI 10.1016/j.colsurfb.2013.12.057
   Deeba F, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftv119
   Donalisio MR, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051006889, 10.1590/s1518-8787.2017051006889]
   Freire MCLC, 2017, ACS OMEGA, V2, P3913, DOI 10.1021/acsomega.7b00608
   Grasset F, 2003, J ALLOY COMPD, V360, P298, DOI 10.1016/S0925-8388(03)00371-2
   Grubhoffer L., 2009, LECTINS BIOL BIOCH C, V7, P313
   Gupta VK, 2013, SENSOR ACTUAT B-CHEM, V188, P1201, DOI 10.1016/j.snb.2013.08.034
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Khan R, 2008, ANAL CHIM ACTA, V616, P207, DOI 10.1016/j.aca.2008.04.010
   Kim SY, 2017, BIOCHEMISTRY-US, V56, P1151, DOI 10.1021/acs.biochem.6b01056
   Kurstack E.K.C., 1981, COMP DIAGNOSIS VIRAL
   Ma XH, 2017, SENSOR ACTUAT B-CHEM, V248, P201, DOI 10.1016/j.snb.2017.03.172
   Moulin E, 2016, New Microbes New Infect, V11, P6, DOI 10.1016/j.nmni.2016.02.003
   Murray Natasha Evelyn Anne, 2013, Clin Epidemiol, V5, P299, DOI 10.2147/CLEP.S34440
   Nascimento HPO, 2011, COLLOID SURFACE B, V86, P414, DOI 10.1016/j.colsurfb.2011.04.028
   Necas D, 2012, CENT EUR J PHYS, V10, P181, DOI 10.2478/s11534-011-0096-2
   Nicolini AM, 2017, J BIOL ENG, V11, DOI 10.1186/s13036-016-0046-z
   Oliveira MDL, 2011, J COLLOID INTERF SCI, V362, P194, DOI 10.1016/j.jcis.2011.06.042
   Oliveira MDL, 2011, SENSOR ACTUAT B-CHEM, V155, P789, DOI 10.1016/j.snb.2011.01.049
   Oliveira MDL, 2009, SYNTHETIC MET, V159, P2162, DOI 10.1016/j.synthmet.2009.09.022
   Oliveira MDL, 2009, BIOSENS BIOELECTRON, V25, P728, DOI 10.1016/j.bios.2009.08.009
   Oliveira N, 2015, SENSORS-BASEL, V15, P15562, DOI 10.3390/s150715562
   ORAM JD, 1971, NATURE-NEW BIOL, V233, P50
   Ozden S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000527
   Pereira EMA, 2008, COLLOID SURFACE B, V66, P45, DOI 10.1016/j.colsurfb.2008.05.013
   Pierson TC, 2016, CELL, V167, P625, DOI 10.1016/j.cell.2016.09.020
   Rey FA, 2003, P NATL ACAD SCI USA, V100, P6899, DOI 10.1073/pnas.1332695100
   Schwartz R.M., 2016, J CHROMATOGR B, V1032, P2
   Simao EP, 2016, J BRAZIL CHEM SOC, V27, P1040, DOI 10.5935/0103-5053.20150361
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Song H, 2016, NAT STRUCT MOL BIOL, V23, P456, DOI 10.1038/nsmb.3213
   Taylor P., 2008, ANAL LETT, V41, P37
   Volk DE, 2009, VIROLOGY, V394, P12, DOI 10.1016/j.virol.2009.09.001
   Yang HY, 2016, SENSOR ACTUAT B-CHEM, V229, P297, DOI 10.1016/j.snb.2015.08.034
   Yola ML, 2019, BIOSENS BIOELECTRON, V126, P418, DOI 10.1016/j.bios.2018.11.016
   Yola ML, 2018, APPL SURF SCI, V458, P648, DOI 10.1016/j.apsusc.2018.07.142
   Yola ML, 2015, SENSOR ACTUAT B-CHEM, V210, P149, DOI 10.1016/j.snb.2014.12.098
   Yola ML, 2014, ELECTROCHIM ACTA, V119, P24, DOI 10.1016/j.electacta.2013.12.028
   Yola ML, 2014, ELECTROCHIM ACTA, V125, P38, DOI 10.1016/j.electacta.2014.01.074
   Yumak T, 2011, COLLOID SURFACE B, V86, P397, DOI 10.1016/j.colsurfb.2011.04.030
   Zhao LZ, 2016, SENSOR ACTUAT B-CHEM, V235, P575, DOI 10.1016/j.snb.2016.05.136
NR 48
TC 2
Z9 2
U1 3
U2 42
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD FEB 1
PY 2020
VL 208
AR 120338
DI 10.1016/j.talanta.2019.120338
PG 7
WC Chemistry, Analytical
SC Chemistry
GA JW8RM
UT WOS:000503314200016
PM 31816752
DA 2020-11-24
ER

PT J
AU Oliveira, RAS
   de Oliveira, EF
   Fernandes, AIV
   Brito, CAA
   Marques, ETA
   Tenorio, MC
   Gil, LHGV
AF Oliveira, Renato A. S.
   de Oliveira-Filho, Edmilson F.
   Fernandes, Ana I., V
   Brito, Carlos A. A.
   Marques, Ernesto T. A.
   Tenorio, Marli C.
   Gil, Laura H. G., V
TI Previous dengue or Zika virus exposure can drive to infection
   enhancement or neutralisation of other flaviviruses
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE ADE; flavivirus; dengue; Zika
ID ANTIBODY-DEPENDENT ENHANCEMENT; PERNAMBUCO; FEVER; STATE
AB BACKGROUND Dengue virus (DENV) has circulated in Brazil for over 30 years. During this time, one serotype has cyclically replaced the other, until recently, when all four distinct serotypes began to circulate together. Persistent circulation of DENV for long time periods makes sequential infections throughout a person's life possible. After primary DENV infection, life-long immunity is developed for the infecting serotype. Since DENV and Zika virus (ZIKV) arc antigenically similar, the possibility of cross-reactions has attracted attention and has been demonstrated in vitro.
   OBJECTIVE The aim of this study was to investigate whether immune-sera from DENV and ZIKV infected patients would cross-react in vitro with other Flaviviridae family members.
   METHODS Cross reaction of the studied samples with yellow fever virus (YFV), West Nile virus (WNV), Rocio virus (ROCV), Saint Louis virus (SLEV) and Ilheus virus (ILHV) has been investigated by plaque reduction neutralisation test (PRNT) and the antibody-dependent enhancement (ADE) by flow-cytometry.
   FINDINGS Antibodies against ZIKV and DENV virus cross-reacted with other flaviviruses either neutralising or enhancing the infection. Thus, viral entrance into FcRFc gamma RII-expressing cells were influenced by the cross-reactive antibodies. ZIKV or DENV immune sera enhanced cellular infection by WNV, ILHV, ROCV and SLEV. Finally, DENV immune sera presented higher neutralising activity for YFV and SLEV. While ZIKV immune sera neutralised WNV, ILHV and ROCV with high frequencies of positivity.
   MAIN CONCLUSIONS The co-circulation of those viruses in the same area represents a risk for the development of severe infections if they spread throughout the country. Successive flavivirus infections may have an impact on disease pathogenesis, as well as on the development of safe vaccine strategies.
C1 [Oliveira, Renato A. S.; de Oliveira-Filho, Edmilson F.; Marques, Ernesto T. A.; Tenorio, Marli C.; Gil, Laura H. G., V] Inst Aggeu Magalhaes, Dept Virol, Fundacao Oswaldo Cruz, Recife, PE, Brazil.
   [Oliveira, Renato A. S.] Univ Fed Paraiba, Dept Fisiol & Patol, Joao Pessoa, Paraiba, Brazil.
   [de Oliveira-Filho, Edmilson F.] Charite Univ Med Berlin, Berlin, Germany.
   [Fernandes, Ana I., V] Univ Fed Paraiba, Hosp Univ Lauro Wanderley, Serv Doencas Infecciosas & Parasitarias, Joao Pessoa, Paraiba, Brazil.
   [Fernandes, Ana I., V] Univ Fed Paraiba, Escola Tecn Saude, Grp Estudos & Pesquisas Imunol Humana, Joao Pessoa, Paraiba, Brazil.
   [Brito, Carlos A. A.] Univ Fed Pernambuco, Dept Med Clin, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Oliveira, RAS (corresponding author), Inst Aggeu Magalhaes, Dept Virol, Fundacao Oswaldo Cruz, Recife, PE, Brazil.; Oliveira, RAS (corresponding author), Univ Fed Paraiba, Dept Fisiol & Patol, Joao Pessoa, Paraiba, Brazil.
EM renaoliveira1977@gmail.com
RI Oliveira, Renato/AAN-9394-2020; Marques, Ernesto T. A/L-4967-2013;
   Oliveira, Renato/AAN-9879-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; Oliveira,
   Renato/0000-0002-4044-0794
FU Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
   (Facepe) [BFP-0117-2.11/13, APQ 1380-5.05/15]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [DCR-0003-5.05/16]
FX To Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
   (Facepe) (grant BFP-0117-2.11/13), for granting RASO a visiting research
   fellowship and EFO-F (grant APQ 1380-5.05/15) and CNPq
   (DCR-0003-5.05/16), and to Louisa F. Ludwig-Begall, for the careful
   English proofreading of this manuscript.
CR Amarilla AA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199071
   Andrade P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08845-3
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Cordeiro MT, 2016, J INFECT DIS, V214, P1897, DOI 10.1093/infdis/jiw477
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   de Oliveira EF, 2018, TRANSBOUND EMERG DIS, V65, P1094, DOI 10.1111/tbed.12829
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Dowd KA, 2014, J VIROL, V88, P11726, DOI 10.1128/JVI.01140-14
   George J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10901-1
   Goldani LZ, 2017, BRAZ J INFECT DIS, V21, P123, DOI 10.1016/j.bjid.2017.02.004
   Katzelnick LC, 2016, P NATL ACAD SCI USA, V113, P728, DOI 10.1073/pnas.1522136113
   Katzelnick LC, 2015, SCIENCE, V349, P1338, DOI 10.1126/science.aac5017
   Kum DB, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0092-2
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Mayer SV, 2017, ACTA TROP, V166, P155, DOI 10.1016/j.actatropica.2016.11.020
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Reynolds CJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18781-1
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Santos JJS, 2014, AN ACAD BRAS CIENC, V86, P1749, DOI 10.1590/0001-3765201420130332
NR 23
TC 8
Z9 8
U1 1
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2019
VL 114
AR e190098
DI 10.1590/0074-02760190098
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA IR8UC
UT WOS:000481716000001
PM 31411310
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU de Oliveira, EF
   dos Santos, DRL
   Duraes-Carvalho, R
   da Silva, A
   de Lima, GB
   Batista, AFB
   Pena, LJ
   Gil, LHVG
AF de Oliveira-Filho, Edmilson Ferreira
   dos Santos, Debora R. L.
   Duraes-Carvalho, Ricardo
   da Silva, Adalucia
   de Lima, Gustavo Barbosa
   Batista Filho, Antonio Fernando B.
   Pena, Lindomar J.
   Gil, Laura H. V. G.
TI Evolutionary study of potentially zoonotic hepatitis E virus genotype 3
   from swine in Northeast Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE zoonotic hepatitis E virus; swine; genotype 3
ID PHYLOGENETIC ANALYSIS; DOMESTIC SWINE; INFECTION; PIGS; PREVALENCE;
   DIVERSITY; HEV; PCR
AB Hepatitis E virus (HEV), an emerging virus associated with acute hepatic disease, leads to thousands of deaths worldwide. HEV has already been reported in Brazil; however, there is a lack of epidemiological and molecular information on the genetic variability, taxonomy, and evolution of HEV. It is thus unclear whether hepatitis E is a neglected disease in Brazil or it has low relevance for public health in this country. Here, for the first time, we report the presence of HEV in Northeast Brazil. A total of 119 swine faecal samples were screened for the presence of HEV RNA using real-time polymerase chain reaction (RT-PCR) and further confirmed by conventional RT-PCR; among these, two samples were identified as positive. Molecular evolution analyses based on capsid sequences revealed that the samples had close proximities to HEV sequences belonging to genotype 3 and were genetically related to subtype 3f isolated in humans. Parsimony ancestral states analysis indicated gene flow events from HEV cross-species infection, suggesting an important role of pig hosts in viral spillover. HEV's ability for zoonotic transmission by inter-species host switching as well as its possible adaptation to new animal species remain important issues for human health.
C1 [de Oliveira-Filho, Edmilson Ferreira; Duraes-Carvalho, Ricardo; da Silva, Adalucia; Pena, Lindomar J.; Gil, Laura H. V. G.] Fundacao Oswaldo Cruz Fiocruz, Inst Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
   [de Oliveira-Filho, Edmilson Ferreira] Charite Univ Med Berlin, Berlin, Germany.
   [de Oliveira-Filho, Edmilson Ferreira] Free Univ Berlin, Berlin, Germany.
   [de Oliveira-Filho, Edmilson Ferreira] Humboldt Univ, Berlin, Germany.
   [de Oliveira-Filho, Edmilson Ferreira] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [dos Santos, Debora R. L.] Univ Fed Rural Rio de Janeiro, Inst Vet, Seropedica, RJ, Brazil.
   [de Lima, Gustavo Barbosa] Fundacao Oswaldo Cruz Fiocruz, Inst Aggeu Magalhaes, Dept Microbiol, Recife, PE, Brazil.
   [Batista Filho, Antonio Fernando B.] Univ Fed Rural Pernambuco, Dept Med Vet, Recife, PE, Brazil.
RP de Oliveira, EF (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.; de Oliveira, EF (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; de Oliveira, EF (corresponding author), Free Univ Berlin, Berlin, Germany.; de Oliveira, EF (corresponding author), Humboldt Univ, Berlin, Germany.; de Oliveira, EF (corresponding author), Berlin Inst Hlth, Inst Virol, Berlin, Germany.
EM edmilsonz@gmail.com
RI Oliveira-Filho, Edmilson/A-6305-2012
OI Oliveira-Filho, Edmilson/0000-0002-3771-1565
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FACEPE
FX CNPq, FACEPE.
CR Anisimova M, 2006, SYST BIOL, V55, P539, DOI 10.1080/10635150600755453
   Brayne AB, 2017, J VIROL, V91, DOI 10.1128/JVI.02241-16
   Lana MVD, 2014, TROP ANIM HEALTH PRO, V46, P399, DOI 10.1007/s11250-013-0503-3
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   de Oliveira EF, 2017, FOOD ENVIRON VIROL, V9, P256, DOI 10.1007/s12560-017-9292-6
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Forni D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-017-0009-6
   Fourment M, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-1
   Geng YS, 2010, VECTOR-BORNE ZOONOT, V10, P765, DOI 10.1089/vbz.2009.0168
   Huang FF, 2002, J CLIN MICROBIOL, V40, P1326, DOI 10.1128/JCM.40.4.1326-1332.2002
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Jothikumar N, 2006, J VIROL METHODS, V131, P65, DOI 10.1016/j.jviromet.2005.07.004
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   dos Santos DRL, 2011, VET MICROBIOL, V149, P236, DOI 10.1016/j.vetmic.2010.10.024
   dos Santos DRL, 2010, J CLIN VIROL, V47, P276, DOI 10.1016/j.jcv.2009.12.021
   dos Santos DRL, 2009, VET J, V182, P474, DOI 10.1016/j.tvjl.2008.08.001
   Maddison W. P., 2018, MESQUITE MODULAR SYS
   Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860
   Moratorio G, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006979
   Muller B, 2007, ARCH VIROL, V152, P1709, DOI 10.1007/s00705-007-0989-y
   Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02396
   Oliveira EF, 2014, VET MICROBIOL, V174, P233, DOI 10.1016/j.vetmic.2014.09.011
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Purdy MA, 2017, J GEN VIROL, V98, P2645, DOI 10.1099/jgv.0.000940
   Sakano C, 2009, J VET MED SCI, V71, P21, DOI 10.1292/jvms.71.21
   Santos D. L. dos, 2013, Veterinaria e Zootecnia, V20, P416
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   Smith DB, 2016, J GEN VIROL, V97, P537, DOI 10.1099/jgv.0.000393
   Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815
   Vivek R, 2011, AM J TROP MED HYG, V84, P647, DOI 10.4269/ajtmh.2011.10-0456
NR 30
TC 0
Z9 0
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2019
VL 114
AR e180585
DI 10.1590/0074-02760180585
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA IC2FP
UT WOS:000470775900001
PM 31166480
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Silva, JVJ
   Ludwig-Begall, LF
   de Oliveira, EF
   Oliveira, RAS
   Duraes-Carvalho, R
   Lopes, TRR
   Silva, DEA
   Gil, LHVG
AF Silva, Jose V. J., Jr.
   Ludwig-Begall, Louisa F.
   de Oliveira-Filho, Edmilson F.
   Oliveira, Renato A. S.
   Duraes-Carvalho, Ricardo
   Lopes, Thaisa R. R.
   Silva, Daisy E. A.
   Gil, Laura H. V. G.
TI A scoping review of Chikungunya virus infection: epidemiology, clinical
   characteristics, viral co-circulation complications, and control
SO ACTA TROPICA
LA English
DT Review
DE Chikungunya fever; Arboviruses; Dengue; Zika
ID GUILLAIN-BARRE-SYNDROME; SEMLIKI-FOREST-VIRUS; AEDES-AEGYPTI; VERTICAL
   TRANSMISSION; NONHUMAN-PRIMATES; IN-VITRO; BIOLOGICAL-CONTROL;
   MOSQUITO-CONTROL; VECTOR CONTROL; PROTECTS MICE
AB Chikungunya fever is a mosquito-borne viral illness characterized by a sudden onset of fever associated with joint pains. It was first described in the 1950s during a Chikungunya virus (CHIKV) outbreak in southern Tanzania and has since (re-) emerged and spread to several other geographical areas, reaching large populations and causing massive epidemics. In recent years, CHIKV has gained considerable attention due to its quick spread to the Caribbean and then in the Americas, with many cases reported between 2014 and 2017. CHIKV has further garnered attention due to the clinical diagnostic difficulties when Zika (ZIKV) and dengue (DENV) viruses are simultaneously present. In this review, topical CHIKV-related issues, such as epidemiology and transmission, are examined. The different manifestations of infection (acute, chronic and atypical) are described and a particular focus is placed upon the diagnostic handling in the case of ZIKV and DENV co-circulating. Natural and synthetic compounds under evaluation for treatment of chikungunya disease, including drugs already licensed for other purposes, are also discussed. Finally, previous and current vaccine strategies, as well as the control of the CHIKV transmission through an integrated vector management, are reviewed in some detail.
C1 [Silva, Jose V. J., Jr.; de Oliveira-Filho, Edmilson F.; Duraes-Carvalho, Ricardo; Silva, Daisy E. A.; Gil, Laura H. V. G.] Fundacao Oswaldo Cruz, Aggeu Magalhcaes Inst, Dept Virol, Recife, PE, Brazil.
   [Silva, Jose V. J., Jr.] Univ Fed Santa Maria, Virol Sect, Dept Prevent Vet Med, Santa Maria, RS, Brazil.
   [Ludwig-Begall, Louisa F.] Univ Liege, Fac Vet Med, Dept Infect & Parasit Dis, Liege, Belgium.
   [Oliveira, Renato A. S.] Univ Fed Paraiba, Dept Fisiol & Pathol, Joao Pessoa, PB, Brazil.
   [Lopes, Thaisa R. R.] Univ Fed Pernambuco, Virol Sect, Lab Immunopathol Keizo Asami, Recife, PE, Brazil.
RP Silva, JVJ (corresponding author), Fed Univ Santa Maria UFSM, Virol Sect, Dept Prevent Vet Med, BR-97105900 Santa Maria, RS, Brazil.; Gil, LHVG (corresponding author), Oswald Cruz Fdn FIOCRUZ, Aggeu Magalhaes Inst IAM, Dept Virol, BR-50670420 Recife, PE, Brazil.
EM josevalterjsilvajr@gmail.com; laura@cpqam.fiocruz.br
RI Oliveira, Renato/AAN-9879-2020; Oliveira, Renato/AAN-9394-2020;
   Oliveira-Filho, Edmilson/A-6305-2012; Duraes-Carvalho,
   Ricardo/X-3065-2018
OI Oliveira, Renato/0000-0002-4044-0794; Oliveira-Filho,
   Edmilson/0000-0002-3771-1565; Duraes-Carvalho,
   Ricardo/0000-0001-5734-7601
FU Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
   (FACEPE); MCT/CNPq DCR grants; Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES)CAPES; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq)
FX E.F. Oliveira-Filho and R. Duraes-Carvalho are supported by Fundacao de
   Amparo a Ciencia e Tecnologia do Estado de Pernambuco (FACEPE) and
   MCT/CNPq DCR grants. J.V.J. Silva Junior is supported by Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). T.R.R. Lopes is
   supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq).
CR Agarwal A, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002990
   Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105
   Alphey L, 2013, PATHOG GLOB HEALTH, V107, P170, DOI 10.1179/2047773213Y.0000000095
   Alphey L, 2010, VECTOR-BORNE ZOONOT, V10, P295, DOI 10.1089/vbz.2009.0014
   Althouse BM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03332-7
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P537, DOI 10.1590/0037-8682-0328-2016
   Appassakij H, 2013, TRANSFUSION, V53, P2567, DOI 10.1111/j.1537-2995.2012.03960.x
   Armengol G, 2006, J ECON ENTOMOL, V99, P1590, DOI 10.1603/0022-0493-99.5.1590
   ATKINSON T, 1986, J GEN VIROL, V67, P1189, DOI 10.1099/0022-1317-67-6-1189
   Ayu SM, 2010, AM J TROP MED HYG, V83, P1245, DOI 10.4269/ajtmh.2010.10-0279
   Azami NAM, 2016, METHODS MOL BIOL, V1426, P273, DOI 10.1007/978-1-4939-3618-2_25
   Bandeira AC, 2016, IDCases, V6, P100, DOI 10.1016/j.idcr.2016.10.007
   Bandeira AC, 2016, IDCases, V5, P57, DOI 10.1016/j.idcr.2016.07.008
   Benelli G, 2019, SAUDI J BIOL SCI, V26, P921, DOI 10.1016/j.sjbs.2018.06.007
   Benelli G, 2018, ENVIRON SCI POLLUT R, V25, P12329, DOI [10.1007/s11356-018-1850-4, 10.1007/s11356-017-9752-4]
   Benelli G, 2018, ACTA TROP, V182, P80, DOI 10.1016/j.actatropica.2018.02.015
   Benelli G, 2017, ACTA TROP, V174, P91, DOI 10.1016/j.actatropica.2017.06.028
   Benelli G, 2016, INSECTS, V7, DOI 10.3390/insects7040052
   Benelli G, 2016, PARASITOL RES, V115, P23, DOI 10.1007/s00436-015-4800-9
   Benelli G, 2015, PARASITOL RES, V114, P1613, DOI 10.1007/s00436-015-4351-0
   Blanford S, 2005, SCIENCE, V308, P1638, DOI 10.1126/science.1108423
   Borgherini G, 2008, CLIN INFECT DIS, V47, P469, DOI 10.1086/590003
   Borgherini G, 2007, CLIN INFECT DIS, V44, P1401, DOI 10.1086/517537
   Boyer S, 2012, Med Trop (Mars), V72 Spec No, P60
   Brandler S, 2013, VACCINE, V31, P3718, DOI 10.1016/j.vaccine.2013.05.086
   BRIGHTON SW, 1984, S AFR MED J, V66, P217
   Briolant S, 2004, ANTIVIR RES, V61, P111, DOI 10.1016/j.antiviral.2003.09.005
   Caglioti C, 2013, NEW MICROBIOL, V36, P211
   Calisher C.H., 1988, ARBOVIRUSES EPIDEMIO, VI
   CDC, 2016, REV DIAGN TEST ZIK C
   CDC, 2018, CHIK VIR GEOGR DISTR
   CDC, 2015, CLIN EV DIS
   Center for Disease Control and Prevention (CDC), 2018, INF DIS REL TRAV
   Chandra G, 2008, INDIAN J MED RES, V127, P13
   Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5
   Chevillon C, 2008, TRENDS MICROBIOL, V16, P80, DOI 10.1016/j.tim.2007.12.003
   Chobu M, 2015, ACTA TROP, V142, P131, DOI 10.1016/j.actatropica.2014.11.012
   Chompoosri J, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1505-6
   Chow A, 2011, J INFECT DIS, V203, P149, DOI 10.1093/infdis/jiq042
   Chusri S, 2011, AM J TROP MED HYG, V85, P386, DOI 10.4269/ajtmh.2011.10-0725
   CIRE, 2006, CIR REUN MAYOTT EP C
   da Cunha RV, 2017, MEM I OSWALDO CRUZ, V112, P523, DOI 10.1590/0074-02760170044
   Azevedo RDD, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049006219
   Danis-Lozano R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186923
   DAS M K, 1991, Indian Journal of Malariology, V28, P171
   Dash Muktikesh, 2011, Indian J Med Sci, V65, P83, DOI 10.4103/0019-5359.104781
   Cavalcanti LPD, 2007, REV SAUDE PUBL, V41, P638, DOI 10.1590/s0034-89102006005000041
   De Lamballerie X, 2008, VECTOR-BORNE ZOONOT, V8, P837, DOI 10.1089/vbz.2008.0049
   Diallo M, 1999, AM J TROP MED HYG, V60, P281, DOI 10.4269/ajtmh.1999.60.281
   Dickens BL, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw103
   Dumont Y, 2010, MATH BIOSCI ENG, V7, P313, DOI 10.3934/mbe.2010.7.313
   ECKELS KH, 1970, APPL MICROBIOL, V19, P321, DOI 10.1128/AEM.19.2.321-325.1970
   Economopoulou A, 2009, EPIDEMIOL INFECT, V137, P534, DOI 10.1017/S0950268808001167
   Edelman R, 2000, AM J TROP MED HYG, V62, P681, DOI 10.4269/ajtmh.2000.62.681
   Edwards CJ, 2007, J CLIN VIROL, V39, P271, DOI 10.1016/j.jcv.2007.05.008
   Erasmus JH, 2017, NAT MED, V23, P192, DOI 10.1038/nm.4253
   Ernould S, 2008, ARCH PEDIATRIE, V15, P253, DOI 10.1016/j.arcped.2007.10.019
   Ferreira CP, 2008, J BIOL SYST, V16, P565, DOI 10.1142/S0218339008002691
   Furuya-Kanamori L, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1417-2
   de Figueiredo MLG, 2014, REV SOC BRAS MED TRO, V47, P677, DOI 10.1590/0037-8682-0246-2014
   Garcia-Arriaza J, 2014, J VIROL, V88, P3527, DOI 10.1128/JVI.03418-13
   Girgin NK, 2014, TURK J ANAESTHESIOL, V42, P100, DOI 10.5152/TJAR.2013.51
   Giry C, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1019-1
   Gopakumar H, 2012, J CLIN NEONATOL, V1, P155, DOI 10.4103/2249-4847.101704
   Gorchakov R, 2012, J VIROL, V86, P6084, DOI 10.1128/JVI.06449-11
   Goupil Brad A, 2016, Open Rheumatol J, V10, P129, DOI 10.2174/1874312901610010129
   Grandadam M, 2011, EMERG INFECT DIS, V17, P910, DOI 10.3201/eid1705.101873
   Grivard P, 2007, PATHOL BIOL, V55, P490, DOI 10.1016/j.patbio.2007.07.002
   Heikema AP, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2015.05.031
   Hemingway J, 2000, ANNU REV ENTOMOL, V45, P371, DOI 10.1146/annurev.ento.45.1.371
   Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255
   Horwood P, 2013, WEST PAC SURVEILL RE, V4, DOI [10.5365/WPSAR.2013.4.2.003, 10.5365/wpsar.2013.4.2.003]
   HOY JB, 1985, J AM MOSQUITO CONTR, V1, P295
   Hua C, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0694-0
   Huang YJS, 2017, INSECTS, V8, DOI 10.3390/insects8010021
   International Committee on Taxonomy of Viruses (ICTV), 2017, VIR TAX 2017 REL
   Islam J, 2017, ACTA TROP, V167, P216, DOI 10.1016/j.actatropica.2016.12.031
   Jain J, 2016, ACTA TROP, V162, P46, DOI 10.1016/j.actatropica.2016.06.004
   Jain M, 2008, TROP DOCT, V38, P70, DOI 10.1258/td.2007.070019
   Johnson BW, 2016, J INFECT DIS, V214, pS471, DOI 10.1093/infdis/jiw274
   Josseran L, 2006, EMERG INFECT DIS, V12, P1994
   Kading RC, 2013, J WILDLIFE DIS, V49, P587, DOI 10.7589/2012-08-212
   Kam YW, 2009, MICROBES INFECT, V11, P1186, DOI 10.1016/j.micinf.2009.09.003
   Kamareddine L, 2012, TOXINS, V4, P748, DOI 10.3390/toxins4090748
   Kaur P, 2013, DRUG DISCOV TODAY, V18, P969, DOI 10.1016/j.drudis.2013.05.002
   Kaur P, 2013, ANTIMICROB AGENTS CH, V57, P155, DOI 10.1128/AAC.01467-12
   Kee ACL, 2010, EMERG INFECT DIS, V16, P1038, DOI 10.3201/eid1606.091115
   Khan M, 2010, J MED VIROL, V82, P817, DOI 10.1002/jmv.21663
   Kim SY, 2016, KOREAN J INTERN MED, V31, P1191, DOI 10.3904/kjim.2015.033
   Knols BGJ, 2010, FUTURE MICROBIOL, V5, P339, DOI [10.2217/fmb.10.11, 10.2217/FMB.10.11]
   Kumar PM, 2012, PARASITOL RES, V111, P609, DOI 10.1007/s00436-012-2876-z
   Kweka EJ, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-128
   Labadie K, 2010, J CLIN INVEST, V120, P894, DOI 10.1172/JCI40104
   Lam PHY, 2010, SE ASIAN J TROP MED, V41, P1071
   Lani R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11421
   Le Coupanec A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081708
   Lebrun G, 2009, EMERG INFECT DIS, V15, P495, DOI 10.3201/eid1503.071482
   Lee SS, 2013, J THEOR BIOL, V331, P78, DOI 10.1016/j.jtbi.2013.04.014
   Lee VJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001786
   Leis A Arturo, 2012, Front Neurol, V3, P37, DOI 10.3389/fneur.2012.00037
   LEVITT NH, 1986, VACCINE, V4, P157, DOI 10.1016/0264-410X(86)90003-4
   Liang GD, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.18
   Lim E. X. Y., 2018, VIRUSES, V10
   Litzba N, 2008, J VIROL METHODS, V149, P175, DOI 10.1016/j.jviromet.2008.01.004
   Lu YPE, 1999, J VIROL, V73, P4272, DOI 10.1128/JVI.73.5.4272-4278.1999
   Lum FM, 2013, J IMMUNOL, V190, P6295, DOI 10.4049/jimmunol.1300304
   LUMSDEN W. H. R., 1955, TANGANYIKA TERRITORY IN 1952 53 II TRANS ROY SOC TROP MED AND HYG, V49, P33, DOI 10.1016/0035-9203(55)90081-X
   Madariaga M, 2016, BRAZ J INFECT DIS, V20, P91, DOI 10.1016/j.bjid.2015.10.004
   Madhiyazhagan P, 2015, PARASITOL RES, V114, P4305, DOI 10.1007/s00436-015-4671-0
   Manimunda SP, 2010, T ROY SOC TROP MED H, V104, P392, DOI 10.1016/j.trstmh.2010.01.011
   Manrique-Saide P, 1998, MED VET ENTOMOL, V12, P386, DOI 10.1046/j.1365-2915.1998.00126.x
   Martinez-Pulgarin DF, 2016, TRAVEL MED INFECT DI, V14, P451, DOI 10.1016/j.tmaid.2016.05.008
   Massonnet-Bruneel B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062711
   Mavale M, 2010, AM J TROP MED HYG, V83, P1242, DOI 10.4269/ajtmh.2010.09-0577
   MCCRAE AWR, 1971, T ROY SOC TROP MED H, V65, P152, DOI 10.1016/0035-9203(71)90212-4
   McIntosh B M, 1970, S Afr J Med Sci, V35, P65
   최현길, 2016, Pediatric Infection and Vaccine, V23, P236
   Ministerio da Saude-SVS, 2014, PREPARACAO RESPOSTA
   Mohan Alladi, 2010, Indian J Dermatol, V55, P54, DOI 10.4103/0019-5154.60355
   Morrison TE, 2014, J VIROL, V88, P11644, DOI 10.1128/JVI.01432-14
   Muthumani K, 2008, VACCINE, V26, P5128, DOI 10.1016/j.vaccine.2008.03.060
   Mylonas AD, 2004, JCR-J CLIN RHEUMATOL, V10, P326, DOI 10.1097/01.rhu.0000147052.11190.36
   Nakkhara P, 2013, T ROY SOC TROP MED H, V107, P789, DOI 10.1093/trstmh/trt083
   Nam VS, 1998, AM J TROP MED HYG, V59, P657, DOI 10.4269/ajtmh.1998.59.657
   Ngoagouni C, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2101-0
   NOVAK RJ, 1985, J AM MOSQUITO CONTR, V1, P449
   Oehler E, 2015, EUROSURVEILLANCE, V20, P13, DOI 10.2807/1560-7917.ES.2015.20.48.30079
   Okabayashi T, 2015, J CLIN MICROBIOL, V53, P382, DOI 10.1128/JCM.02033-14
   Ozden S, 2008, J BIOL CHEM, V283, P21899, DOI 10.1074/jbc.M802444200
   Pabbaraju K, 2016, J CLIN VIROL, V83, P66, DOI 10.1016/j.jcv.2016.09.001
   Padmakumar B., 2009, INDIAN J RHEUMATOL, V4, P4
   PAHO, 2017, TOOL DIAGN CAR PAT S
   Panning M, 2008, EMERG INFECT DIS, V14, P416, DOI 10.3201/eid1403.070906
   Patterson J, 2016, WEST J EMERG MED, V17, P671, DOI 10.5811/westjem.2016.9.30904
   Paula AR, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-91
   Paula AR, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-8
   Pavela R, 2015, PARASITOL RES, V114, P3835, DOI 10.1007/s00436-015-4614-9
   Pereira Boscolli Barbosa, 2014, Cad. saúde colet., V22, P241, DOI 10.1590/1414-462X201400030004
   Perri S, 2000, J VIROL, V74, P9802, DOI 10.1128/JVI.74.20.9802-9807.2000
   PHILLIPS PE, 1973, LANCET, V1, P720
   Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X
   Plante K, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002142
   Plante KS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004007
   Pohjala L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028923
   Poo YS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003354
   Powers AM, 2000, J GEN VIROL, V81, P471, DOI 10.1099/0022-1317-81-2-471
   Pruetz J.D., 2010, African Primates, V7, P64
   Rampal, 2007, J Assoc Physicians India, V55, P765
   Ramsauer K, 2015, LANCET INFECT DIS, V15, P519, DOI 10.1016/S1473-3099(15)70043-5
   Rawlins SC, 1997, J AM MOSQUITO CONTR, V13, P18
   Reddy V, 2012, J MED VIROL, V84, P1771, DOI 10.1002/jmv.23406
   Resnik DB, 2014, DEV WORLD BIOETH, V14, P37, DOI 10.1111/dewb.12011
   Lyra PPR, 2016, AJP REP, V6, pE299, DOI 10.1055/s-0036-1587323
   Ritchie SA, 2010, AM J TROP MED HYG, V82, P1053, DOI 10.4269/ajtmh.2010.09-0603
   Robin S, 2010, EUR J PEDIATR, V169, P67, DOI 10.1007/s00431-009-0986-0
   ROSS R. W., 1956, JOUR HYG, V54, P177
   Roy CJ, 2014, J INFECT DIS, V209, P1891, DOI 10.1093/infdis/jiu014
   Roze B, 2017, CLIN INFECT DIS, V65, P1462, DOI 10.1093/cid/cix588
   Ruckert C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15412
   Russell C. A., LANCET, V370, P1840
   Sankari T, 2008, LANCET INFECT DIS, V8, P3, DOI 10.1016/S1473-3099(07)70295-5
   Schaper S, 1999, J AM MOSQUITO CONTR, V15, P510
   Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137
   Schuffenecker I, 2006, PLOS MED, V3, P1058, DOI 10.1371/journal.pmed.0030263
   Seng CM, 2008, J VECTOR ECOL, V33, P139, DOI 10.3376/1081-1710(2008)33[139:CUOTLF]2.0.CO;2
   Sergon K, 2008, AM J TROP MED HYG, V78, P333, DOI 10.4269/ajtmh.2008.78.333
   Sergon K, 2007, AM J TROP MED HYG, V76, P1189, DOI 10.4269/ajtmh.2007.76.1189
   Sharma A, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-301
   Sharma S, 2010, MOL BIOTECHNOL, V45, P49, DOI 10.1007/s12033-009-9238-9
   Shulse CD, 2013, J APPL ECOL, V50, P1244, DOI 10.1111/1365-2664.12126
   Silva LA, 2017, J CLIN INVEST, V127, P737, DOI 10.1172/JCI84417
   Simon F, 2008, MED CLIN N AM, V92, P1323, DOI 10.1016/j.mcna.2008.07.008
   Simon Fabrice, 2011, Curr Infect Dis Rep, V13, P218, DOI 10.1007/s11908-011-0180-1
   Simon O, 2016, J CLIN VIROL, V77, P29, DOI 10.1016/j.jcv.2016.01.016
   Sissoko D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000389
   Smalley C, 2016, VACCINE, V34, P2976, DOI 10.1016/j.vaccine.2016.03.076
   Staples JE, 2014, NEW ENGL J MED, V371, P887, DOI 10.1056/NEJMp1407698
   Staples JE, 2009, CLIN INFECT DIS, V49, P942, DOI 10.1086/605496
   Steger CM, 2012, CASE REP CARDIOL, V2012, DOI 10.1155/2012/506290
   Stoddard PK, 2018, ACTA TROP, V187, P108, DOI 10.1016/j.actatropica.2018.07.031
   Subudhi BB, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050235
   Sujitha V, 2015, PARASITOL RES, V114, P3315, DOI 10.1007/s00436-015-4556-2
   Tandale BV, 2009, J CLIN VIROL, V46, P145, DOI 10.1016/j.jcv.2009.06.027
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Thiberville SD, 2013, ANTIVIR RES, V99, P345, DOI 10.1016/j.antiviral.2013.06.009
   Tiwari M, 2009, VACCINE, V27, P2513, DOI 10.1016/j.vaccine.2009.02.062
   Tretyakova I, 2014, J INFECT DIS, V209, P1882, DOI 10.1093/infdis/jiu114
   Tsetsarkin K, 2006, VECTOR-BORNE ZOONOT, V6, P325, DOI 10.1089/vbz.2006.6.325
   Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201
   Tsetsarkin KA, 2011, CURR OPIN VIROL, V1, P310, DOI 10.1016/j.coviro.2011.07.004
   van den Doel P, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003101
   van Duijl-Richter MKS, 2015, VIRUSES-BASEL, V7, P3647, DOI 10.3390/v7072792
   Vashishtha M, 1998, J CELL BIOL, V140, P91, DOI 10.1083/jcb.140.1.91
   Vega-Rua A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003780
   Vega-Rua A, 2014, J VIROL, V88, P6294, DOI 10.1128/JVI.00370-14
   Venugopalan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111305
   Villamil-Gomez WE, 2016, INT J INFECT DIS, V51, P135, DOI 10.1016/j.ijid.2016.07.017
   Volk SM, 2010, J VIROL, V84, P6497, DOI 10.1128/JVI.01603-09
   Walker T, 2011, NATURE, V476, P450, DOI 10.1038/nature10355
   Walton WE, 2007, J AM MOSQUITO CONTR, V23, P184, DOI 10.2987/8756-971X(2007)23[184:LFIG]2.0.CO;2
   Wang D, 2011, VACCINE, V29, P2803, DOI 10.1016/j.vaccine.2011.01.108
   Wang E, 2008, VACCINE, V26, P5030, DOI 10.1016/j.vaccine.2008.07.054
   Weaver SC, 2006, CURR TOP MICROBIOL, V299, P285
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   WEINBREN M. P., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P253, DOI 10.1016/0035-9203(58)90084-1
   WHO, 2018, CHIK
   Wichit S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03316-5
   Wilke ABB, 2018, TRENDS PARASITOL, V34, P456, DOI 10.1016/j.pt.2018.02.003
   Wintachai P, 2015, MICROBIOL IMMUNOL, V59, P129, DOI 10.1111/1348-0421.12230
   Wintachai P, 2012, J MED VIROL, V84, P1757, DOI 10.1002/jmv.23403
   World Health Organization, 2008, GUID CLIN MAN CHIK F
   World Health Organization, 2016, MON MAN INS RES AED
   Yaren O, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2382-0
   Carrillo-Hernandez MY, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2976-1
   Zeller H, 2016, J INFECT DIS, V214, pS436, DOI 10.1093/infdis/jiw391
   Zhang DJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135194
   Zhang DJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121126
NR 217
TC 17
Z9 17
U1 0
U2 57
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD DEC
PY 2018
VL 188
BP 213
EP 224
DI 10.1016/j.actatropica.2018.09.003
PG 12
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA GX9BH
UT WOS:000448093000026
PM 30195666
OA Green Published
DA 2020-11-24
ER

PT J
AU Silva, JVJ
   Lopes, TRR
   de Oliveira, EF
   Oliveira, RAS
   Durdes-Carvalho, R
   Gil, LHVG
AF Silva, Jose V. J., Jr.
   Lopes, Thaisa R. R.
   de Oliveira-Filho, Edmilson F.
   Oliveira, Renato A. S.
   Durdes-Carvalho, Ricardo
   Gil, Laura H. V. G.
TI Current status, challenges and perspectives in the development of
   vaccines against yellow fever, dengue, Zika and chikungunya viruses
SO ACTA TROPICA
LA English
DT Review
DE Arboviruses; Disease control; Vaccination; Public health
ID DNA VACCINE; PROTECTIVE EFFICACY; CROSS-REACTIVITY; PROTEIN NS1;
   IN-VITRO; ANTIBODIES; STRAIN; IMMUNOGENICITY; ATTENUATION; STRATEGIES
AB Emerging and re-emerging viral infections transmitted by insect vectors (arthopode-borne viruses, arbovirus) are a serious threat to global public health. Among them, yellow fever (YFV), dengue (DENV), chikungunya (CHIKV) and Zika (ZIKV) viruses are particularly important in tropical and subtropical regions. Although vector control is one of the most used prophylactic measures against arboviruses, it often faces obstacles, such as vector diversity, uncontrolled urbanization and increasing resistance to insecticides. In this context, vaccines may be the best control strategy for arboviral diseases. Here, we provide a general overview about licensed vaccines and the most advanced vaccine candidates against YFV, DENV, CHIKV and ZIKV. In particular, we highlight vaccine difficulties, the current status of the most advanced strategies and discuss how the molecular characteristics of each virus can influence the choice of the different vaccine formulations.
C1 [Silva, Jose V. J., Jr.; de Oliveira-Filho, Edmilson F.; Oliveira, Renato A. S.; Durdes-Carvalho, Ricardo; Gil, Laura H. V. G.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Dept Virol & Expt Therapy, BR-50670420 Recife, PE, Brazil.
   [Lopes, Thaisa R. R.] Univ Fed Pernambuco, Lab Immunopathol Keizo Asami, Virol Sect, Recife, PE, Brazil.
   [Oliveira, Renato A. S.] Univ Fed Pernambuco, Dept Pharmaceut Sci, Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Dept Virol & Expt Therapy, BR-50670420 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Oliveira, Renato/AAN-9394-2020; Oliveira-Filho, Edmilson F/A-6305-2012;
   Oliveira, Renato/AAN-9879-2020; Oliveira, Renato/A-2863-2013;
   Duraes-Carvalho, Ricardo/X-3065-2018
OI Oliveira-Filho, Edmilson F/0000-0002-3771-1565; Oliveira,
   Renato/0000-0002-4044-0794; Oliveira, Renato/0000-0002-4044-0794;
   Duraes-Carvalho, Ricardo/0000-0001-5734-7601
FU Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
   (FACEPE); MCT/CNPq DCR grants; Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES)CAPES; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq)
FX E.F. Oliveira-Filho and R. Durales-Carvalho are supported by Fundacao de
   Amparo a Ciencia e Tecnologia do Estado de Pernambuco (FACEPE) and
   MCT/CNPq DCR grants. J.V.J. Silva Junior is supported by Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). T.R.R. Lopes is
   supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq). We thank Dr. Rodolfo Garcia and Dr. Awanish Kumar
   for the English correction and critics of the manuscript.
CR Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105
   Barrett ADT, 2017, VACCINE, V35, P5951, DOI 10.1016/j.vaccine.2017.03.032
   Barrett ADT, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.23
   Benelli G, 2017, ENTOMOL GEN, V36, P309, DOI 10.1127/entomologia/2017/0496
   Benelli G, 2017, ACTA TROP, V174, P91, DOI 10.1016/j.actatropica.2017.06.028
   Benelli G, 2016, PARASITOL RES, V115, P23, DOI 10.1007/s00436-015-4800-9
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Blitvich B, 2016, AM J TROP MED HYG, V95, P488, DOI DOI 10.4269/AJTMH.16-0281
   Bonaldo MC, 2017, MEM I OSWALDO CRUZ, V112, P447, DOI 10.1590/0074-02760170134
   Butrapet S, 2000, J VIROL, V74, P3011, DOI 10.1128/JVI.74.7.3011-3019.2000
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   CDC, 2017, YELL FEV MAPS
   Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5
   Cheng HJ, 2009, MOL IMMUNOL, V47, P398, DOI 10.1016/j.molimm.2009.08.033
   Chotiwan N, 2014, VIROLOGY, V456, P238, DOI 10.1016/j.virol.2014.03.031
   Collins MH, 2017, EMERG INFECT DIS, V23, P773, DOI 10.3201/eid2305.161630
   Costa SM, 2006, VACCINE, V24, P4562, DOI 10.1016/j.vaccine.2005.08.022
   Dawes BE, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.7
   Zara ALDA, 2016, EPIDEMIOL SERV SAUDE, V25, P391, DOI [10.5123/S1679-49742016000200017, 10.5123/s1679-49742016000200017]
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137
   Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049
   Durbin AP, 2016, SEMIN REPROD MED, V34, P299, DOI 10.1055/s-0036-1592070
   Durbin AP, 2011, VACCINE, V29, P7242, DOI 10.1016/j.vaccine.2011.07.023
   Edelman R, 2000, AM J TROP MED HYG, V62, P681, DOI 10.4269/ajtmh.2000.62.681
   Erasmus JH, 2017, NAT MED, V23, P192, DOI 10.1038/nm.4253
   Fernandez E, 2017, CURR OPIN VIROL, V23, P59, DOI 10.1016/j.coviro.2017.03.006
   Galler R, 1997, BRAZ J MED BIOL RES, V30, P157, DOI 10.1590/S0100-879X1997000200002
   George J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10901-1
   Gorchakov R, 2012, J VIROL, V86, P6084, DOI 10.1128/JVI.06449-11
   Gosling R, 2016, PLOS MED, V13, P1, DOI DOI 10.1371/J0URNAL.PMED.1001994
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   HAHN CS, 1987, P NATL ACAD SCI USA, V84, P2019, DOI 10.1073/pnas.84.7.2019
   Halstead SB, 2016, AM J TROP MED HYG, V95, P741, DOI 10.4269/ajtmh.16-0222
   Imperato PJ, 2016, J COMMUN HEALTH, V41, P674, DOI 10.1007/s10900-016-0177-7
   International Committee on Taxonomy of Viruses (ICTV), 2016, TAX
   Ishikawa T, 2014, VACCINE, V32, P1326, DOI 10.1016/j.vaccine.2014.01.040
   Silva JVJ, 2017, REV INST MED TROP SP, V59, DOI [10.1590/s1678-9946201759021, 10.1590/S1678-9946201759021]
   Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517
   Lanciotti R. R. J., 2016, MANUAL MOL CLIN LAB, P648
   LEVITT NH, 1986, VACCINE, V4, P157, DOI 10.1016/0264-410X(86)90003-4
   Li Y, 2017, AM J TROP MED HYG, V96, P727, DOI 10.4269/ajtmh.16-0698
   Liang GD, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.18
   Lin CF, 2003, J MED VIROL, V69, P82, DOI 10.1002/jmv.10261
   LLOYD Wray, 1936, Transactions of the Royal Society of Tropical Medicine and Hygiene, V29, P481, DOI 10.1016/S0035-9203(36)90002-0
   Lucey D, 2017, JAMA-J AM MED ASSOC, V317, P1368, DOI 10.1001/jama.2017.1553
   Maciel M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003693
   Marston HD, 2016, NEW ENGL J MED, V375, P1209, DOI 10.1056/NEJMp1607762
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863
   Monath TP, 2011, NEW ENGL J MED, V364, P1326, DOI 10.1056/NEJMoa1009303
   Monath TP, 2005, EXPERT REV VACCINES, V4, P553, DOI 10.1586/14760584.4.4.553
   Muthumani K, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.21
   NIH, 2017, PHAS 2 ZIK VACC TRIA
   Osorio JE, 2011, VACCINE, V29, P7251, DOI 10.1016/j.vaccine.2011.07.020
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Parashar D, 2014, BIOMED RES INT, V2014, P1
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Resnik DB, 2014, DEV WORLD BIOETH, V14, P37, DOI 10.1111/dewb.12011
   Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sahadeo NSD, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex010
   Schafer B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024505
   Sirivichayakul C, 2016, J INFECT DIS, V213, P1562, DOI 10.1093/infdis/jiv762
   Smalley C, 2016, VACCINE, V34, P2976, DOI 10.1016/j.vaccine.2016.03.076
   Smith SA, 2016, J VIROL, V90, P780, DOI 10.1128/JVI.01805-15
   Staples JE, 2009, CLIN INFECT DIS, V49, P942, DOI 10.1086/605496
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Stokes A, 2001, REV MED VIROL, V11, P141, DOI 10.1002/rmv.311
   Talceda, 2016, TAK DENG VACC CAND A
   Theiler M, 1937, J EXP MED, V65, P767, DOI 10.1084/jem.65.6.767
   Theiler M, 1937, J EXP MED, V65, P787, DOI 10.1084/jem.65.6.787
   Thomas RE, 2016, DRUG DES DEV THER, V10, P3345, DOI 10.2147/DDDT.S99600
   Vicente CR, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1668-y
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   WHO, 2017, DIS OUTBREAK NE 0208
   WHO, 2017, YELLOW FEVER
   WHO, 2017, DENG FEV
   World Health Organization, 2016, MON MAN INS RES AED
   World Health Organization [WHO], 2017, UPD QUEST ANSW REL D
   World Health Organization-WHO, 2017, CHIK
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
NR 83
TC 19
Z9 19
U1 4
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD JUN
PY 2018
VL 182
BP 257
EP 263
DI 10.1016/j.actatropica.2018.03.009
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA GD5BT
UT WOS:000430520700039
PM 29551394
DA 2020-11-24
ER

PT J
AU Pinheiro, TM
   Mota, MTD
   Watanabe, ASA
   Biselli-Perico, JM
   Drumond, BP
   Ribeiro, MR
   Vedovello, D
   Araujo, JP
   Pimenta, PFP
   Chaves, BA
   da Silva, MMC
   Batista, ICA
   Papa, MP
   Meuren, LM
   Lucas, CGD
   Matassoli, FL
   Gil, LHVG
   Bozzi, A
   Calzavara-Silva, CE
   de Arruda, LB
   de Souza, DD
   Teixeira, MM
   Vasilakis, N
   Nogueira, ML
AF Pinheiro, Tauyne Menegaldo
   de Oliveira Mota, Manlio Tasso
   Aranha Watanabe, Aripuana Sakurada
   Biselli-Perico, Joice Matos
   Drumond, Betania Paiva
   Ribeiro, Milene Rocha
   Vedovello, Danila
   Araujo, Joao Pessoa, Jr.
   Paolucci Pimenta, Paulo Filemon
   Chaves, Barbara Aparecida
   Carneiro da Silva, Mayara Marques
   Andrade Batista, Izabella Cristina
   Papa, Michelle Premazzi
   Meuren, Lana Monteiro
   de Oliveira Lucas, Carolina Goncalves
   Matassoli, Flavio Lemos
   Vega Gonzales Gil, Laura Helena
   Bozzi, Adriana
   Calzavara-Silva, Carlos Eduardo
   de Arruda, Luciana Barros
   de Souza, Danielle da Gloria
   Teixeira, Mauro Martins
   Vasilakis, Nikos
   Nogueira, Mauricio Lacerda
TI Viral immunogenicity determines epidemiological fitness in a cohort of
   DENV-1 infection in Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID DENGUE VIRUS; POPULATION-DYNAMICS; CO-CIRCULATION; IDENTIFICATION;
   REPLACEMENT; MOSQUITOS; SEVERITY; DISEASE; CLADE; FEVER
AB The dynamics of dengue virus (DENV) circulation depends on serotype, genotype and lineage replacement and turnover. In Sao Jose do Rio Preto, Brazil, we observed that the L6 lineage of DENV-1 (genotype V) remained the dominant circulating lineage even after the introduction of the L1 lineage. We investigated viral fitness and immunogenicity of the L1 and L6 lineages and which factors interfered with the dynamics of DENV epidemics. The results showed a more efficient replicative fitness of L1 over L6 in mosquitoes and in human and non-human primate cell lines. Infections by the L6 lineage were associated with reduced antigenicity, weak B and T cell stimulation and weak host immune system interactions, which were associated with higher viremia. Our data, therefore, demonstrate that reduced viral immunogenicity and consequent greater viremia determined the increased epidemiological fitness of DENV-1 L6 lineage in Sao Jose do Rio Preto.
C1 [Pinheiro, Tauyne Menegaldo; de Oliveira Mota, Manlio Tasso; Aranha Watanabe, Aripuana Sakurada; Biselli-Perico, Joice Matos; Ribeiro, Milene Rocha; Vedovello, Danila; Nogueira, Mauricio Lacerda] Fac Med Sao Jose do Rio Preto, Lab Pesquisa Virol, Dept Doencas Dermatol Infecciosas & Parasitarias, Sao Jose Do Rio Preto, SP, Brazil.
   [Drumond, Betania Paiva] Univ Fed Minas Gerais, Lab Virus, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Araujo, Joao Pessoa, Jr.] Univ Estadual Paulista Julio de Mesquita, Inst Biociencias, Lab Virol, Dept Microbiol & Imunol, Botucatu, SP, Brazil.
   [Paolucci Pimenta, Paulo Filemon; Chaves, Barbara Aparecida] Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Entomol Med, Belo Horizonte, MG, Brazil.
   [Chaves, Barbara Aparecida] Univ Estado Amazonas, Programa Posgrad Med Trop, Manaus, AM, Brazil.
   [Chaves, Barbara Aparecida] Fundacao Med Trop Dr Heitor Vieira Dourado FMT HV, Manaus, AM, Brazil.
   [Carneiro da Silva, Mayara Marques; Vega Gonzales Gil, Laura Helena] Fiocruz MS, Dept Virol, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   [Andrade Batista, Izabella Cristina; Bozzi, Adriana; Calzavara-Silva, Carlos Eduardo] Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
   [Papa, Michelle Premazzi; Meuren, Lana Monteiro; de Oliveira Lucas, Carolina Goncalves; Matassoli, Flavio Lemos; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Virol, Lab Genet & Imunol Infeccoes Virais, Rio De Janeiro, RJ, Brazil.
   [de Souza, Danielle da Gloria] Univ Fed Minas Gerais, Dept Microbiol, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Teixeira, Mauro Martins] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Inst Ciencias Biol, Lab Imunofarmacol, Belo Horizonte, MG, Brazil.
   [Vasilakis, Nikos] Univ Texas Med Branch, Ctr Trop Dis, Inst Human Infect & Immun, Dept Pathol,Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA.
   [Aranha Watanabe, Aripuana Sakurada] Univ Fed Juiz de Fora, Lab Virol, Dept Parasitol Microbiol & Imunol, Juiz De Fora, MG, Brazil.
   [Biselli-Perico, Joice Matos] Univ Estadual Paulista, Dept Biol, Inst Biociencias Letras & Ciencias Exatas, Sao Jose Do Rio Preto, SP, Brazil.
RP Nogueira, ML (corresponding author), Fac Med Sao Jose do Rio Preto, Lab Pesquisa Virol, Dept Doencas Dermatol Infecciosas & Parasitarias, Sao Jose Do Rio Preto, SP, Brazil.
EM mauriciolnogueira@gmail.com
RI Teixeira, Mauro M/A-4587-2008; Nogueira, Mauricio L/B-7599-2012;
   Biselli, Joice Matos/B-6913-2014; Vasilakis, Nikos/ABE-7318-2020; de
   Oliveira Mota, Manlio Tasso/E-2619-2013; Pimenta, Paulo/AAH-1502-2020;
   Araujo, Joao Pessoa/C-2444-2012; Bozzi, Adriana/M-6795-2013; Arruda,
   Luciana B/N-9086-2013; Bozzi, Adriana/ABE-3750-2020; Araujo,
   JP/Q-3043-2019; Vedovello, Danila/M-5757-2014
OI Teixeira, Mauro M/0000-0002-6944-3008; Nogueira, Mauricio
   L/0000-0003-1102-2419; Araujo, Joao Pessoa/0000-0002-9153-1485; Bozzi,
   Adriana/0000-0002-8242-5584; Araujo, JP/0000-0002-9153-1485; Matos
   Biselli, Joice/0000-0001-5105-9537; Chaves, Barbara/0000-0003-2079-6096;
   Vedovello, Danila/0000-0001-8585-8206; , Aripuana/0000-0003-0875-2269;
   CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/11733-6,
   2013/21719-3, 2015/22750-7]; INCT-Dengue/CNPq; NIH/NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01 AI115577]
FX Viral This work is funded by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), Grants # 2012/11733-6 and 2013/21719-3 to MLN and
   2015/22750-7 to TMP and by INCT-Dengue/CNPq. MLN and MMT are CNPq
   Fellows. NV is supported by a NIH/NIAID Grant # U01 AI115577. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abu Choudhury M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107264
   Azeredo EL, 2010, IMMUNOLOGY, V130, P202, DOI 10.1111/j.1365-2567.2009.03224.x
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bidet K, 2014, BIOCHEM J, V462, P215, DOI 10.1042/BJ20140456
   Bronzoni RVD, 2005, J CLIN MICROBIOL, V43, P696, DOI 10.1128/JCM.43.2.696-702.2005
   Chapman EG, 2014, SCIENCE, V344, P307, DOI 10.1126/science.1250897
   Chaturvedi UC, 2000, FEMS IMMUNOL MED MIC, V28, P183, DOI 10.1111/j.1574-695X.2000.tb01474.x
   Chen RB, 2011, VIRUSES-BASEL, V3, P1562, DOI 10.3390/v3091562
   Christenbury JG, 2010, J VIROL METHODS, V169, P202, DOI 10.1016/j.jviromet.2010.06.013
   Chutinimitkul S, 2005, J VIROL METHODS, V129, P8, DOI 10.1016/j.jviromet.2005.05.006
   Cologna R, 2005, J VIROL, V79, P853, DOI 10.1128/JVI.79.2.853-859.2005
   Cunha MD, 2016, INFECT GENET EVOL, V43, P130, DOI 10.1016/j.meegid.2016.05.021
   dos Santos FB, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-387
   Drummond A.J., 2002, BEAST BAYESIAN EVOLU
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drumond BP, 2012, ARCH VIROL, V157, P2061, DOI 10.1007/s00705-012-1393-9
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   Goncalves CM, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-320
   Goncalvez AP, 2002, VIROLOGY, V303, P110, DOI 10.1006/viro.2002.1686
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Ho LJ, 2005, J IMMUNOL, V174, P8163, DOI 10.4049/jimmunol.174.12.8163
   Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI 10.1016/S1567-1348(03)00004-2
   Horstick O, 2015, PATHOG GLOB HEALTH, V109, P19, DOI 10.1179/2047773215Y.0000000003
   Jain A, 2013, J CLIN IMMUNOL, V33, P613, DOI 10.1007/s10875-012-9855-0
   Katzelnick LC, 2016, P NATL ACAD SCI USA, V113, P728, DOI 10.1073/pnas.1522136113
   Lambeth CR, 2005, J CLIN MICROBIOL, V43, P3267, DOI 10.1128/JCM.43.7.3267-3272.2005
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Liu-Helmersson J, 2016, EBIOMEDICINE, V7, P267, DOI 10.1016/j.ebiom.2016.03.046
   Machado DC, 2012, INTERVIROLOGY, V55, P475, DOI 10.1159/000337166
   Manakkadan A, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-37
   Manokaran G, 2015, SCIENCE, V350, P217, DOI 10.1126/science.aab3369
   Mendez JA, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-226
   Messina JP, 2014, TRENDS MICROBIOL, V22, P138, DOI 10.1016/j.tim.2013.12.011
   OhAinle M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003084
   Quiner CA, 2014, J VIROL, V88, P13125, DOI 10.1128/JVI.01822-14
   Raghwani J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002064
   Rambaut A, 2002, TREEANOTATOR V1 8 1
   Rambaut A., 2003, TRACER MCMC TRACE AN
   Sariol CA, 2018, TRENDS MICROBIOL, V26, P186, DOI 10.1016/j.tim.2017.10.004
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Vedovello D, 2015, ARCH VIROL, V160, P1189, DOI 10.1007/s00705-015-2378-2
   Villabona-Arenas CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062649
   Wargo AR, 2012, CURR OPIN VIROL, V2, P538, DOI 10.1016/j.coviro.2012.07.007
   Zhang CL, 2005, J VIROL, V79, P15123, DOI 10.1128/JVI.79.24.15123-15130.2005
NR 44
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2018
VL 12
IS 5
AR e0006525
DI 10.1371/journal.pntd.0006525
PG 25
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA GH9WW
UT WOS:000434021900060
PM 29813061
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU de Oliveira, EF
   Lopes, KGS
   Cunha, DS
   Silva, VS
   Barbosa, CN
   Brandespim, DF
   Pinheiro, JW
   Bertani, GR
   Gil, LHVG
AF de Oliveira-Filho, Edmilson F.
   Lopes, Kennya G. S.
   Cunha, Deivson S.
   Silva, Virginia S.
   Barbosa, Clara N.
   Brandespim, Daniel F.
   Pinheiro Junior, Jose Wilton
   Bertani, Giovani R.
   Gil, Laura H. V. G.
TI Risk Analysis and Occurrence of Hepatitis E Virus (HEV) in Domestic
   Swine in Northeast Brazil
SO FOOD AND ENVIRONMENTAL VIROLOGY
LA English
DT Article
DE HEV; Brazil; Pig; Zoonosis
ID PHYLOGENETIC ANALYSIS; INFECTION; TRANSMISSION; ANTIBODIES; SUBTYPES;
   FRANCE; LIVER; WATER; PIGS; RNA
AB Anti-HEV antibodies were detected in animals from abattoir and in farms from northeast Brazil. Our results suggest that HEV is highly disseminated in the swine population and might present a great risk to animal handlers and for consumption of raw or undercooked meat and meat products in northeast Brazil.
C1 [de Oliveira-Filho, Edmilson F.; Lopes, Kennya G. S.; Gil, Laura H. V. G.] Oswaldo Cruz Fdn FIOCRUZ, Dept Virol, Aggeu Magalhaes Res Ctr, Ave Prof Moraes Rego S-N,Cidade Univ, BR-50670420 Recife, PE, Brazil.
   [Cunha, Deivson S.; Barbosa, Clara N.; Brandespim, Daniel F.; Pinheiro Junior, Jose Wilton] Univ Fed Rural Pernambuco UFRPE, Ave Prof Moraes Rego S-N, BR-50670420 Recife, PE, Brazil.
   [Silva, Virginia S.] Embrapa Suinos & Aves, BR 153,Km 110,Caixa Postal 21, BR-89700000 Concordia, SC, Brazil.
   [Bertani, Giovani R.] Univ Fed Pernambuco, Dept Biochem, Ave Prof Moraes Rego S-N, BR-50670420 Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Dept Virol, Aggeu Magalhaes Res Ctr, Ave Prof Moraes Rego S-N,Cidade Univ, BR-50670420 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Oliveira-Filho, Edmilson F/A-6305-2012
OI Oliveira-Filho, Edmilson F/0000-0002-3771-1565
FU FACEPE (Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco); CNPq
   (Brazilian Nacional Council for Scientific and Technological
   Development); CNPqNational Council for Scientific and Technological
   Development (CNPq); Coordination for the Improvement of Higher Education
   Personnel (CAPES)CAPES
FX EF Oliveira-Filho is suported by FACEPE (Fundacao de Amparo a Ciencia e
   Tecnologia de Pernambuco) and CNPq (Brazilian Nacional Council for
   Scientific and Technological Development). KGS Lopes was supported by a
   CNPq MSc scholarship and is currently recipient of a PhD scholarship
   from the Coordination for the Improvement of Higher Education Personnel
   (CAPES).
CR Arankalle VA, 2003, J MED VIROL, V69, P391, DOI 10.1002/jmv.10301
   Berto A, 2013, EMERG INFECT DIS, V19, P264, DOI 10.3201/eid1902.121255
   Chang YB, 2009, HEPATOL RES, V39, P1153, DOI 10.1111/j.1872-034X.2009.00558.x
   Cook N, 2015, FOOD ENVIRON VIROL, V7, P189, DOI 10.1007/s12560-015-9196-2
   Crossan C, 2012, EMERG INFECT DIS, V18, P2085, DOI 10.3201/eid1812.120924
   Di Bartolo I, 2011, VET MICROBIOL, V149, P330, DOI 10.1016/j.vetmic.2010.12.007
   Donia D, 2012, J VIROL METHODS, V186, P198, DOI 10.1016/j.jviromet.2012.06.007
   dos Santos D. L., 2013, J VET MED ANIMAL SCI, V20, P416
   Feagins AR, 2007, J GEN VIROL, V88, P912, DOI 10.1099/vir.0.82613-0
   Girones R, 2014, J WATER HEALTH, V12, P436, DOI 10.2166/wh.2014.027
   Guimaraes F. R., 2005, BRAZ J MICROBIOL, V36, P1517
   Guimaraes FR, 2005, BRAZ J MICROBIOL, V36, P223, DOI 10.1590/S1517-83822005000300004
   Heldt FH, 2016, FOOD ENVIRON VIROL, V8, P200, DOI 10.1007/s12560-016-9243-7
   Hosmer D. W., 1989, APPL LOGISTIC REGRES, P8
   Kaba M, 2009, J MED VIROL, V81, P1750, DOI 10.1002/jmv.21553
   Li TC, 2007, AM J TROP MED HYG, V76, P170, DOI 10.4269/ajtmh.2007.76.170
   dos Santos DRL, 2011, VET MICROBIOL, V149, P236, DOI 10.1016/j.vetmic.2010.10.024
   dos Santos DRL, 2010, J CLIN VIROL, V47, P276, DOI 10.1016/j.jcv.2009.12.021
   dos Santos DRL, 2009, VET J, V182, P474, DOI 10.1016/j.tvjl.2008.08.001
   Lorenzo FR, 2007, J MED VIROL, V79, P1128, DOI 10.1002/jmv.20905
   Matsuda H, 2003, J INFECT DIS, V188, P944, DOI 10.1086/378074
   Merino-Ramos T, 2016, FOOD ENVIRON VIROL, V8, P156, DOI 10.1007/s12560-016-9231-y
   Munne MS, 2006, J MED VIROL, V78, P1579, DOI 10.1002/jmv.20741
   Nantel-Fortier N, 2016, FOOD ENVIRON VIROL, V8, P296, DOI 10.1007/s12560-016-9252-6
   Oliveira EF, 2014, VET MICROBIOL, V174, P233, DOI 10.1016/j.vetmic.2014.09.011
   Passos-Castilho AM, 2016, BRAZ J INFECT DIS, V20, P262, DOI 10.1016/j.bjid.2016.03.001
   Pina S, 2000, J HEPATOL, V33, P826, DOI 10.1016/S0168-8278(00)80316-5
   Smith DB, 2016, J GEN VIROL, V97, P537, DOI 10.1099/jgv.0.000393
   de Souza AJS, 2012, COMP IMMUNOL MICROB, V35, P477, DOI 10.1016/j.cimid.2012.04.004
   Tanaka H, 2004, XENOTRANSPLANTATION, V11, P503, DOI 10.1111/j.1399-3089.2004.00170.x
   Tei S, 2003, LANCET, V362, P371, DOI 10.1016/S0140-6736(03)14025-1
   Thiry D, 2017, TRANSBOUND EMERG DIS, V64, P37, DOI 10.1111/tbed.12351
   Vitral CL, 2005, MEM I OSWALDO CRUZ, V100, P117, DOI 10.1590/S0074-02762005000200003
NR 33
TC 3
Z9 3
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1867-0334
EI 1867-0342
J9 FOOD ENVIRON VIROL
JI Food Environ. Virol.
PD SEP
PY 2017
VL 9
IS 3
BP 256
EP 259
DI 10.1007/s12560-017-9292-6
PG 4
WC Environmental Sciences; Microbiology; Virology
SC Environmental Sciences & Ecology; Microbiology; Virology
GA FD2PW
UT WOS:000407378300002
PM 28349492
DA 2020-11-24
ER

PT J
AU Vidotto, A
   Morais, ATS
   Ribeiro, MR
   Pacca, CC
   Terzian, ACB
   Gil, LHVG
   Mohana-Borges, R
   Gallay, P
   Nogueira, ML
AF Vidotto, Alessandra
   Morais, Ana T. S.
   Ribeiro, Milene R.
   Pacca, Carolina C.
   Terzian, Ana C. B.
   Gil, Laura H. V. G.
   Mohana-Borges, Ronaldo
   Gallay, Philippe
   Nogueira, Mauricio L.
TI Systems Biology Reveals NS4B-Cyclophilin A Interaction: A New Target to
   Inhibit YFV Replication
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE yellow fever virus; NS4B; proteomics; protein interactions; systems
   biology; cyclophilin A; cyclosporine A; sirolimus
ID HEPATITIS-C VIRUS; YELLOW-FEVER VIRUS; QUANTITATIVE PROTEOMIC ANALYSIS;
   NONSTRUCTURAL PROTEINS NS1; DENGUE VIRUS; HOST PROTEINS; NS4B PROTEIN;
   RNA-BINDING; IN-VITRO; NUCLEOTIDE-SEQUENCE
AB Yellow fever virus (YFV) replication is highly dependent on host cell factors. YFV NS4B is reported to be involved in viral replication and immune evasion. Here interactions between NS4B and human proteins were determined using a GST pull-down assay and analyzed using 1-DE and LC-MS/MS. We present a total of 207 proteins confirmed using Scaffold 3 Software. Cyclophilin A (CypA), a protein that has been shown to be necessary for the positive regulation of flavivirus replication, was identified as a possible NS4B partner. 59 proteins were found to be significantly increased when compared with a negative control, and CypA exhibited the greatest difference, with a 22-fold change. Fisher's exact test was significant for 58 proteins, and the p value of CypA was the most significant (0.000000019). The Ingenuity Systems software identified 16 pathways, and this analysis indicated sirolimus, an mTOR pathway inhibitor, as a potential inhibitor of CypA. Immunofluorescence and viral plaque assays showed a significant reduction in YFV replication using sirolimus and cyclosporine A (CsA) as inhibitors. Furthermore, YFV replication was strongly inhibited in treated with both inhibitors using reporter BHK-21-rep-YFV17DLucNeolres cells. Taken together, these data suggest that CypA-NS4B interaction regulates YFV replication. Finally, we present the first evidence that YFV inhibition may depend on NS4B-CypA interaction.
C1 [Vidotto, Alessandra; Morais, Ana T. S.; Ribeiro, Milene R.; Pacca, Carolina C.; Terzian, Ana C. B.; Nogueira, Mauricio L.] Fac Med Jose do Rio Preto, Lab Virol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
   [Gil, Laura H. V. G.] Fundacao Oswaldo Cruz FIOCRUZ, Dept Virol, Ctr Pesquisa Aggeu Magalhaes, BR-50740465 Recife, PE, Brazil.
   [Mohana-Borges, Ronaldo] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Genom Estrutural, BR-21941902 Rio de Janeiro, RJ, Brazil.
   [Gallay, Philippe] Scripps Res Inst La Jolla, Dept Immunol & Microbial Sci, San Diego, CA 92037 USA.
RP Nogueira, ML (corresponding author), Fac Med Jose do Rio Preto, Lab Virol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM mnogueira@famerp.br
RI Borges, Ronaldo S Mohana/C-5575-2013; Nogueira, Mauricio L/B-7599-2012
OI Nogueira, Mauricio L/0000-0003-1102-2419
FU Fundacao de Amparo a Pesquisa do Estado de sao Paulo, or FAPESP
   [2010/05043-1, 2009/01400-7]; Conselho Nacional de Pesquisa, or CNPq
   [566289/2008-3]; CNPq fellowshipNational Council for Scientific and
   Technological Development (CNPq); Rede Proteoma do Estado de sao Paulo;
   Financiadora de Estudes e Projetos, or FINEP [2004/14846-0,
   01.07.0290.00]; Coordenagao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)
FX We thank the Mass Spectrometry at Brazilian Biosciences National
   Laboratory (LNBio), CNPEM, Campinas, sao Paulo, Brazil for their support
   with the use of NanoAcquity Ultra Performance LC coupled with
   nanoelectrospray source on a Q-TOF Ultima mass spectrometer (Waters
   Corporation, Milford, MA). This work was supported by Grants from the
   Fundacao de Amparo a Pesquisa do Estado de sao Paulo, or FAPESP (no.
   2010/05043-1 and no. 2009/01400-7 to M.L.N.), and by Conselho Nacional
   de Pesquisa, or CNPq (no. 566289/2008-3 to M.L.N.). M.L.N. is supported
   by a CNPq fellowship. We also thank FAPESP, the Rede Proteoma do Estado
   de sao Paulo, the Financiadora de Estudes e Projetos, or FINEP (FAPESP
   grant number 2004/14846-0 and FINEP grant number 01.07.0290.00), and the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) for
   the financial support and fellowships.
CR Abraham R, 2015, J PROTEOMICS, V120, P126, DOI 10.1016/j.jprot.2015.03.007
   Albarnaz JD, 2014, ANTIVIR RES, V111, P82, DOI 10.1016/j.antiviral.2014.09.004
   Albuquerque LM, 2009, J PROTEOME RES, V8, P5431, DOI 10.1021/pr900236f
   Allaya N, 2015, TUMOR BIOL, V36, P3807, DOI 10.1007/s13277-014-3022-6
   Ambagala AP, 2009, J VIROL, V83, P200, DOI 10.1128/JVI.00645-08
   [Anonymous], 2016, PROTEIN
   [Anonymous], 2016, GENE
   [Anonymous], 2016, UNIPROT
   Antrobus R, 2009, PROTEOMICS, V9, P3913, DOI 10.1002/pmic.200900207
   Ashford P, 2016, MOL CELL PROTEOMICS, V15, P2939, DOI 10.1074/mcp.M116.058552
   Barrero CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068376
   Bassett JD, 2012, MOL THER, V20, P860, DOI 10.1038/mt.2011.281
   BEAUD G, 1994, J GEN VIROL, V75, P283, DOI 10.1099/0022-1317-75-2-283
   Blazquez AB, 2014, FRONT MICROBIOL, V5, DOI [10.3389/fmicb.2014.00266, 10.3389/fmicb.2014.00797]
   Bobardt M, 2013, J HEPATOL, V58, P16, DOI 10.1016/j.jhep.2012.08.007
   Bosco DA, 2010, J MOL BIOL, V403, P723, DOI 10.1016/j.jmb.2010.08.001
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brown RE, 2012, ANN CLIN LAB SCI, V42, P243
   Burgener A, 2008, J PROTEOME RES, V7, P4446, DOI 10.1021/pr800406r
   Byron A., 2011, SCI SIGNALING 2, V4
   Byron A, 2012, PROTEOMICS, V12, P2107, DOI 10.1002/pmic.201100487
   Cao WP, 2008, NAT IMMUNOL, V9, P1157, DOI 10.1038/ni.1645
   Carpp LN, 2014, MOL CELL PROTEOMICS, V13, P2836, DOI 10.1074/mcp.M114.038984
   Caruso MB, 2017, J PROTEOMICS, V151, P106, DOI 10.1016/j.jprot.2016.07.011
   Castello A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000562
   Chai F, 2015, BBA-PROTEINS PROTEOM, V1854, P967, DOI 10.1016/j.bbapap.2015.04.016
   Chatterji U, 2015, ANTIMICROB AGENTS CH, V59, P2496, DOI 10.1128/AAC.04958-14
   Chatterji U, 2010, J HEPATOL, V53, P50, DOI 10.1016/j.jhep.2010.01.041
   Chatterji U, 2010, J GEN VIROL, V91, P1189, DOI 10.1099/vir.0.018531-0
   Chen SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027551
   Chen Z, 2010, IMMUNOL LETT, V131, P11, DOI 10.1016/j.imlet.2010.04.003
   Cheng S, 2012, J PROTEOMICS, V75, P3258, DOI 10.1016/j.jprot.2012.03.039
   Chiu HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093305
   Ciborowski P, 2007, VIROLOGY, V363, P198, DOI 10.1016/j.virol.2007.01.013
   Coombs KM, 2010, J VIROL, V84, P10888, DOI 10.1128/JVI.00431-10
   Courtney SC, 2012, J VIROL, V86, P3647, DOI 10.1128/JVI.06549-11
   De Iaco A, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-11
   Munoz MD, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/875958
   Deighton RF, 2010, PROTEOMICS, V10, P1307, DOI 10.1002/pmic.200900112
   Dhanwani R, 2011, PROTEOMICS, V11, P1936, DOI 10.1002/pmic.201000500
   Ding XM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156017
   Doolittle JM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000954
   DOSSANTOS CND, 1995, VIRUS RES, V35, P35
   Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002
   Einav S, 2008, NAT BIOTECHNOL, V26, P1019, DOI 10.1038/nbt.1490
   Emmott E, 2010, J PROTEOME RES, V9, P5335, DOI 10.1021/pr100593g
   Eng JK, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.R111.009522
   Evans JD, 2007, J VIROL, V81, P11809, DOI 10.1128/JVI.00791-07
   Fania C, 2009, ELECTROPHORESIS, V30, P2193, DOI 10.1002/elps.200800800
   Felciano Ramon M, 2013, Pac Symp Biocomput, P17
   Fonseca B.A.L., 2005, TRATADO INFECTOLOGIA, P343
   Foster TL, 2011, J VIROL, V85, P7460, DOI 10.1128/JVI.00393-11
   Fragnoud R, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1271-7
   Friedrich S, 2014, J VIROL, V88, P11586, DOI 10.1128/JVI.01283-14
   Gagne JP, 2008, NUCLEIC ACIDS RES, V36, P6959, DOI 10.1093/nar/gkn771
   Gerold G, 2015, CELL REP, V12, P864, DOI 10.1016/j.celrep.2015.06.063
   Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X
   Gregan J, 2007, NAT PROTOC, V2, P1145, DOI 10.1038/nprot.2007.172
   Gretton SN, 2005, J GEN VIROL, V86, P1415, DOI 10.1099/vir.0.80768-0
   Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015
   Hojlund K, 2009, J PROTEOME RES, V8, P4954, DOI 10.1021/pr9007267
   Holmes B, 2016, J BIOL CHEM, V291, P14146, DOI 10.1074/jbc.M116.726927
   Hopkins S, 2012, ANTIMICROB AGENTS CH, V56, P3888, DOI 10.1128/AAC.00693-12
   Hoque M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-90
   Humphries JD, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000396
   Ikezoe T, 2007, LEUKEMIA RES, V31, P673, DOI 10.1016/j.leukres.2006.08.001
   Ingenuity, 2016, INGENUITY
   Issac THK, 2014, J PROTEOMICS, V108, P445, DOI 10.1016/j.jprot.2014.06.003
   Ji WT, 2009, J GEN VIROL, V90, P3002, DOI 10.1099/vir.0.013953-0
   Ji WT, 2009, BIOCHEM BIOPH RES CO, V384, P301, DOI 10.1016/j.bbrc.2009.04.116
   Kadam SD, 2012, ARCH DERMATOL RES, V304, P229, DOI 10.1007/s00403-012-1210-z
   Kalia M, 2013, J VIROL, V87, P148, DOI 10.1128/JVI.01399-12
   Kang SM, 2005, PROTEOMICS, V5, P2227, DOI 10.1002/pmic.200401093
   Karsani SA, 2014, PROTEOME SCI, V12, DOI 10.1186/1477-5956-12-3
   Keshamouni VG, 2009, J PROTEOME RES, V8, P35, DOI 10.1021/pr8006478
   Keyes LR, 2012, J GEN VIROL, V93, P722, DOI 10.1099/vir.0.037309-0
   Kozak SL, 2006, J BIOL CHEM, V281, P29105, DOI 10.1074/jbc.M601901200
   Kroeker AL, 2012, J PROTEOME RES, V11, P4132, DOI 10.1021/pr300239r
   Kudchodkar SB, 2004, J VIROL, V78, P11030, DOI 10.1128/JVI.78.20.11030-11039.2004
   Labudova M, 2009, J VIROL, V83, P7842, DOI 10.1128/JVI.00309-09
   Lahaye X, 2016, CELL REP, V15, P879, DOI 10.1016/j.celrep.2016.03.074
   Lam YW, 2010, MOL CELL PROTEOMICS, V9, P117, DOI 10.1074/mcp.M900338-MCP200
   Lee N, 2012, RNA, V18, P2073, DOI 10.1261/rna.034900.112
   Lee RCH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002050
   Li F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021977
   Li YJ, 2012, AM J TRANSPLANT, V12, P2348, DOI 10.1111/j.1600-6143.2012.04116.x
   Li ZJ, 2011, ACTA PHARMACOL SIN, V32, P1116, DOI 10.1038/aps.2011.86
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Lietzen N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001340
   Lim PJ, 2012, J BIOL CHEM, V287, P30861, DOI 10.1074/jbc.M112.376822
   Lin AE, 2013, MOL CELL PROTEOMICS, V12, P3237, DOI 10.1074/mcp.M113.030866
   Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999
   Liu C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10714
   Liu JF, 2011, J NEUROIMMUNE PHARM, V6, P308, DOI 10.1007/s11481-011-9265-8
   Liu JO, 2009, IMMUNOL REV, V228, P184, DOI 10.1111/j.1600-065X.2008.00756.x
   Liu L, 2006, ONCOGENE, V25, P7029, DOI 10.1038/sj.onc.1209691
   Liu Q, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/278652
   Liu XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037277
   Liu XY, 2008, PROTEOMICS, V8, P582, DOI 10.1002/pmic.200700514
   Lloyd RE, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002741
   Lu MM, 2015, P NATL ACAD SCI USA, V112, P14617, DOI 10.1073/pnas.1516920112
   Lund N, 2012, NUCLEIC ACIDS RES, V40, P3663, DOI 10.1093/nar/gkr1238
   Madan V, 2014, GASTROENTEROLOGY, V146, P1361, DOI 10.1053/j.gastro.2014.01.055
   Mairiang D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053535
   Martin-Liberal J, 2014, BRIT J CANCER, V111, P858, DOI 10.1038/bjc.2014.370
   McNulty S, 2013, J VIROL, V87, P912, DOI 10.1128/JVI.02415-12
   Mohankumar V, 2011, BIOCHEM BIOPH RES CO, V406, P262, DOI 10.1016/j.bbrc.2011.02.030
   Munday DC, 2010, MOL CELL PROTEOMICS, V9, P2438, DOI 10.1074/mcp.M110.001859
   Munoz-Jordan JL, 2005, J VIROL, V79, P8004, DOI 10.1128/JVI.79.13.8004-8013.2005
   Munoz-Jordan JL, 2010, CURR TOP MICROBIOL, V338, P35, DOI 10.1007/978-3-642-02215-9_3
   Muraoka T, 2012, MOL MED REP, V5, P331, DOI 10.3892/mmr.2011.662
   Nag A, 2012, J VIROL, V86, P12616, DOI 10.1128/JVI.01351-12
   Ngwa Julius S, 2011, BMC Proc, V5 Suppl 9, pS18, DOI 10.1186/1753-6561-5-S9-S18
   Nichols LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014535
   Pacca C, 2009, VIRUS GENES, V38, P224, DOI 10.1007/s11262-009-0328-3
   Paek KY, 2008, J VIROL, V82, P12082, DOI 10.1128/JVI.01405-08
   Paingankar MS, 2010, ARCH VIROL, V155, P1453, DOI 10.1007/s00705-010-0728-7
   Pando-Robles V, 2014, J PROTEOMICS, V111, P16, DOI 10.1016/j.jprot.2014.06.029
   Pang XD, 2011, EUR J MED CHEM, V46, P1701, DOI 10.1016/j.ejmech.2011.02.023
   Park JS, 2000, BIOCHEM BIOPH RES CO, V267, P581, DOI 10.1006/bbrc.1999.1999
   Pastorino B, 2010, ANTIVIR RES, V87, P281, DOI 10.1016/j.antiviral.2010.04.014
   Paudel N, 2012, J VIROL, V86, P1589, DOI 10.1128/JVI.05754-11
   Peng H, 2010, P NATL ACAD SCI USA, V107, P2461, DOI 10.1073/pnas.0911128107
   Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200
   Pike L, 2006, J GENE MED, V8, P804, DOI 10.1002/jgm.909
   Poenisch M, 2010, SEMIN LIVER DIS, V30, P333, DOI 10.1055/s-0030-1267535
   Qing J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004422
   Qing M, 2009, ANTIMICROB AGENTS CH, V53, P3226, DOI 10.1128/AAC.00189-09
   Queiroz SRA, 2013, AN ACAD BRAS CIENC, V85, P159, DOI 10.1590/S0001-37652013005000008
   Rehman S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030071
   RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707
   Roland K, 2013, AQUAT TOXICOL, V128, P43, DOI 10.1016/j.aquatox.2012.10.016
   Rosnoblet C, 2012, J BIOL CHEM, V287, P44249, DOI 10.1074/jbc.M112.392209
   Ross-Thriepland D, 2013, J GEN VIROL, V94, P1009, DOI 10.1099/vir.0.050633-0
   Satoh JI, 2009, MULT SCLER J, V15, P531, DOI 10.1177/1352458508101943
   Saxena V, 2012, J VIROL, V86, P4139, DOI 10.1128/JVI.06327-11
   Shah VB, 2013, J VIROL, V87, P422, DOI 10.1128/JVI.07177-11
   Shih YT, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-214
   Shoemaker JE, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-117
   Silvestri E, 2010, MOL BIOSYST, V6, P2256, DOI 10.1039/c0mb00040j
   Sin SH, 2007, BLOOD, V109, P2165, DOI 10.1182/blood-2006-06-028092
   Soderholm S, 2016, MOL CELL PROTEOMICS, V15, P3203, DOI 10.1074/mcp.M116.057984
   Solbak SM, 2010, BMC STRUCT BIOL, V10, DOI 10.1186/1472-6807-10-31
   Solbak SMO, 2012, BBA-PROTEINS PROTEOM, V1824, P667, DOI 10.1016/j.bbapap.2012.02.002
   Solbak SMO, 2011, BMC STRUCT BIOL, V11, DOI 10.1186/1472-6807-11-49
   Spoden G, 2013, J VIROL, V87, P7765, DOI 10.1128/JVI.00370-13
   Stelzer MK, 2010, CANCER PREV RES, V3, P1542, DOI 10.1158/1940-6207.CAPR-10-0228
   Tawaratsumida K, 2014, J VIROL, V88, P9038, DOI 10.1128/JVI.00830-14
   Tian YS, 2013, J MOL MODEL, V19, P465, DOI 10.1007/s00894-012-1560-7
   Tong AP, 2008, PROTEOMICS, V8, P2012, DOI 10.1002/pmic.200700849
   Tong WY, 2002, BIOCHEM BIOPH RES CO, V299, P366, DOI 10.1016/S0006-291X(02)02638-4
   Trinh Hung V, 2013, Int J Proteomics, V2013, P581862, DOI 10.1155/2013/581862
   Umareddy I, 2006, J GEN VIROL, V87, P2605, DOI 10.1099/vir.0.81844-0
   Vanheel A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035544
   Veillette M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-25
   Verdegem D, 2011, J BIOL CHEM, V286, P20441, DOI 10.1074/jbc.M110.182436
   Vester D, 2009, PROTEOMICS, V9, P3316, DOI 10.1002/pmic.200800893
   von Hahn T, 2012, GASTROENTEROLOGY, V143, P439, DOI 10.1053/j.gastro.2012.04.053
   Wagner D, 2010, INT IMMUNOPHARMACOL, V10, P990, DOI 10.1016/j.intimp.2010.05.006
   Wang S, 2013, GENE, V512, P89, DOI 10.1016/j.gene.2012.10.006
   Wang XJ, 2012, J PROTEOMICS, V75, P1411, DOI 10.1016/j.jprot.2011.11.011
   Wang YD, 2015, INT J CLIN EXP MED, V8, P10723
   Welsch C, 2007, J MOL GRAPH MODEL, V26, P546, DOI 10.1016/j.jmgm.2007.03.012
   Weng LY, 2012, BBA-GEN SUBJECTS, V1820, P1886, DOI 10.1016/j.bbagen.2012.08.017
   Wikan N, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-96
   Woodham AW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043519
   Wright C, 2009, ANN RHEUM DIS, V68, P1626, DOI 10.1136/ard.2008.097204
   Wu JH, 2005, J VIROL, V79, P10268, DOI 10.1128/JVI.79.16.10268-10277.2005
   Xie XP, 2011, J VIROL, V85, P11183, DOI 10.1128/JVI.05468-11
   Yang F, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001118
   Yang S, 2015, J MED CHEM, V58, P9546, DOI 10.1021/acs.jmedchem.5b01064
   Zhao DM, 2012, PROTEOMICS, V12, P1970, DOI 10.1002/pmic.201100619
NR 172
TC 6
Z9 6
U1 1
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD APR
PY 2017
VL 16
IS 4
BP 1542
EP 1555
DI 10.1021/acs.jproteome.6b00933
PG 14
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA ER7IO
UT WOS:000398985700016
PM 28317380
DA 2020-11-24
ER

PT J
AU Oliveira, RAD
   Cordeiro, MT
   de Moura, PMMF
   Baptista, PNB
   Braga-Neto, UD
   Marques, ETD
   Gil, LHVG
AF dos Santos Oliveira, Renato Antonio
   Cordeiro, Marli Tenorio
   Mendes Freire de Moura, Patricia Muniz
   Bapti Baptista Filho, Paulo Neves
   Braga-Neto, Ulisses de Mendonca
   de Azevedo Marques Junior, Ernesto Torres
   Vega Gonzales Gil, Laura Helena
TI Serum cytokine/chemokine profiles in patients with dengue fever (DF) and
   dengue hemorrhagic fever (FHD) by using protein array
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Dengue fever; Dengue hemorrhagic fever; Cytokines protein array;
   Prognostic marker
ID CD40 LIGAND; GRO-ALPHA; CHEMOKINES; PATHOGENESIS; EXPRESSION; INFECTION;
   CYTOKINE; RESPONSES; COHORT
AB Background: DENV infection can induce different clinical manifestations varying from mild forms to dengue fever (DF) or the severe hemorrhagic fever (DHF). Several factors are involved in the progression from DF to DHF. No marker is available to predict this progression. Such biomarker could allow a suitable medical care at the beginning of the infection, improving patient prognosis.
   Objectives: The aim of this study was to compare the serum expression levels of acute phase proteins in a well-established cohort of dengue fever (DF) and dengue hemorrhagic fever (DHF) patients, in order to individuate a prognostic marker of diseases severity.
   Study design: The serum levels of 36 cytokines, chemokines and acute phase proteins were determined in DF and DHF patients and compared to healthy volunteers using a multiplex protein array and near infrared (NIR) fluorescence detection. Serum levels of IL-lra, IL-23, MIF, sCD40 ligand, IP-10 and GRO-alpha were also determined by ELISA.
   Results: At the early stages of infection, GRO-alpha and IP-10 expression levels were different in DF compared to DHF patients. Besides, GRO-a was positively correlated with platelet counts and IP-10 was negatively correlated with total protein levels.
   Conclusions: These findings suggest that high levels of GRO-alpha during acute DENV infection may be associated with a good prognosis, while high levels of IP-10 may be a warning sign of infection severity. (C) 2017 Elsevier B.V. All rights reserved.
C1 [dos Santos Oliveira, Renato Antonio; Cordeiro, Marli Tenorio; de Azevedo Marques Junior, Ernesto Torres; Vega Gonzales Gil, Laura Helena] Fundacao Oswaldo Cruz Fiocruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
   [Mendes Freire de Moura, Patricia Muniz; Braga-Neto, Ulisses de Mendonca] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX 77843 USA.
   [de Azevedo Marques Junior, Ernesto Torres] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Mendes Freire de Moura, Patricia Muniz] Univ Pernambuco, Inst Ciencias Biol, Recife, PE, Brazil.
   [Bapti Baptista Filho, Paulo Neves] Univ Pernambuco, Fac Ciencias Med, Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Ctr Pesquisas Aggeu Magalhaes CPqAM, Ave Prof Moraes Rego S-N Campus UFPE Cidade Univ, BR-50740465 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Oliveira, Renato/AAN-9879-2020;
   Oliveira, Renato/A-2863-2013; Oliveira, Renato/AAN-9394-2020
OI Marques, Ernesto T. A/0000-0003-3826-9358; Oliveira,
   Renato/0000-0002-4044-0794; Oliveira, Renato/0000-0002-4044-0794; Moura,
   Patricia/0000-0003-4259-388X
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [CNPq404453/2012-0]
FX This work was supported by the Brazilian Council for Scientific and
   Technological Development (CNPq) [Grant number CNPq404453/2012-0].
CR Aloui C, 2014, INT J MOL SCI, V15, P22342, DOI 10.3390/ijms151222342
   Amaral DCG, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-23
   Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01
   Back A.T., 2013, INFECT ECOL EPIDEMIO, V3
   Bakaysa SL, 2014, MOL HUM REPROD, V20, P701, DOI 10.1093/molehr/gau028
   Bellinato DF, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8603263
   Boehlen F, 2001, TRANSFUSION MED, V11, P403, DOI 10.1046/j.1365-3148.2001.00340.x
   Bowman LR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004551
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Chintakuntlawar AV, 2009, J INTERF CYTOK RES, V29, P657, DOI 10.1089/jir.2009.0006
   Conroy AL, 2015, INT J INFECT DIS, V40, P45, DOI 10.1016/j.ijid.2015.07.027
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Danese S, 2003, GUT, V52, P1435, DOI 10.1136/gut.52.10.1435
   Fares RCG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321873
   Freedman JE, 2003, CIRC RES, V92, P944, DOI 10.1161/01.RES.0000074030.98009.FF
   Gleissner CA, 2012, CURR VASC PHARMACOL, V10, P563
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Johansson S, 2015, ALIMENT PHARM THER, V42, P1111, DOI 10.1111/apt.13389
   Kumar Y, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001887
   Kurane I, 2007, COMP IMMUNOL MICROB, V30, P329, DOI 10.1016/j.cimid.2007.05.010
   Liu ML, 2011, CYTOKINE GROWTH F R, V22, P121, DOI 10.1016/j.cytogfr.2011.06.001
   Malavige GN, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-341
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Moreno-Altamirano MMB, 2004, SCAND J IMMUNOL, V60, P631, DOI 10.1111/j.0300-9475.2004.01519.x
   Nischalke HD, 2012, J HEPATOL, V56, P758, DOI 10.1016/j.jhep.2011.10.019
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Persson-Dajotoy T, 2003, J IMMUNOL, V170, P5309, DOI 10.4049/jimmunol.170.10.5309
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Saito M, 2004, CLIN EXP IMMUNOL, V138, P299, DOI 10.1111/j.1365-2249.2004.02626.x
   Samanta J, 2015, WORLD J CLIN CASES, V3, P125, DOI 10.12998/wjcc.v3.i2.125
   Sanz MJ, 2012, EUR J IMMUNOL, V42, P278, DOI 10.1002/eji.201142231
   Souza L.J., 2004, BRAZ J INFECT DIS, V8, P150
   Stanaway J.D., 2016, LANCET INFECT DIS
   Sun PF, 2006, J IMMUNOL, V177, P6497, DOI 10.4049/jimmunol.177.9.6497
   Tseng YL, 2010, CYTOKINE, V51, P195, DOI 10.1016/j.cyto.2010.05.002
   Whitehorn J, 2011, VACCINE, V29, P7221, DOI 10.1016/j.vaccine.2011.07.022
   Ferreira RAX, 2015, ACTA TROP, V149, P138, DOI 10.1016/j.actatropica.2015.04.023
   Yamashita K, 2005, INFLAMMATION, V29, P17, DOI 10.1007/s10753-006-8964-4
   Zhao LZ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1596-x
NR 41
TC 9
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD APR
PY 2017
VL 89
BP 39
EP 45
DI 10.1016/j.jcv.2017.02.007
PG 7
WC Virology
SC Virology
GA EO6FW
UT WOS:000396788400009
PM 28242509
DA 2020-11-24
ER

PT J
AU Xavier-Neto, J
   Carvalho, M
   Pascoalino, BD
   Cardoso, AC
   Costa, AMS
   Pereira, AHM
   Santos, LN
   Saito, A
   Marques, RE
   Smetana, JHC
   Consonni, SR
   Bandeira, C
   Costa, VV
   Bajgelman, MC
   de Oliveira, PSL
   Cordeiro, MT
   Gil, LHVG
   Pauletti, BA
   Granato, DC
   Leme, AFP
   Freitas, L
   de Freitas, CBMH
   Teixeira, MM
   Bevilacqua, E
   Franchini, K
AF Xavier-Neto, Jose
   Carvalho, Murilo
   Pascoalino, Bruno dos Santos
   Cardoso, Alisson Campos
   Sousa Costa, Angela Maria
   Macedo Pereira, Ana Helena
   Santos, Luana Nunes
   Saito, Angela
   Marques, Rafael Elias
   Costa Smetana, Juliana Helena
   Consonni, Silvio Roberto
   Bandeira, Carla
   Costa, Vivian Vasconcelos
   Bajgelman, Marcio Chaim
   Lopes de Oliveira, Paulo Sergio
   Cordeiro, Marli Tenorio
   Vega Gonzales Gil, Laura Helena
   Pauletti, Bianca Alves
   Granato, Daniela Campos
   Paes Leme, Adriana Franco
   Freitas-Junior, Lucio
   Moraes Holanda de Freitas, Carolina Borsoi
   Teixeira, Mauro Martins
   Bevilacqua, Estela
   Franchini, Kleber
TI Hydrocephalus and arthrogryposis in an immunocompetent mouse model of
   ZIKA teratogeny: A developmental study
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM;
   VIRUS-INFECTION; MICE; EXPRESSION; INTERFACE; PREGNANCY; PLACENTA;
   BRAZIL; DAMAGE
AB The teratogenic mechanisms triggered by ZIKV are still obscure due to the lack of a suitable animal model. Here we present a mouse model of developmental disruption induced by ZIKV hematogenic infection. The model utilizes immunocompetent animals from wild-type FVB/NJ and C57BL/6J strains, providing a better analogy to the human condition than approaches involving immunodeficient, genetically modified animals, or direct ZIKV injection into the brain. When injected via the jugular vein into the blood of pregnant females harboring conceptuses from early gastrulation to organogenesis stages, akin to the human second and fifth week of pregnancy, ZIKV infects maternal tissues, placentas and embryos/fetuses. Early exposure to ZIKV at developmental day 5 (second week in humans) produced complex manifestations of anterior and posterior dysraphia and hydrocephalus, as well as severe malformations and delayed development in 10.5 days post-coitum (dpc) embryos. Exposure to the virus at 7.5-9.5 dpc induces intra-amniotic hemorrhage, widespread edema, and vascular rarefaction, often prominent in the cephalic region. At these stages, most affected embryos/fetuses displayed gross malformations and/or intrauterine growth restriction (IUGR), rather than isolated microcephaly. Disrupted conceptuses failed to achieve normal developmental landmarks and died in utero. Importantly, this is the only model so far to display dysraphia and hydrocephalus, the harbinger of microcephaly in humans, as well as arthrogryposis, a set of abnormal joint postures observed in the human setting. Late exposure to ZIKV at 12.5 dpc failed to produce noticeable malformations. We have thus characterized a developmental window of opportunity for ZIKV-induced teratogenesis encompassing early gastrulation, neurulation and early organogenesis stages. This should not, however, be interpreted as evidence for any safe developmental windows for ZIKV exposure. Late developmental abnormalities correlated with damage to the placenta, particularly to the labyrinthine layer, suggesting that circulatory changes are integral to the altered phenotypes.
C1 [Xavier-Neto, Jose; Carvalho, Murilo; Pascoalino, Bruno dos Santos; Cardoso, Alisson Campos; Sousa Costa, Angela Maria; Macedo Pereira, Ana Helena; Santos, Luana Nunes; Saito, Angela; Marques, Rafael Elias; Costa Smetana, Juliana Helena; Consonni, Silvio Roberto; Bajgelman, Marcio Chaim; Lopes de Oliveira, Paulo Sergio; Pauletti, Bianca Alves; Granato, Daniela Campos; Paes Leme, Adriana Franco; Freitas-Junior, Lucio; Moraes Holanda de Freitas, Carolina Borsoi; Franchini, Kleber] Brazilian Biosci Natl Lab, LNBio, Rua Giuseppe Maximo Scolfaro 10-000, Campinas, SP, Brazil.
   [Santos, Luana Nunes; Bandeira, Carla; Bevilacqua, Estela] Univ Sao Paulo, Dept Cell & Dev Biol, Inst Biomed Sci, Sao Paulo, SP, Brazil.
   [Costa, Vivian Vasconcelos; Teixeira, Mauro Martins] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Inst Ciencias Biol, Lab Imunofarmacol, Ave Antonio Carlos 6627, Belo Horizonte, MG, Brazil.
   [Cordeiro, Marli Tenorio; Vega Gonzales Gil, Laura Helena] Univ Fed Pernambuco, FIOCRUZ, CPqAM, Ave Prof Moraes Rego S-N,Cidade Univ, Recife, PE, Brazil.
RP Xavier-Neto, J; Franchini, K (corresponding author), Brazilian Biosci Natl Lab, LNBio, Rua Giuseppe Maximo Scolfaro 10-000, Campinas, SP, Brazil.
EM xavier.neto@lnbio.cnpem.br; kleber.franchini@lnbio.cnpem.br
RI Moraes, Carolina Borsoi/I-4408-2014; Bajgelman, Marcio/A-8146-2019;
   Carvalho, Murilo/B-7950-2012; Consonni, Silvio Roberto/R-9281-2019;
   Teixeira, Mauro M/A-4587-2008; Costa, Vivian VVC/I-2499-2018; Saito,
   Angela/G-6107-2019; Saito, Angela/AAY-9404-2020; Oliveira,
   Paulo/K-5588-2013; Bandeira, Carla Leticia/U-8685-2017; Marques, Rafael
   Elias/R-4890-2016; Freitas-Junior, Lucio H/C-8677-2011; Bevilacqua,
   Estela/H-3354-2011; Smetana, Juliana/J-5354-2013
OI Moraes, Carolina Borsoi/0000-0002-0689-2770; Bajgelman,
   Marcio/0000-0003-3371-1143; Carvalho, Murilo/0000-0001-6881-5271;
   Teixeira, Mauro M/0000-0002-6944-3008; Costa, Vivian
   VVC/0000-0002-0175-642X; Saito, Angela/0000-0003-4421-9226; Bandeira,
   Carla Leticia/0000-0002-0796-3462; Marques, Rafael
   Elias/0000-0002-6949-0947; Freitas-Junior, Lucio H/0000-0002-8904-7897;
   Bevilacqua, Estela/0000-0003-4178-4625; Smetana,
   Juliana/0000-0001-9827-7013; Consonni, Silvio
   Roberto/0000-0003-3149-021X
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq) [CNPq
   440379/2016-4]; Fundacao de Amparo a Pesquisa do Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [FAPESP 2013/22695-0]; individual CNPq fellowship for Productivity in
   Science [CNPq 305537/2014-8]; FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2016/07632-0]
FX This study was partially funded by grants from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq 440379/2016-4), Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 2013/22695-0) and an
   individual CNPq fellowship for Productivity in Science to JXN (CNPq
   305537/2014-8). The results in the manuscript constitute preliminary
   evidence in an application to a FAPESP grant (Project 2016/07632-0). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004682
   Alvarado MG, 2017, ARCH PATHOL LAB MED, V141, P26, DOI 10.5858/arpa.2016-0382-RA
   Ashwal S, 2009, NEUROLOGY, V73, P887, DOI 10.1212/WNL.0b013e3181b783f7
   BELL TM, 1971, ARCH GES VIRUSFORSCH, V35, P183, DOI 10.1007/BF01249709
   Bevilacqua E, 2014, PLACENTA, V35, pS51, DOI 10.1016/j.placenta.2013.10.015
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Coyne CB, 2016, NAT REV MICROBIOL, V14, P707, DOI 10.1038/nrmicro.2016.125
   Creasy RK, 2009, CREASY RESNIKS MATER, pxvii
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Davis GH, 2003, CLIN PERINATOL, V30, P531, DOI 10.1016/S0095-5108(03)00053-8
   de Oliveira-Szejnfeld PS, 2016, RADIOLOGY, V281, P203, DOI 10.1148/radiol.2016161584
   de Paula Freitas B, 2016, JAMA OPHTHALMOLOGY
   Doce N, 2016, BRAZIL SCI SEEK UNRA
   Dowall SD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004658
   DOWNS KM, 1993, DEVELOPMENT, V118, P1255
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Hannon T, 2012, OBSTET GYNECOL, V120, P1345, DOI [10.1097/AOG.0b013e3182732b53, http://10.1097/AOG.0b013e3182732b53]
   Julander JG, 2006, VIROLOGY, V347, P175, DOI 10.1016/j.virol.2005.11.040
   Kauffman MH., 1994, ATLAS MOUSE DEV
   Kostyuchenko VA, 2016, NATURE, V533, P425, DOI 10.1038/nature17994
   Kwon YJ, 2014, ANTIVIR RES, V110, P20, DOI 10.1016/j.antiviral.2014.07.006
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   MCLONE DG, 1989, PEDIATR NEUROSCI, V15, P1, DOI 10.1159/000120432
   Medina F, 2012, CURRENT PROTOCOLS MI
   Menkes JH, 2006, CHILD NEUROLOGY, pxiii
   Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI [10.1016/j.ctim.2007.01.003, 10.1002/0471142735.im1501s77]
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mouillet JF, 2014, INT J DEV BIOL, V58, P281, DOI 10.1387/ijdb.130349ys
   Nagai A, 2010, PLACENTA, V31, P126, DOI 10.1016/j.placenta.2009.11.013
   Oehler E, 2013, EUROSURVEILLANCE, V2014, P19, DOI DOI 10.2807/1560-7917.ES2014.19.9.20720
   Parisi MA, 2003, MOL GENET METAB, V80, P36, DOI 10.1016/j.ymgme.2003.08.010
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rajan AJ, 2000, J IMMUNOL, V164, P2120, DOI 10.4049/jimmunol.164.4.2120
   Ribeiro LS, 2016, CURR OPIN VIROL, V18, P76, DOI 10.1016/j.coviro.2016.04.002
   Richardson J, 2006, AM J TROP MED HYG, V74, P132, DOI 10.4269/ajtmh.2006.74.132
   Rosenberg AZ, 2017, ARCH PATHOL LAB MED, V141, P43, DOI 10.5858/arpa.2016-0401-OA
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Sav A, 2008, SPINA BIFIDA MANAGEM, P43
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Schwartz DA, 2017, ARCH PATHOL LAB MED, V141, P18, DOI [10.5858/arpa.2016-0429-ED, 10.5858/arpa.2016-04]
   Seaman WT, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-194
   Shao Q, 2016, DEVELOPMENT, V143, P4127, DOI 10.1242/dev.143768
   Steel CD, 2008, LAB ANIMAL, V37, P26, DOI 10.1038/laban0108-26
   Stevens DB, 1999, J IMMUNOL, V162, P7501
   Theiler K., 1989, HOUSE MOUSE ATLAS EM
   Tonra James R, 2002, Cerebellum, V1, P57, DOI 10.1080/147342202753203096
   Ueno M, 2013, DEV CELL, V27, P373, DOI 10.1016/j.devcel.2013.10.019
   Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58
   XavierNeto J, 1996, AM J PHYSIOL-HEART C, V271, pH1407
   Yadav RK, 2014, J SCI INNOVATIVE RES, V3, P258
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Zanluca C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110620
NR 53
TC 25
Z9 25
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2017
VL 11
IS 2
AR e0005363
DI 10.1371/journal.pntd.0005363
PG 29
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EN1AD
UT WOS:000395741700032
PM 28231241
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Silva, JVJ
   Lopes, TRR
   de Oliveira, EF
   Oliveira, RAD
   Gil, LHVG
AF Joaquim Silva Junior, Jose Valter
   Rocha Lopes, Thaisa Regina
   de Oliveira-Filho, Edmilson Ferreira
   dos Santos Oliveira, Renato Antonio
   Vega Gonzales Gil, Laura Helena
TI Perspectives on the Zika outbreak: herd immunity, antibodydependent
   enhancement and vaccine
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Letter
ID CROSS-REACTIVITY; VIRUS
C1 [Joaquim Silva Junior, Jose Valter; de Oliveira-Filho, Edmilson Ferreira; dos Santos Oliveira, Renato Antonio; Vega Gonzales Gil, Laura Helena] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Rocha Lopes, Thaisa Regina] Univ Fed Pernambuco, Lab Imunopatol Keizo Asami, Setor Virol, Recife, PE, Brazil.
RP Silva, JVJ (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
EM josevalterjsilvajr@gmail.com
RI Oliveira, Renato/A-2863-2013; Oliveira-Filho, Edmilson F/A-6305-2012;
   Oliveira, Renato/AAN-9879-2020; Oliveira, Renato/AAN-9394-2020
OI Oliveira, Renato/0000-0002-4044-0794; Oliveira-Filho, Edmilson
   F/0000-0002-3771-1565; Oliveira, Renato/0000-0002-4044-0794; 
CR Abushouk AI, 2016, J CLIN VIROL, V84, P53, DOI 10.1016/j.jcv.2016.09.012
   Brasil. Ministerio da Saude, 2016, B EPIDEMIOL, V47, P1
   Brasil Ministerio da Saude, 2017, B EPIDEMIOL, V48, P1, DOI DOI 10.5588/IJTLD.11.0170
   Augusto LGD, 2016, LANCET, V387, P1052, DOI 10.1016/S0140-6736(16)00626-7
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049
   Josseran L, 2006, EMERG INFECT DIS, V12, P1994
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Tripp RA, 2016, EXPERT REV VACCINES, V15, P1083, DOI 10.1080/14760584.2016.1192474
   World Health Organization, 2016, DENG VACC RES
NR 11
TC 8
Z9 8
U1 0
U2 4
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2017
VL 59
AR e21
DI 10.1590/S1678-9946201759021
PG 2
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EZ3KO
UT WOS:000404610000010
PM 28423096
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Kassar, TC
   Magalhaes, T
   Junior, JVJS
   Carvalho, AGO
   Da Silva, ANMR
   Queiroz, SRA
   Bertani, GR
   Gil, LHVG
AF Kassar, Telissa C.
   Magalhaes, Tereza
   Junior, Jose V. J. S.
   Carvalho, Amanda G. O.
   Da Silva, Andrea N. M. R.
   Queiroz, Sabrina R. A.
   Bertani, Giovani R.
   Gil, Laura H. V. G.
TI Construction and characterization of a recombinant yellow fever virus
   stably expressing Gaussia luciferase
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE Gaussia luciferase; homologous recombination in yeast; reporter gene;
   yellow fever virus
ID DENGUE VIRUS; IN-VIVO; VACCINE; SUSCEPTIBILITY; REPLICATION; VECTOR;
   SYSTEM; GENE
AB Yellow fever is an arthropod-borne viral disease that still poses high public health concerns, despite the availability of an effective vaccine. The development of recombinant viruses is of utmost importance for several types of studies, such as those aimed to dissect virus-host interactions and to search for novel antiviral strategies. Moreover, recombinant viruses expressing reporter genes may greatly facilitate these studies. Here, we report the construction of a recombinant yellow fever virus (YFV) expressing Gaussia luciferase (GLuc) (YFV-GLuc). We show, through RT-PCR, sequencing and measurement of GLuc activity, that stability of the heterologous gene was maintained after six passages. Furthermore, a direct association between GLuc expression and viral replication was observed (r(2)= 0.9967), indicating that measurement of GLuc activity may be used to assess viral replication in different applications. In addition, we evaluated the use of the recombinant virus in an antiviral assay with recombinant human alfa-2b interferon. A 60% inhibition of GLuc expression was observed in cells infected with YFV-GLuc and incubated with IFN alfa-2b. Previously tested on YFV inhibition by plaque assays indicated a similar fold-decrease in viral replication. These results are valuable as they show the stability of YFV-GLuc and one of several possible applications of this construct.
C1 [Kassar, Telissa C.; Magalhaes, Tereza; Junior, Jose V. J. S.; Carvalho, Amanda G. O.; Da Silva, Andrea N. M. R.; Queiroz, Sabrina R. A.; Gil, Laura H. V. G.] Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol & Terapia Expt, Av Prof Moraes Rego S-N,Cidade Univ, BR-50740465 Recife, PE, Brazil.
   [Bertani, Giovani R.] Univ Fed Pernambuco UFPE, Dept Bioquim, Av Prof Moraes Rego S-N,Cidade Univ, BR-50670420 Recife, PE, Brazil.
   [Kassar, Telissa C.] Univ Fed Minas Gerais, Escola Vet, Dept Med Vet Prevent, Ave Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
   [Da Silva, Andrea N. M. R.] Univ Fed Para, Inst Ciencias Biol, Lab Virol, Rua Augusto Correa 01, BR-66075110 Belem, PA, Brazil.
   [Queiroz, Sabrina R. A.] Univ Sao Paulo, Fac Zootecnia & Engn Alimentos, Dept Med Vet, Ave Duque Caxias Norte 225, BR-13635000 Pirassununga, SP, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol & Terapia Expt, Av Prof Moraes Rego S-N,Cidade Univ, BR-50740465 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Magalhaes, Tereza/V-6632-2019
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq)
   [CNPq-470453/2012-5]
FX This work has received financial support from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq-470453/2012-5).
CR Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Arenhart S, 2014, RES VET SCI, V97, P439, DOI 10.1016/j.rvsc.2014.07.007
   Aubry F, 2015, ANTIVIR RES, V114, P67, DOI 10.1016/j.antiviral.2014.12.007
   Bonaldo MC, 2014, HUM VACC IMMUNOTHER, V10, P1256, DOI 10.4161/hv.28117
   Bonaldo MC, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-115
   Carvalho-Leandro D, 2012, ACTA TROP, V124, P113, DOI 10.1016/j.actatropica.2012.07.006
   Santos JJD, 2013, MEM I OSWALDO CRUZ, V108, P983, DOI 10.1590/0074-0276130298
   Dag F, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-197
   Dash PK, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-27
   De Baets S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121491
   Ding CB, 2015, INT J MOL MED, V35, P791, DOI 10.3892/ijmm.2015.2063
   Franco D, 2010, VACCINE, V28, P5676, DOI 10.1016/j.vaccine.2010.06.052
   Green N, 2008, EXPERT OPIN DRUG DIS, V3, P671, DOI 10.1517/17460441.3.6.671
   Hanley KA, 2013, INFECT GENET EVOL, V19, P292, DOI 10.1016/j.meegid.2013.03.008
   Ishikawa T, 2014, VACCINE, V32, P1326, DOI 10.1016/j.vaccine.2014.01.040
   Julander JG, 2013, ANTIVIR RES, V97, P169, DOI 10.1016/j.antiviral.2012.12.002
   Kato F, 2014, JPN J INFECT DIS, V67, P209, DOI 10.7883/yoken.67.209
   Lindenbach B., 2013, FIELDS VIROLOGY, V1, P712
   Mayhoub AS, 2011, J MED CHEM, V54, P1704, DOI 10.1021/jm1013538
   Monath TP, 2015, VACCINE, V33, P62, DOI 10.1016/j.vaccine.2014.10.004
   Nogueira RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059347
   Patkar CG, 2009, ANTIMICROB AGENTS CH, V53, P4103, DOI 10.1128/AAC.00074-09
   RICE C M, 1989, New Biologist, V1, P285
   Roth JP, 2009, ANTIVIR RES, V82, P12, DOI 10.1016/j.antiviral.2009.01.001
   Rumyantsev AA, 2010, VIROLOGY, V396, P329, DOI 10.1016/j.virol.2009.10.033
   Sambrook J, 2001, MOL CLONING LAB MANU
   Schoggins JW, 2012, P NATL ACAD SCI USA, V109, P14610, DOI 10.1073/pnas.1212379109
   Song BH, 2012, J MICROBIOL, V50, P698, DOI 10.1007/s12275-012-2336-6
   Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016
   Umamaheswari A, 2011, INTERDISCIP SCI, V3, P64, DOI 10.1007/s12539-011-0064-y
   van den Worm SHE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032857
   Vandergaast R, 2014, VIRUSES-BASEL, V6, P1637, DOI 10.3390/v6041637
   Venisnik KM, 2007, MOL IMAGING BIOL, V9, P267, DOI 10.1007/s11307-007-0101-8
   Zhang PT, 2016, VIRUS RES, V211, P17, DOI 10.1016/j.virusres.2015.09.015
   Zou G, 2011, ANTIVIR RES, V91, P11, DOI 10.1016/j.antiviral.2011.05.001
NR 35
TC 2
Z9 2
U1 0
U2 2
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PY 2017
VL 89
IS 3
SU 3
BP 2119
EP 2130
DI 10.1590/0001-3765201720160196
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FN4TU
UT WOS:000416000400015
PM 28746549
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Cordeiro, MT
   Brito, CAA
   Pena, LJ
   Castanha, PMS
   Gil, LHVG
   Lopes, KGS
   Dhalia, R
   Meneses, JA
   Ishigami, AC
   Mello, LM
   Alencar, LXE
   Guarines, KM
   Rodrigues, LC
   Marques, ETA
AF Cordeiro, Marli T.
   Brito, Carlos A. A.
   Pena, Lindomar J.
   Castanha, Priscila M. S.
   Gil, Laura H. V. G.
   Lopes, Kennya G. S.
   Dhalia, Rafael
   Meneses, Jucille A.
   Ishigami, Ana C.
   Mello, Luisa M.
   Alencar, Liciana X. E.
   Guarines, Klarissa M.
   Rodrigues, Laura C.
   Marques, Ernesto T. A.
TI Results of a Zika Virus (ZIKV) Immunoglobulin M-Specific Diagnostic
   Assay Are Highly Correlated With Detection of Neutralizing Anti-ZIKV
   Antibodies in Neonates With Congenital Disease
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; microcephaly; congenital Zika; anti-ZIKV IgM; ZIKV
   antibodies
ID INFECTION; DENGUE; BRAZIL
AB Background. Usually, immunoglobulin M (IgM) serologic analysis is not sufficiently specific to confirm Zika virus (ZIKV) infection. However, since IgM does not cross the placenta, it may be a good marker of infection in neonates.
   Methods. We tested blood from 42 mothers and neonates with microcephaly and collected cerebrospinal fluid (CSF) specimens from 30 neonates. Molecular assays were performed for detection of ZIKV, dengue virus, and chikungunya virus; IgM enzyme-linked immunosorbent assays and plaque-reduction neutralization tests (PRNTs) were performed to detect ZIKV and dengue virus. No control neonates without microcephaly were evaluated.
   Results. Among neonates, all 42 tested positive for ZIKV IgM: 38 of 42 serum specimens (90.5%) were positive, whereas 30 of 30 CSF specimens (100%) were positive. ZIKV IgM-specific ELISA ratios, calculated as the mean optical density (OD) of the test sample when reacted on viral antigen divided by the mean OD of the negative control when reacted with viral antigen, were higher in CSF specimens (median, 14.9 [range, 9.3-16.4]) than in serum (median, 8.9 [range, 2.1-20.6]; P =.0003). All ZIKV IgM-positive results among the neonates were confirmed by the detection of neutralizing antibodies. Mother/neonate pairs with primary ZIKV infection had neutralizing antibodies to ZIKV only, and mother/neonate pairs with ZIKV virus infection secondary to infection with another flavivirus had high titers of neutralizing antibodies to ZIKV. Among secondary infections, median titers in serum were 2072 (range, 232-12 980) for mothers and 2730 (range, 398-12 980) for neonates (P < .0001), and the median titer in CSF was 93 (range, 40-578) among neonates (P < .0001).
   Conclusions. Among neonates, detection of ZIKV IgM in serum is confirmatory of congenital ZIKV infection, and detection of ZIKV IgM in CSF is confirmatory of neurologic infection. Therefore, we recommend testing for ZIKV IgM in neonates suspected of having congenital ZIKV infection and performance of PRNTs in equivocal cases.
C1 [Cordeiro, Marli T.; Pena, Lindomar J.; Castanha, Priscila M. S.; Gil, Laura H. V. G.; Lopes, Kennya G. S.; Dhalia, Rafael; Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Dept Virol, Recife, PE, Brazil.
   [Brito, Carlos A. A.] Univ Fed Pernambuco, Dept Clin Med, Recife, PE, Brazil.
   [Meneses, Jucille A.; Ishigami, Ana C.; Mello, Luisa M.] Inst Med Integral Prof Fernando Figueira, Dept Pediat, Recife, PE, Brazil.
   [Alencar, Liciana X. E.; Guarines, Klarissa M.] Secretaria Saude Estado Pernambuco, Cent Publ Hlth Lab, Recife, PE, Brazil.
   [Rodrigues, Laura C.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
RP Marques, ETA (corresponding author), FIOCRUZ PE, Dept Virol, Ctr Pesquisas Aggeu Magalhaes CPqAM, Av Prof Moraes Rego SN,Campus UFPE,Cidade Univ, BR-50740465 Recife, PE, Brazil.
EM marques@pitt.edu
RI Dhalia, Rafael/AAD-5432-2020; Da Silva Castanha, Priscila
   Mayrelle/G-1785-2012; Marques, Ernesto T. A/L-4967-2013
OI Da Silva Castanha, Priscila Mayrelle/0000-0002-1220-5308; Marques,
   Ernesto T. A/0000-0003-3826-9358
FU Brazilian government "Programa de pesquisas para o SUS / Fundacao de
   amparo a ciencia e tecnologia de PE" (PPSUS/FACEPE) [APQ: 0302-4.01/13];
   Medical Research CouncilMedical Research Council UK (MRC) [MC_PC_15088]
   Funding Source: researchfish
FX This study was supported by the Brazilian government "Programa de
   pesquisas para o SUS / Fundacao de amparo a ciencia e tecnologia de PE"
   (PPSUS/FACEPE - grant APQ: 0302-4.01/13).
CR Brasil P, 2016, NEW ENGL J MED, DOI [10.1056/NEJMoa160241412, DOI 10.1056/NEJMOA160241412]
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Castanha PMS, 2013, EPIDEMIOL INFECT, V141, P1080, DOI 10.1017/S0950268812001367
   Chen LH, 2016, ANN INTERN MED, V164, P613, DOI 10.7326/M16-0150
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Paula Freitas B, 2016, JAMA OPHTHALMOL, DOI [10.1001/jamaophthlmol.2016.0267, DOI 10.1001/JAMAOPHTHLMOL.2016.0267]
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Fenton TR, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-59
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Staples JE, 2016, MMWR-MORBID MORTAL W, V65, P63, DOI 10.15585/mmwr.mm6503e3
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Tunkel AR, 2008, CLIN INFECT DIS, V47, P303, DOI 10.1086/589747
   Ventura CV, 2016, ARQ BRAS OFTALMOL, V79, P1, DOI 10.5935/0004-2749.20160002
   WHO, INT HLTH REG EM COMM
NR 23
TC 28
Z9 28
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 15
PY 2016
VL 214
IS 12
BP 1897
EP 1904
DI 10.1093/infdis/jiw477
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA EJ3RT
UT WOS:000393130000018
PM 27923950
OA Green Accepted, Bronze
DA 2020-11-24
ER

PT J
AU Oliveira, JC
   da Silva, AC
   Oliveira, RAD
   Pereira, VRA
   Gil, LHVG
AF Oliveira, Janaina Correia
   da Silva, Aline Caroline
   dos Santos Oliveira, Renato Antonio
   Alves Pereira, Valeria Rego
   Vega Gonzales Gil, Laura Helena
TI In vivo near-infrared fluorescence imaging of Leishmania amazonensis
   expressing infrared fluorescence protein (iRFP) for real-time monitoring
   of cutaneous leishmaniasis in mice
SO JOURNAL OF MICROBIOLOGICAL METHODS
LA English
DT Article
DE Leishmania amazonensis; iRFP; BALB/c mouse; Cutaneous leishmaniasis;
   Near-infrared molecular imaging
ID MILTEFOSINE; LUCIFERASE; INFECTION; APPRAISAL; VACCINE; VITRO; MODEL
AB The use of Leishmania amazonensis-infected BALB/c mice is an important model for the study of experimental cutaneous leishmaniasis. Here we report the development of a non-invasive method to directly evaluate and measure parasite burden during the course of the infection, based on the near-infrared fluorescence detection of a recombinant L. amazonensis strain. So, we generated a L. amazonensis strain that stably expresses the near-infrared protein (iRFP) gene and compared the maintenance of its vitro and in vivo characteristics, such as fitness, pathogenicity and fluorescence emission. After that, we followed the disease development, as well as the parasite burden in BALB/c mice footpads infected with L. amazonensis-iRFP, by using an in vivo near-infrared fluorescence scanner. In vitro results showed a linear correlation between the fluorescence emission and the number of parasites. The in vivo study showed that the use of iRFP-transfected L. amazonensis enables the monitoring of parasite burden by measuring fluorescence signals. Therefore, this technique can be confidently used to directly monitor parasitic load and infection overtime and could be an excellent tool for in vitro and in vivo screening of anti-leishmanial drugs and vaccine efficiency. This is the first report of the use of the near-infrared fluorescence imaging technique for monitoring in vivo cutaneous leishmaniasis. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Oliveira, Janaina Correia; dos Santos Oliveira, Renato Antonio; Vega Gonzales Gil, Laura Helena] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Res Ctr, Dept Virol, Av Prof Moraes Rego,S-N Cidade Univ, BR-50740465 Recife, PE, Brazil.
   [da Silva, Aline Caroline; Alves Pereira, Valeria Rego] Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Res Ctr, Dept Immunol, Av Prof Moraes Rego,S-N Cidade Univ, BR-50740465 Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Aggeu Magalhaes Res Ctr, Dept Virol, Av Prof Moraes Rego,S-N Cidade Univ, BR-50740465 Recife, PE, Brazil.
EM janacoliveira@hotmail.com; aline.caroline.bm@gmail.com;
   renatoasoliveira@hotmail.com; valeria@cpqam.fiocruz.br;
   laura@cpqam.fiocruz.br
RI Oliveira, Renato/AAN-9879-2020; Santos, Aline/AAE-4637-2020; Oliveira,
   Renato/A-2863-2013; Oliveira, Renato/AAN-9394-2020
OI Oliveira, Renato/0000-0002-4044-0794; Santos, Aline/0000-0002-8592-395X;
   Oliveira, Renato/0000-0002-4044-0794; Alves Pereira, Valeria
   Rego/0000-0002-7995-7360
FU CAPES foundation (Ministry of Education, Brazil)CAPES
FX We thank CAPES foundation (Ministry of Education, Brazil) for J.C.O. and
   A.C.S scholarships.
CR Bolhassani A, 2011, EXP PARASITOL, V127, P637, DOI 10.1016/j.exppara.2010.12.006
   Calvo-Alvarez E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003666
   Calvo-Alvarez E, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001927
   Guedes HLD, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-448
   Dortay H, 2010, MICROB CELL FACT, V9, DOI 10.1186/1475-2859-9-29
   de Brito MEF, 2012, REV SOC BRAS MED TRO, V45, P425, DOI 10.1590/s0037-86822012005000006
   Filonov GS, 2011, NAT BIOTECHNOL, V29, P757, DOI 10.1038/nbt.1918
   Fonseca-Silva F, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004442
   Franca-Costa J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036595
   Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007
   Handler MZ, 2015, J AM ACAD DERMATOL, V73, P897, DOI 10.1016/j.jaad.2014.08.051
   Hilderbrand SA, 2010, CURR OPIN CHEM BIOL, V14, P71, DOI 10.1016/j.cbpa.2009.09.029
   Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608
   Kevric I, 2015, DERMATOL CLIN, V33, P579, DOI 10.1016/j.det.2015.03.018
   Marlow MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056177
   Mehta SR, 2008, CLIN VACCINE IMMUNOL, V15, P1764, DOI 10.1128/CVI.00270-08
   Michel G, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001323
   Millington OR, 2010, EXP PARASITOL, V126, P310, DOI 10.1016/j.exppara.2010.05.014
   Reimao JQ, 2013, J MICROBIOL METH, V93, P95, DOI 10.1016/j.mimet.2013.02.007
   Rocha MN, 2013, DIAGN MICR INFEC DIS, V75, P282, DOI 10.1016/j.diagmicrobio.2012.11.018
   Shcherbakova DM, 2015, CURR OPIN CHEM BIOL, V27, P52, DOI 10.1016/j.cbpa.2015.06.005
   Shcherbakova DM, 2013, NAT METHODS, V10, P751, DOI 10.1038/nmeth.2521
   Shcherbo D, 2010, NAT METHODS, V7, P827, DOI [10.1038/nmeth.1501, 10.1038/NMETH.1501]
   Shu XK, 2009, SCIENCE, V324, P804, DOI 10.1126/science.1168683
   Sousa LMA, 2014, PARASITE IMMUNOL, V36, P13, DOI 10.1111/pim.12078
   Tong HJ, 2015, ACTA PHARM SIN B, V5, P25, DOI 10.1016/j.apsb.2014.12.006
   Trinconi CT, 2016, J ANTIMICROB CHEMOTH, V71, P1314, DOI 10.1093/jac/dkv495
   Zerpa O, 2007, BRIT J DERMATOL, V156, P1328, DOI 10.1111/j.1365-2133.2007.07872.x
NR 28
TC 11
Z9 12
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-7012
EI 1872-8359
J9 J MICROBIOL METH
JI J. Microbiol. Methods
PD NOV
PY 2016
VL 130
BP 189
EP 195
DI 10.1016/j.mimet.2016.08.003
PG 7
WC Biochemical Research Methods; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA EA2EZ
UT WOS:000386406900031
PM 27498229
DA 2020-11-24
ER

PT J
AU Arenhart, S
   Silva, JV
   Flores, EF
   Weiblen, R
   Gil, LHVG
AF Arenhart, Sandra
   Joaquim Silva Junior, Jose Valter
   Flores, Eduardo Furtado
   Weiblen, Rudi
   Vega Gonzales Gil, Laura Helena
TI Use of homologous recombination in yeast to create chimeric bovine viral
   diarrhea virus cDNA clones
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE BVDV; Pestivirus; Reverse genetics; Infectious clone; Yeast homologous
   recombination
ID LENGTH INFECTIOUS CLONE; N-PRO; MUTATIONS; PESTIVIRUS; CONSTRUCTION;
   EFFICIENT; ISOLATE; VECTOR; GENOME; BRAZIL
AB The open reading frame of a Brazilian bovine viral diarrhea virus (BVDV) strain, IBSP4ncp, was recombined with the untranslated regions of the reference NADL strain by homologous recombination in Saccharomyces cereuisiae, resulting in chimeric full-length cDNA clones of BVDV (chi-NADL/IBSP4ncp#2 and chi-NADL/IBSP4ncp#3). The recombinant clones were successfully recovered, resulting in viable viruses, having the kinetics of replication, focus size, and morphology similar to those of the parental virus, IBSP4ncp. In addition, the chimeric viruses remained stable for at least 10 passages in cell culture, maintaining their replication efficiency unaltered. Nucleotide sequencing revealed a few point mutations; nevertheless, the phenotype of the rescued viruses was nearly identical to that of the parental virus in all experiments. Thus, genetic stability of the chimeric clones and their phenotypic similarity to the parental virus confirm the ability of the yeast-based homologous recombination to maintain characteristics of the parental virus from which the recombinant viruses were derived. The data also support possible use of the yeast system for the manipulation of the BVDV genome. (C) 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda.
C1 [Arenhart, Sandra; Joaquim Silva Junior, Jose Valter; Vega Gonzales Gil, Laura Helena] Fundacao Oswaldo Cruz Fiocruz, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol & Terapia Expt, Recife, PE, Brazil.
   [Arenhart, Sandra; Flores, Eduardo Furtado; Weiblen, Rudi] Univ Fed Santa Maria, CCR, DMVP, Santa Maria, RS, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Lab Virol & Terapia Expt LaViTE, Dept Virol & Terapia Expt, Ctr Pesquisas Aggeu Magalhaes CPqAM, BR-50670420 Recife, PE, Brazil.
EM laura@cpcqam.fiocruz.br
RI Weiblen, Rudi/H-7003-2014
OI Weiblen, Rudi/0000-0002-1737-9817
CR Becher P, 2000, J VIROL, V74, P7884, DOI 10.1128/JVI.74.17.7884-7894.2000
   Bianchi E, 2011, PESQUI VET BRASIL, V31, P649, DOI 10.1590/S0100-736X2011000800003
   Bolin SR, 2004, VET CLIN N AM-FOOD A, V20, P51, DOI 10.1016/j.cvfa.2003.11.009
   CORAPI WV, 1989, J VIROL, V63, P3934, DOI 10.1128/JVI.63.9.3934-3943.1989
   Dehan P, 2005, VACCINE, V23, P4236, DOI 10.1016/j.vaccine.2005.03.026
   DENG RT, 1992, VIROLOGY, V191, P867, DOI 10.1016/0042-6822(92)90262-N
   Fan ZC, 2008, J VIROL METHODS, V149, P309, DOI 10.1016/j.jviromet.2008.01.011
   Fan ZC, 2010, VIRUS GENES, V41, P218, DOI 10.1007/s11262-010-0503-6
   Fan ZC, 2008, VIRUS RES, V138, P97, DOI 10.1016/j.virusres.2008.08.015
   Flores EE, 2005, PESQUI VET BRASIL, V25, P125, DOI 10.1590/S0100-736X2005000300002
   Gibson DG, 2008, P NATL ACAD SCI USA, V105, P20404, DOI 10.1073/pnas.0811011106
   Henningson JN, 2009, AM J VET RES, V70, P1117, DOI 10.2460/ajvr.70.9.1117
   Hofmann MA, 2003, J VIROL METHODS, V114, P77, DOI 10.1016/j.jviromet.2003.09.004
   Joska TM, 2014, J MICROBIOL METH, V100, P46, DOI 10.1016/j.mimet.2013.11.013
   Kamboj A, 2015, J VIROL METHODS, V226, P60, DOI 10.1016/j.jviromet.2015.10.006
   Kawai Shigeyuki, 2010, Bioeng Bugs, V1, P395, DOI 10.4161/bbug.1.6.13257
   Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9
   Liu LH, 2009, VIROLOGY, V385, P351, DOI 10.1016/j.virol.2008.12.004
   Meyers G, 1996, J VIROL, V70, P8606, DOI 10.1128/JVI.70.12.8606-8613.1996
   Meyers G, 2007, J VIROL, V81, P3327, DOI 10.1128/JVI.02372-06
   Moormann RJM, 1996, J VIROL, V70, P763, DOI 10.1128/JVI.70.2.763-770.1996
   Park GS, 2012, J VET SCI, V13, P81, DOI 10.4142/jvs.2012.13.1.81
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   Qu L, 2001, J VIROL, V75, P10651, DOI 10.1128/JVI.75.22.10651-10662.2001
   Rasmussen TB, 2010, VET MICROBIOL, V142, P13, DOI 10.1016/j.vetmic.2009.09.037
   Reimann I, 2004, VIROLOGY, V322, P143, DOI 10.1016/j.virol.2004.01.028
   RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987
   Ridpath JF, 2005, PREV VET MED, V72, P17, DOI 10.1016/j.prevetmed.2005.08.003
   Santos JJS, 2014, AN ACAD BRAS CIENC, V86, P1749, DOI 10.1590/0001-3765201420130332
   Silva JVJ, 2014, BRAZ J MICROBIOL, V45, P1555, DOI 10.1590/S1517-83822014000400054
NR 30
TC 1
Z9 2
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD OCT-DEC
PY 2016
VL 47
IS 4
BP 993
EP 999
DI 10.1016/j.bjm.2016.07.022
PG 7
WC Microbiology
SC Microbiology
GA ED1QI
UT WOS:000388619600030
PM 27522929
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Oliveira, RAD
   da Silva, MMC
   Calzavara-Silva, CE
   Silva, AM
   Cordeiro, MT
   de Moura, PMMF
   Baptista, PN
   Marques, ETD
   Gil, LHVG
AF dos Santos Oliveira, Renato Antonio
   Carneiro da Silva, Mayara Marques
   Calzavara-Silva, Carlos Eduardo
   Silva, Ana Maria
   Cordeiro, Marli Tenorio
   Mendes Freire de Moura, Patricia Muniz
   Baptista Filho, Paulo Neves
   de Azevedo Marques Junior, Ernesto Torres
   Vega Gonzales Gil, Laura Helena
TI Primary dengue haemorrhagic fever in patients from northeast of Brazil
   is associated with high levels of interferon-beta during acute phase
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue fever; dengue haemorrhagic fever; type I interferon; innate
   immunity
ID VIRUS-INFECTION; DISEASE SEVERITY; ANTIBODY-RESPONSE; ALPHA PRODUCTION;
   CELL-LINES; IN-VITRO; EXPRESSION; CYTOKINES; VIREMIA; GAMMA
AB Dengue is an acute febrile disease caused by the mosquito-borne dengue virus (DENV) that according to clinical manifestations can be classified as asymptomatic, mild or severe dengue. Severe dengue cases have been associated with an unbalanced immune response characterised by an over secretion of inflammatory cytokines. In the present study we measured type I interferon (IFN-I) transcript and circulating levels in primary and secondary DENV infected patients. We observed that dengue fever (DF) and dengue haemorrhagic fever (DHF) patients express IFN-I differently. While DF and DHF patients express interferon-a similarly (52,71 +/- 7,40 and 49,05 +/- 7,70, respectively), high levels of circulating IFN-beta were associated with primary DHF patients. On the other hand, secondary DHF patients were not able to secrete large amounts of IFN-beta which in turn may have influenced the high-level of viraemia. Our results suggest that, in patients from our cohort, infection by DENV serotype 3 elicits an innate response characterised by higher levels of IFN-beta in the DHF patients with primary infection, which could contribute to control infection evidenced by the low-level of viraemia in these patients. The present findings may contribute to shed light in the role of innate immune response in dengue pathogenesis.
C1 [dos Santos Oliveira, Renato Antonio; Carneiro da Silva, Mayara Marques; Silva, Ana Maria; Cordeiro, Marli Tenorio; de Azevedo Marques Junior, Ernesto Torres; Vega Gonzales Gil, Laura Helena] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
   [Calzavara-Silva, Carlos Eduardo] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Dept Imunol, Lab Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
   [de Azevedo Marques Junior, Ernesto Torres] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Mendes Freire de Moura, Patricia Muniz] Univ Pernambuco, Inst Ciencias Biol, Recife, PE, Brazil.
   [Baptista Filho, Paulo Neves] Univ Pernambuco, Fac Ciencias Med, Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol, Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Oliveira, Renato/AAN-9879-2020; Oliveira, Renato/A-2863-2013; Oliveira,
   Renato/AAN-9394-2020; Marques, Ernesto T. A/L-4967-2013
OI Oliveira, Renato/0000-0002-4044-0794; Oliveira,
   Renato/0000-0002-4044-0794; Marques, Ernesto T. A/0000-0003-3826-9358;
   CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU NIAID/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI56541, N01 AI 40085]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
   [CNPq-550140/2010-7, CNPq-404453/2012-0]; FACEPE [APQ-1516-4.01/10];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040085, U19AI056541, R01AI040085, U19AI056541, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, U19AI056541, R21AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, U19AI056541, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, U19AI056541,
   R01AI040085] Funding Source: NIH RePORTER
FX NIAID/NIH (grants U19 AI56541 and N01 AI 40085), CNPq (grants
   CNPq-550140/2010-7 and CNPq-404453/2012-0 (RASO's visiting research
   fellowship)), FACEPE (grant APQ-1516-4.01/10 (MTC's research
   fellowship)). RASO and MMCS contributed equally to this work.
CR Aguirre S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002934
   Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Applied Biosystems, 2010, APPL BIOS US B
   Applied Biosystems, 2012, AMPL EFF TAQMANR GEN
   Ashour J, 2009, J VIROL, V83, P5408, DOI 10.1128/JVI.02188-08
   Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Back Anne Tuiskunen, 2013, Infect Ecol Epidemiol, V3, DOI 10.3402/iee.v3i0.19839
   Becquart P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-356
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Chen HW, 2013, J IMMUNOL, V191, P4194, DOI 10.4049/jimmunol.1300799
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Hernandez SID, 2014, J CLIN VIROL, V60, P196, DOI 10.1016/j.jcv.2014.04.002
   Diamond MS, 2000, J VIROL, V74, P4957, DOI 10.1128/JVI.74.11.4957-4966.2000
   Dong T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001192
   Fink J, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000086
   Gandini M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002257
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Halstead SB, 1988, J CHALL MOL BIO, V239, P476, DOI DOI 10.1126/SCIENCE.3277268
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Jones M, 2005, J VIROL, V79, P5414, DOI 10.1128/JVI.79.9.5414-5420.2005
   Kurane I, 2007, COMP IMMUNOL MICROB, V30, P329, DOI 10.1016/j.cimid.2007.05.010
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Li YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055108
   Liang ZD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023346
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Messina JP, 2015, NAT REV MICROBIOL, V13, P230, DOI 10.1038/nrmicro3430
   Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100
   Reis SRNI, 2007, MEM I OSWALDO CRUZ, V102, P983, DOI 10.1590/S0074-02762007000800014
   Torres REP, 2016, J MED VIROL, V88, P395, DOI 10.1002/jmv.24343
   Pozner FG, 2010, PLOS PATHOG, V6, P1
   Pozo-Aguilar JO, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0590-7
   Priyadarshini D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008709
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Ross TM, 2010, CLIN LAB MED, V30, P149, DOI 10.1016/j.cll.2009.10.007
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255
   Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835
   Tang YQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012644
   Umareddy I, 2008, J GEN VIROL, V89, P3052, DOI 10.1099/vir.0.2008/001594-0
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   WHO, 2009, DENG GUID DIAGN TREA
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   Wu SY, 2013, J INFECTION, V67, P329, DOI 10.1016/j.jinf.2013.05.003
   Ferreira RAX, 2015, ACTA TROP, V149, P138, DOI 10.1016/j.actatropica.2015.04.023
NR 51
TC 11
Z9 10
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUN
PY 2016
VL 111
IS 6
BP 378
EP 384
DI 10.1590/0074-02760150453
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DQ0LC
UT WOS:000378889800004
PM 27223651
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Cordeiro, MT
   Pena, LJ
   Brito, CA
   Gil, LH
   Marques, ET
AF Cordeiro, Marli Tenorio
   Pena, Lindomar J.
   Brito, Carlos A.
   Gil, Laura H.
   Marques, Ernesto T.
TI Positive IgM for Zika virus in the cerebrospinal fluid of 30 neonates
   with microcephaly in Brazil
SO LANCET
LA English
DT Letter
C1 [Cordeiro, Marli Tenorio; Pena, Lindomar J.; Gil, Laura H.; Marques, Ernesto T.] Fiocruz MS, Dept Virol, Ctr Pesquisas Aggeu Magalhaes CPqAM, BR-50670420 Recife, PE, Brazil.
   [Brito, Carlos A.] Univ Fed Pernambuco, Dept Clin Med, Recife, PE, Brazil.
   [Marques, Ernesto T.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Cordeiro, MT (corresponding author), Fiocruz MS, Dept Virol, Ctr Pesquisas Aggeu Magalhaes CPqAM, BR-50670420 Recife, PE, Brazil.
EM marli@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
CR Carrolla ID, 2007, TRAVEL MED INFECT DI, V5, P3183
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Organization W. H., 2016, WHO DIR GEN SUMM OUT
   Tunkel AR, 2008, CLIN INFECT DIS, V47, P303, DOI 10.1086/589747
NR 4
TC 82
Z9 82
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD APR 30
PY 2016
VL 387
IS 10030
BP 1811
EP 1812
DI 10.1016/S0140-6736(16)30253-7
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA DK6SS
UT WOS:000375056100017
PM 27103126
OA Bronze, Green Published
DA 2020-11-24
ER

PT J
AU Branco, MSD
   Sousa, DMC
   Sousa, DMC
   Monteiro, JD
   Costa, DMP
   Almeida, RF
   Lima, TLC
   Farias, KJS
   Medeiros, RC
   Queiroz, MGL
   Gil, LHVG
   Fernandes, JV
   Nogueira, RMR
   Araujo, JMG
AF Branco, Mario S. D.
   Sousa, Denise M. C.
   Sousa, Daise M. C.
   Monteiro, Joelma D.
   Costa, Diego M. P.
   Almeida Junior, Renato F.
   Lima, Tabata L. C.
   Farias, Kleber J. S.
   Medeiros, Ralfo C.
   Queiroz, Maria Goretti L.
   Gil, Laura H. V. G.
   Fernandes, Jose V.
   Nogueira, Rita M. R.
   Araujo, Joselio M. G.
TI Dengue in the State of Rio Grande do Norte, Brazil, 2010-2012
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE Dengue; Rio Grande do Norte; Epidemiology; Virological Surveillance
AB ObjectiveTo present results of virological surveillance and epidemiological aspects of dengue in the State of Rio Grande do Norte, Brazil.
   MethodsA total of 1581 cases, reported from 2010 to 2012 at various health centres in the state, were analysed by viral isolation and/or RT-PCR for viral detection and typing. To identify whether different genotypes were circulating in the state during this period, sequencing of the complete E gene for DENV (1485 bp in length) was performed directly from patient serum samples.
   ResultsAll four serotypes of dengue virus circulated in Rio Grande do Norte, with the introduction of DENV-4 in the state in 2011. In 2012, DENV-4 represented 100% of positive confirmed cases. 53.97% of cases occurred in Natal. Case numbers peaked in April (21%) and May (23%). Genetic characterisation of circulating strains confirmed the circulation of genotypes V, south-east Asian/American and II, respectively, for DENV-1, DENV-2 and DENV-4.
   ConclusionsThis work furthers a better understanding of dengue viruses in the State of Rio Grande do Norte. Strengthening control efforts in the region is important considering the impact of dengue.
C1 [Branco, Mario S. D.; Sousa, Denise M. C.; Sousa, Daise M. C.; Monteiro, Joelma D.; Costa, Diego M. P.; Almeida Junior, Renato F.; Lima, Tabata L. C.; Farias, Kleber J. S.; Fernandes, Jose V.; Araujo, Joselio M. G.] Univ Fed Rio Grande do Norte, Lab Mol Biol Infect Dis & Canc, BR-59072910 Natal, RN, Brazil.
   [Branco, Mario S. D.; Nogueira, Rita M. R.] Inst Oswaldo Cruz, Lab Flavivirus, BR-20001 Rio De Janeiro, Brazil.
   [Medeiros, Ralfo C.; Queiroz, Maria Goretti L.] Lab Cent Doutor Almino Fernandes, Natal, RN, Brazil.
   [Gil, Laura H. V. G.] Aggeu Magalhaes Res Ctr, Dept Virol & Expt Therapy, Recife, PE, Brazil.
RP Araujo, JMG (corresponding author), Univ Fed Rio Grande do Norte, Lab Mol Biol Infect Dis & Canc, Campus Univ, BR-59072910 Natal, RN, Brazil.
EM joselio@cb.ufrn.br
RI Araujo, Joselio M G/B-5502-2013; FARIAS, KLEBER/AAC-9815-2019
OI Araujo, Joselio M G/0000-0003-3548-2786; Fernandes, Jose
   Verissimo/0000-0002-5169-6496
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX We gratefully acknowledge the Laboratorio Central Doutor Almino
   Fernandes for providing clinical samples. This investigation received
   financial support from the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq.
CR Araujo JMG, 2009, VIRUS DENGUE TIPO 3, P111
   Barbosa IR, 2012, EPIDEMIOL SERV SAUDE, V21, P149, DOI 10.5123/S1679-49742012000100015
   Cunha RV, 1999, T ROY SOC TROP MED H, V93, P247, DOI 10.1016/S0035-9203(99)90008-1
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lindenbach B.D., 2007, FIELDS VIROLOGY, P1101, DOI DOI 10.1016/0038-092X(88)90131-4
   Rodenhuis-Zybert IA, 2010, CELL MOL LIFE SCI, V67, P2773, DOI 10.1007/s00018-010-0357-z
   Ross TM, 2010, CLIN LAB MED, V30, P149, DOI 10.1016/j.cll.2009.10.007
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
NR 13
TC 3
Z9 3
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD DEC
PY 2015
VL 20
IS 12
BP 1707
EP 1710
DI 10.1111/tmi.12612
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CZ8JA
UT WOS:000367344800011
PM 26426773
OA Bronze
DA 2020-11-24
ER

PT J
AU Santos, JJD
   Magalhaes, T
   Silva, JVJ
   da Silva, ANMR
   Cordeiro, MT
   Gil, LHVG
AF da Silva Santos, Jefferson Jose
   Magalhaes, Tereza
   Joaquim Silva Junior, Jose Valter
   Jonteiro Rangel da Silva, Andrea Nazare
   Cordeiro, Marli Tenorio
   Vega Gonzales Gil, Laura Helena
TI Full-length infectious clone of a low passage dengue virus serotype 2
   from Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE infectious clone; yeast homologous recombination; flavivirus
ID CDNA-CLONES; RAPID DETECTION; AEDES-AEGYPTI; CONSTRUCTION; TYPE-2;
   VACCINE; STRAIN; IDENTIFICATION; MUTATIONS; EVOLUTION
AB Full-length dengue virus (DENV) cDNA clones are an invaluable tool for many studies, including those on the development of attenuated or chimeric vaccines and on host-virus interactions. Furthermore, the importance of low passage DENV infectious clones should be highlighted, as these may harbour critical and unique strain-specific viral components from field-circulating isolates. The successful construction of a functional Brazilian low passage DENV serotype 2 full-length clone through homologous recombination reported here supports the use of a strategy that has been shown to be highly useful by our group for the development of flavivirus infectious clones and replicons.
C1 [da Silva Santos, Jefferson Jose; Magalhaes, Tereza; Joaquim Silva Junior, Jose Valter; Jonteiro Rangel da Silva, Andrea Nazare; Cordeiro, Marli Tenorio; Vega Gonzales Gil, Laura Helena] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Lab Virol & Terapia Expt, Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio] Lab Cent Saude Publ, Dept Saude Estado Pernambuco, Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Lab Virol & Terapia Expt, Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Magalhaes, Tereza/V-6632-2019; Santos, Jefferson/W-9610-2019
OI Santos, Jefferson/0000-0001-5895-4163
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [CNPq-470892/2007-2]; FIOCRUZ (PAPES V)
FX FIOCRUZ (PAPES V), CNPq (CNPq-470892/2007-2)
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Blaney JE, 2004, AM J TROP MED HYG, V71, P811, DOI 10.4269/ajtmh.2004.71.811
   Blaney JE, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-39
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   Carvalho-Leandro D, 2012, ACTA TROP, V124, P113, DOI 10.1016/j.actatropica.2012.07.006
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Chen RB, 2011, VIRUSES-BASEL, V3, P1562, DOI 10.3390/v3091562
   Santos JJD, 2013, MEM I OSWALDO CRUZ, V108, P983, DOI 10.1590/0074-0276130298
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   GRUENBERG A, 1988, J GEN VIROL, V69, P1391, DOI 10.1099/0022-1317-69-6-1391
   Gualano RC, 1998, J GEN VIROL, V79, P437, DOI 10.1099/0022-1317-79-3-437
   Horstick O, 2015, PATHOG GLOB HEALTH, V109, P19, DOI 10.1179/2047773215Y.0000000003
   Ishikawa T, 2014, VACCINE, V32, P1326, DOI 10.1016/j.vaccine.2014.01.040
   Kelly EP, 2011, VIRUS GENES, V43, P18, DOI 10.1007/s11262-011-0602-z
   Kelly EP, 2010, VACCINE, V28, P3030, DOI 10.1016/j.vaccine.2009.10.084
   Kinney RM, 1997, VIROLOGY, V230, P300, DOI 10.1006/viro.1997.8500
   Kong YY, 2006, J VIROL METHODS, V138, P123, DOI 10.1016/j.jviromet.2006.08.003
   LAI CJ, 1991, P NATL ACAD SCI USA, V88, P5139, DOI 10.1073/pnas.88.12.5139
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lee E, 1997, VIROLOGY, V232, P281, DOI 10.1006/viro.1997.8570
   Nene V, 2007, SCIENCE, V316, P1718, DOI 10.1126/science.1138878
   Pierro DJ, 2006, J GEN VIROL, V87, P2263, DOI 10.1099/vir.0.81958-0
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   Pu SY, 2011, J VIROL, V85, P2927, DOI 10.1128/JVI.01986-10
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   Queiroz SRA, 2013, AN ACAD BRAS CIENC, V85, P159, DOI 10.1590/S0001-37652013005000008
   Rico-Hesse R, 2007, CLIN INFECT DIS, V44, P1462, DOI 10.1086/517587
   Ruggli N, 1999, ADV VIRUS RES, V53, P183, DOI 10.1016/S0065-3527(08)60348-6
   Sriburi R, 2001, J VIROL METHODS, V92, P71, DOI 10.1016/S0166-0934(00)00277-9
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Tajima S, 2006, VIRUS RES, V116, P38, DOI 10.1016/j.virusres.2005.08.015
   Usme-Ciro JA, 2014, VIRUS RES, V180, P12, DOI 10.1016/j.virusres.2013.12.001
   Vasilakis N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000467
   Zhu W, 2007, VIRUS RES, V126, P226, DOI 10.1016/j.virusres.2007.03.004
   Zou G, 2011, J BIOL CHEM, V286, P14362, DOI 10.1074/jbc.M110.214189
NR 35
TC 0
Z9 0
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD AUG
PY 2015
VL 110
IS 5
BP 677
EP 683
DI 10.1590/0074-02760150053
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA CQ3LQ
UT WOS:000360504200015
PM 26200712
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Ferreira, MC
   Vieira, MDA
   Zani, CL
   Alves, TMD
   Sales, PA
   Murta, SMF
   Romanha, AJ
   Gil, LHVG
   Amanda, GDC
   Zilli, JE
   Vital, MJS
   Rosa, CA
   Rosa, LH
AF Ferreira, Mariana Costa
   Almeida Vieira, Mariana de Lourdes
   Zani, Carlos Leomar
   de Almeida Alves, Tania Maria
   Sales Junior, Policarpo Ademar
   Murta, Silvane M. F.
   Romanha, Alvaro Jose
   Vega Gonzales Gil, Laura Helena
   de Oliveira Carvalho, Amanda Gomes
   Zilli, Jerri Edson
   Salgado Vital, Marcos Jose
   Rosa, Carlos Augusto
   Rosa, Luiz Henrique
TI Molecular phylogeny, diversity, symbiosis and discover of bioactive
   compounds of endophytic fungi associated with the medicinal Amazonian
   plant Carapa guianensis Aublet (Meliaceae)
SO BIOCHEMICAL SYSTEMATICS AND ECOLOGY
LA English
DT Article
DE Endophytes; Ecology; Medicinal plant; Chagas's disease; Yellow fever
ID DESCHAMPSIA-ANTARCTICA DESV.; PRIMER SETS; IN-VITRO; PHOMOPSIS;
   METABOLITES; TELEOMORPH; DIAPORTHE; ECOLOGY; PCR
AB We investigated the endophytic fungal community associated with the Amazonian medicinal plant Carapa guianensis and its potential for providing bioactive compounds. A total of 162 endophytic fungal isolates were obtained and identified by molecular methods. These isolates were classified into 35 different taxa in the genera Aspergilllus, Beltrania, Botryosphaeria, Colletotrichum, Diaporthe, Endomelanconiopsis, Fusarium, Guignardia, Pestalotiopsis, Phomopsis, Pilidiella, Trichoderma, and Xylaria. The most frequent colonisers recovered of C. guianensis were Colletotrichum sp. 1, Diaporthe cf. mayteni, and Pestalotiopsis sp. 1. The fungal community had a moderate richness but high diversity and evenness indices. Colletotrichum sp. and Pilidiella wangiensis displayed selective antibacterial activity; Diaporthe cf. mayteni and Endomelanconiopsis endophytica showed high activity against amastigote forms of Trypanosoma cruzi; and Colletrotrichum sp. Guignardia mangiferae, Pestalotiopsis sp., and Diaporthe melonis were able to inhibit yellow fever virus proliferation. Our results suggest that the plants living in the tropical forest, such as the Amazonian hotspot region, can live in symbiosis with hidden and underestimated rich communities of endophytic fungi, which deserve protocols and/or specific laws to keep its future conservation. The capability of these endophytic fungi to produce bioactive compounds may be part of their chemical defense and adaptive response to survive and colonizing the plant host in wild environment. consequently, these fungal communities may provide a source of bioactive molecules, including those able to inhibit or control neglected tropical diseases. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ferreira, Mariana Costa; Almeida Vieira, Mariana de Lourdes; Rosa, Carlos Augusto; Rosa, Luiz Henrique] Univ Fed Minas Gerais, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Zani, Carlos Leomar; de Almeida Alves, Tania Maria] Fiocruz MS, Rene Rachou Res Ctr, Lab Chem Nat Prod, Belo Horizonte, MG, Brazil.
   [Sales Junior, Policarpo Ademar; Murta, Silvane M. F.; Romanha, Alvaro Jose] Fiocruz MS, Rene Rachou Res Ctr, Lab Cellular & Mol Parasitol, Belo Horizonte, MG, Brazil.
   [Romanha, Alvaro Jose] Univ Fed Santa Catarina, Dept Microbiol Immunol & Parasitol, Florianopolis, SC, Brazil.
   [Vega Gonzales Gil, Laura Helena; de Oliveira Carvalho, Amanda Gomes] Fiocruz MS, Aggeu Magalhaes Res Ctr, Dept Virol & Expt Therapy, Recife, PE, Brazil.
   [de Oliveira Carvalho, Amanda Gomes] Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil.
   [Zilli, Jerri Edson] Embrapa Agrobiol, Rio De Janeiro, RJ, Brazil.
   [Salgado Vital, Marcos Jose] Univ Fed Roraima, Biodivers Study Ctr, Roraima, RR, Brazil.
RP Rosa, LH (corresponding author), Univ Fed Minas Gerais, Dept Microbiol, Lab Sistemat & Biomol Fungos, POB 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM lhrosa@icb.ufmg.br
RI Zani, Carlos L/A-9658-2008
OI Zani, Carlos L/0000-0003-1859-177X
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (PROCAD-NF -
   CAPES) [23038.003478/2013-92]; Conselho Nacional de Desenvolvimento
   Cientifico and Tecnologico, CNPq Universal [471721/2013-1,
   470453/2012-5]; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG) [0050-13]
FX This work received support from the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (PROCAD-NF - CAPES) (23038.003478/2013-92),
   Conselho Nacional de Desenvolvimento Cientifico and Tecnologico, CNPq
   Universal 471721/2013-1 and 470453/2012-5, and Fundacao de Amparo a
   Pesquisa do Estado de Minas Gerais (FAPEMIG) (0050-13), Process
   Universal 0050-13. The authors thank the Program for Technological
   Development of Tools for Health-PDTIS-FIOCRUZ for use of its facilities.
   We also thank Dr. M.A. Soares for your help with sequence deposit
CR Agusta A, 2006, CHEM PHARM BULL, V54, P579, DOI 10.1248/cpb.54.579
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Bacon C. W., 2000, MICROBIAL ENDOPHYTES
   Carbone I, 1999, MYCOLOGIA, V91, P553, DOI 10.2307/3761358
   Carvalho CR, 2012, SYMBIOSIS, V57, P95, DOI 10.1007/s13199-012-0182-2
   Collado J, 1996, NOVA HEDWIGIA, V63, P347
   Crous P. W., 2012, STUD MYCOL, V75, P35
   de Siqueira VM, 2011, SYMBIOSIS, V53, P89, DOI 10.1007/s13199-011-0113-7
   Fischbach MA, 2009, SCIENCE, V325, P1089, DOI 10.1126/science.1176667
   Furbino LE, 2014, MICROB ECOL, V67, P775, DOI 10.1007/s00248-014-0374-9
   Gazis R, 2011, MOL ECOL, V20, P3001, DOI 10.1111/j.1365-294X.2011.05110.x
   GLASS NL, 1995, APPL ENVIRON MICROB, V61, P1323, DOI 10.1128/AEM.61.4.1323-1330.1995
   Godinho VM, 2013, ISME J, V7, P1434, DOI 10.1038/ismej.2013.77
   Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated
   Ho Min-Yuan, 2012, Taiwania, V57, P229
   Huang WY, 2008, FUNGAL DIVERS, V33, P61
   Kirk P.M., 2008, AINSWORTH BISBYS DIC
   Kusari S, 2012, CHEM BIOL, V19, P792, DOI 10.1016/j.chembiol.2012.06.004
   Liu HP, 2003, J INVERTEBR PATHOL, V82, P139, DOI 10.1016/S0022-2011(03)00018-1
   Liu L, 2008, BIOORGAN MED CHEM, V16, P6021, DOI 10.1016/j.bmc.2008.04.052
   Marcelino J, 2008, MYCOLOGIA, V100, P353, DOI 10.3852/07-174R
   Naik BS, 2008, FUNGAL ECOL, V1, P89, DOI 10.1016/j.funeco.2008.05.001
   Niekerk JM, 2004, MYCOL RES, V108, P283, DOI 10.1017/S0953756204009268
   Petrini O., 1991, MICROBIAL ECOLOGY LE, DOI DOI 10.1007/978-1-4612-3168-4_9
   Phongpaichit S, 2006, FEMS IMMUNOL MED MIC, V48, P367, DOI 10.1111/j.1574-695X.2006.00155.x
   Rodrigues KF, 2004, MYCOL RES, V108, P45, DOI 10.1017/S0953756203008840
   Rojas EI, 2008, MYCOLOGIA, V100, P760, DOI 10.3852/07-207
   Romanha AJ, 2010, MEM I OSWALDO CRUZ, V105, P233, DOI 10.1590/S0074-02762010000200022
   Rosa L.H., 2011, DRUG DEV CASE STUDY, P1
   Rosa LH, 2010, BRAZ J MICROBIOL, V41, P420, DOI [10.1590/S1517-83822010000200024, 10.1590/S1517-838220100002000024]
   Rosa LH, 2009, POLAR BIOL, V32, P161, DOI 10.1007/s00300-008-0515-z
   Santiago IF, 2012, EXTREMOPHILES, V16, P95, DOI 10.1007/s00792-011-0409-9
   Santos JM, 2010, FUNGAL BIOL-UK, V114, P255, DOI 10.1016/j.funbio.2010.01.007
   Schulz B, 2005, MYCOL RES, V109, P661, DOI 10.1017/S095375620500273X
   Soca-Chafre G, 2011, FUNGAL BIOL-UK, V115, P143, DOI 10.1016/j.funbio.2010.11.004
   Strobel GA, 2003, MICROBES INFECT, V5, P535, DOI 10.1016/S1286-4579(03)00073-X
   van Niekerk JM, 2005, AUSTRALAS PLANT PATH, V34, P27, DOI 10.1071/AP04072
   Vieira MLA, 2012, CAN J MICROBIOL, V58, P54, DOI [10.1139/W11-105, 10.1139/w11-105]
   Wei JG, 2007, FUNGAL DIVERS, V24, P55
   White TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1
   Yu BZ, 2008, PHYTOCHEMISTRY, V69, P2523, DOI 10.1016/j.phytochem.2008.07.013
NR 41
TC 20
Z9 24
U1 0
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0305-1978
EI 1873-2925
J9 BIOCHEM SYST ECOL
JI Biochem. Syst. Ecol.
PD APR
PY 2015
VL 59
BP 36
EP 44
DI 10.1016/j.bse.2014.12.017
PG 9
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
   Evolutionary Biology
GA CH1AM
UT WOS:000353753500007
DA 2020-11-24
ER

PT J
AU Santos, JJS
   Cordeiro, MT
   Bertani, GR
   Marques, ETA
   Gil, LHVG
AF Santos, Jefferson J. S.
   Cordeiro, Marli T.
   Bertani, Giovani R.
   Marques, Ernesto T. A.
   Gil, Laura H. V. G.
TI A two-plasmid strategy for engineering a dengue virus type 3 infectious
   clone from primary Brazilian isolate
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE reverse genetics; dengue virus; molecular cloning; infectious clone
ID REVERSE GENETICS SYSTEM; CDNA-CLONES; SUBGENOMIC REPLICONS;
   CONSTRUCTION; RNA; PROTEIN; STRAIN; EXPRESSION; YEAST
AB Dengue infections represent one of the most prevalent arthropod-borne diseases worldwide, causing a wide spectrum of clinical outcomes. Engineered infectious clone is an important tool to study Dengue virus (DENV) biology. Functional full-length cDNA clones have been constructed for many positive-strand RNA viruses and have provided valuable tools for studying the molecular mechanisms involved in viral genome replication, virion assembly, virus pathogenesis and vaccine development. We report herein the successful development of an infectious clone from a primary Brazilian isolate of dengue virus 3 (DENV3) of the genotype III. Using a two-plasmid strategy, DENV3 genome was divided in two parts and cloned separately into a yeast-bacteria shuttle vector. All plasmids were assembled in yeast by homologous recombination technique and a full-length template for transcription was obtained by in vitro ligation of the two parts of the genome. Transcript-derived DENV3 is infectious upon transfection into BHK-21 cells and in vitro characterization confirmed its identity. Growth kinetics of transcript-derived DENV3 was indistinguishable from wild type DENV3. This system is a powerful tool that will help shed light on molecular features of DENV biology, as the relationship of specific mutations and DENV pathogenesis.
C1 [Santos, Jefferson J. S.; Cordeiro, Marli T.; Marques, Ernesto T. A.; Gil, Laura H. V. G.] Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Cordeiro, Marli T.] Secretaria Saude Estado Pernambuco, Lab Cent Saude Publ, BR-50050210 Recife, PE, Brazil.
   [Bertani, Giovani R.] Univ Fed Pernambuco, Dept Bioquim, BR-50760420 Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
RP Gil, LHVG (corresponding author), Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Av Prof Moraes Rego S-N,Campus UFPE, BR-50670420 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Santos, Jefferson/W-9610-2019
OI Marques, Ernesto T. A/0000-0003-3826-9358; Santos,
   Jefferson/0000-0001-5895-4163
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao Oswaldo Cruz - FIOCRUZ (Papes V); Fundacao de Amparo a
   Ciencia e Tecnologia do Estado de Pernambuco (FACEPE)
   [APQ-0519-2.12/06]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [470892/2007-2]; National Institute of
   Allergy and Infectious Diseases (NIAID/NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U19
   AI56541]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R21AI040085, U19AI082632, U19AI056541,
   R01AI040085, R01AI040085, U19AI056541, R01AI040085, U19AI056541,
   U19AI082632, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, U19AI056541, U19AI056541,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085] Funding Source: NIH
   RePORTER
FX The authors thank the Program for Technological Development in Tools for
   Health-PDTISFIOCRUZ for the use of its facilities, Dr. Pedro Vasconcelos
   at the Evandro Chagas Institute (Belem, Para, Brazil) for kindly
   supplying the polyclonal hyperimmune ascitic fluid used in this paper
   and the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq) for supporting J.J.S.S. through a graduate scholarship. This work
   is supported by research grants from Fundacao Oswaldo Cruz - FIOCRUZ
   (Papes V), Fundacao de Amparo a Ciencia e Tecnologia do Estado de
   Pernambuco (FACEPE) (APQ-0519-2.12/06), the CNPq (470892/2007-2), and
   the National Institute of Allergy and Infectious Diseases (NIAID/NIH) -
   Grant U19 AI56541.
CR Alvarez DE, 2008, VIROLOGY, V375, P223, DOI 10.1016/j.virol.2008.01.014
   Ansari IH, 2004, J VIROL, V78, P9612, DOI 10.1128/JVI.78.18.9612-9623.2004
   Blaney JE, 2004, AM J TROP MED HYG, V71, P811, DOI 10.4269/ajtmh.2004.71.811
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   Santos JJD, 2013, MEM I OSWALDO CRUZ, V108, P983, DOI 10.1590/0074-0276130298
   Das Suchismita, 2007, J Vis Exp, P220, DOI 10.3791/220
   FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980
   Galler R, 2011, MEM I OSWALDO CRUZ, V106, P905, DOI 10.1590/S0074-02762011000800001
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   Gil LHVG, 2006, VIRUS RES, V116, P69, DOI 10.1016/j.virusres.2005.08.011
   Gil LHVG, 2006, J VIROL, V80, P900, DOI 10.1128/JVI.80.2.900-911.2006
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Hershkovitz O, 2008, J VIROL, V82, P7666, DOI 10.1128/JVI.02274-07
   Jetten TH, 1997, AM J TROP MED HYG, V57, P285, DOI 10.4269/ajtmh.1997.57.285
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   KAPOOR M, 1995, GENE, V162, P175, DOI 10.1016/0378-1119(95)00332-Z
   Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997
   Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005
   LAI CJ, 1991, P NATL ACAD SCI USA, V88, P5139, DOI 10.1073/pnas.88.12.5139
   Laurent-Rolle M, 2010, J VIROL, V84, P3503, DOI 10.1128/JVI.01161-09
   Leung JY, 2008, J VIROL, V82, P4731, DOI 10.1128/JVI.00002-08
   Lindenbach BD, 2007, FIELDS VIROLOGY, V1, P1102
   McElroy KL, 2006, J GEN VIROL, V87, P2993, DOI 10.1099/vir.0.82023-0
   Messer WB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001486
   MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395
   Noble CG, 2010, ANTIVIR RES, V85, P450, DOI 10.1016/j.antiviral.2009.12.011
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   Pu SY, 2011, J VIROL, V85, P2927, DOI 10.1128/JVI.01986-10
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   Queiroz SRA, 2013, AN ACAD BRAS CIENC, V85, P159, DOI 10.1590/S0001-37652013005000008
   RICE C M, 1989, New Biologist, V1, P285
   Ruggli N, 1999, ADV VIRUS RES, V53, P183, DOI 10.1016/S0065-3527(08)60348-6
   Sambrook J, 2001, MOL CLONING LAB MANU
   Shanks RMQ, 2009, PLASMID, V62, P88, DOI 10.1016/j.plasmid.2009.05.002
   Sriburi R, 2001, J VIROL METHODS, V92, P71, DOI 10.1016/S0166-0934(00)00277-9
   SUMIYOSHI H, 1992, J VIROL, V66, P5425, DOI 10.1128/JVI.66.9.5425-5431.1992
   Sutherst RW, 2004, CLIN MICROBIOL REV, V17, P136, DOI 10.1128/CMR.17.1.136-173.2004
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Yamshchikov VF, 2001, VIROLOGY, V281, P294, DOI 10.1006/viro.2000.0795
   Yun SI, 2003, J VIROL, V77, P6450, DOI 10.1128/JVI.77.11.6450-6465.2003
NR 42
TC 6
Z9 8
U1 0
U2 12
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD DEC
PY 2014
VL 86
IS 4
BP 1749
EP 1759
DI 10.1590/0001-3765201420130332
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AY4CQ
UT WOS:000347526200017
PM 25590713
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Silva, JVJ
   Arenhart, S
   Santos, HF
   Almeida-Queiroz, SR
   Silva, ANMR
   Trevisol, IM
   Bertani, GR
   Gil, LHVG
AF Silva, J. V. J., Jr.
   Arenhart, S.
   Santos, H. F.
   Almeida-Queiroz, S. R.
   Silva, A. N. M. R.
   Trevisol, I. M.
   Bertani, G. R.
   Gil, L. H. V. G.
TI Efficient assembly of full-length infectious clone of Brazilian IBDV
   isolate by homologous recombination in yeast
SO BRAZILIAN JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE infectious bursal disease virus; reverse genetics; yeast-based
   homologous recombination
ID BURSAL DISEASE VIRUS; DOUBLE-STRANDED-RNA; REVERSE GENETICS; POLYMERASE;
   CHICKENS; PROTEIN; RESCUE; GENOME; CONSTRUCTION; CDNA
AB The Infectious Bursal Disease Virus (IBDV) causes immunosuppression in young chickens. Advances in molecular virology and vaccines for IBDV have been achieved by viral reverse genetics (VRG). VRG for IBDV has undergone changes over time, however all strategies used to generate particles of IBDV involves multiple rounds of amplification and need of in vitro ligation and restriction sites. The aim of this research was to build the world's first VRG for IBDV by yeast-based homologous recombination; a more efficient, robust and simple process than cloning by in vitro ligation. The wild type IBDV (Wt-IBDV-Br) was isolated in Brazil and had its genome cloned in pJG-CMV-HDR vector by yeast-based homologous recombination. The clones were transfected into chicken embryo fibroblasts and the recovered virus (IC-IBDV-Br) showed genetic stability and similar phenotype to Wt-IBDV-Br, which were observed by nucleotide sequence, focus size/morphology and replication kinetics, respectively. Thus, IBDV reverse genetics by yeast-based homologous recombination provides tools to IBDV understanding and vaccines/viral vectors development.
C1 [Silva, J. V. J., Jr.; Arenhart, S.; Almeida-Queiroz, S. R.; Silva, A. N. M. R.; Gil, L. H. V. G.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Arenhart, S.] Univ Fed Santa Maria, Setor Virol, Dept Med Vet Prevent, Ctr Ciencias Rurais, BR-97119900 Santa Maria, RS, Brazil.
   [Santos, H. F.] Univ Fed Rio Grande do Sul, Lab Virol, Dept Microbiol Imunol & Parasitol, Inst Ciencias Basicas Saude, Porto Alegre, RS, Brazil.
   [Trevisol, I. M.] Embrapa Suinos & Aves, Concordia, SC, Brazil.
   [Bertani, G. R.] Univ Fed Pernambuco, Dept Bioquim, Recife, PE, Brazil.
   [Bertani, G. R.] Univ Fed Pernambuco, Lab Imunopatol Keiso Asami, Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
CR Zanetti FA, 2012, J VET SCI, V13, P199, DOI 10.4142/jvs.2012.13.2.199
   AZAD AA, 1985, VIROLOGY, V143, P35, DOI 10.1016/0042-6822(85)90094-7
   Balamurugan V, 2006, VET RES COMMUN, V30, P541, DOI 10.1007/s11259-006-3278-4
   Ben Abdeljelil N, 2008, ARCH VIROL, V153, P1131, DOI 10.1007/s00705-008-0080-3
   Boot HJ, 2001, J VIROL METHODS, V97, P67, DOI 10.1016/S0166-0934(01)00340-8
   Boot HJ, 1999, VIROLOGY, V265, P330, DOI 10.1006/viro.1999.0042
   COSGROVE AS, 1962, AVIAN DIS, V6, P385, DOI 10.2307/1587909
   Di Fabio J, 1999, VET REC, V145, P203
   Gao L, 2011, VACCINE, V29, P5550, DOI 10.1016/j.vaccine.2011.04.106
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   HUDSON PJ, 1986, NUCLEIC ACIDS RES, V14, P5001, DOI 10.1093/nar/14.12.5001
   JACKWOOD DJ, 1982, AVIAN DIS, V26, P871, DOI 10.2307/1589875
   Lim BL, 1999, J VIROL, V73, P2854, DOI 10.1128/JVI.73.4.2854-2862.1999
   Marozsan AJ, 2003, J VIROL METHODS, V111, P111, DOI 10.1016/S0166-0934(03)00166-6
   MULLER H, 1979, J VIROL, V31, P584
   Mundt E, 1996, P NATL ACAD SCI USA, V93, P11131, DOI 10.1073/pnas.93.20.11131
   MUNDT E, 1995, J GEN VIROL, V76, P437, DOI 10.1099/0022-1317-76-2-437
   NAKANO M, 1972, Biologico (Sao Paulo), V38, P60
   Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451
   Pan JH, 2007, P NATL ACAD SCI USA, V104, P7385, DOI 10.1073/pnas.0611599104
   Perera CL, 2002, REV CUBANA CIENCIA A, V26, P111
   Qi X, 2007, J VIROL METHODS, V142, P81, DOI 10.1016/j.jviromet.2007.01.021
   Queiroz SRA, 2013, AN ACAD BRAS CIENC, V85, P159, DOI 10.1590/S0001-37652013005000008
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Reynolds DL, 1998, ENTERIC VIRUSES LAB
   ROMERO CH, 1987, MANUAL TECNICAS VIRO
   Sambrook J, 2001, MOL CLONING LAB MANU
   Saukas TN, 1978, THESIS U RURAL DO RI
   Shanks RMQ, 2009, PLASMID, V62, P88, DOI 10.1016/j.plasmid.2009.05.002
   von Einem UI, 2004, J GEN VIROL, V85, P2221, DOI 10.1099/vir.0.19772-0
   Wang YS, 2012, VACCINE, V30, P2125, DOI 10.1016/j.vaccine.2012.01.040
NR 31
TC 3
Z9 4
U1 0
U2 3
PU SOC BRASILEIRA MICROBIOLOGIA
PI SAO PAULO
PA AV PROF LINEU PRESTES,1374, 05508 SAO PAULO, BRAZIL
SN 1517-8382
EI 1678-4405
J9 BRAZ J MICROBIOL
JI Braz. J. Microbiol.
PD OCT-DEC
PY 2014
VL 45
IS 4
BP 1555
EP 1563
DI 10.1590/S1517-83822014000400054
PG 9
WC Microbiology
SC Microbiology
GA CC2UM
UT WOS:000350200100054
PM 25763067
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Arenhart, S
   Flores, EF
   Weiblen, R
   Gil, LHVG
AF Arenhart, S.
   Flores, E. F.
   Weiblen, R.
   Gil, L. H. V. G.
TI Insertion and stable expression of Gaussia luciferase gene by the genome
   of bovine viral diarrhea virus
SO RESEARCH IN VETERINARY SCIENCE
LA English
DT Article
DE Pestivirus; Reverse genetics; Infectious clone; Reporter gene; Yeast
   homologous recombination
ID INFECTIOUS RNA TRANSCRIPTS; CDNA-CLONES; N-PRO; IN-VIVO; POINT
   MUTATIONS; DNA FRAGMENTS; BAC CDNA; PESTIVIRUS; YEAST; CYTOPATHOGENICITY
AB As a tool to address selected issues of virus biology, we constructed a recombinant cDNA clone of bovine viral diarrhea virus (BVDV) expressing Gaussia luciferase (Gluc) reporter gene. A full-length genomic cDNA clone of a non-cytopathic BVDV isolate was assembled by recombination in yeast Saccharomyces cerevisiae. The Gluc gene was inserted between the N-Pro and Core protein coding regions by recombination. The cDNA transcribed in vitro was infectious upon transfection of MDBK cells, resulting in reporter gene expression and productive virus replication. The rescued viruses were stable for 15 passages in cell culture, maintaining the replication kinetics, focus size and morphology similar to those of the parental virus. Expression and correct processing of the reporter protein were also maintained, as demonstrated by Gluc activity. These results demonstrate that genes up to 555 bp are simply assembled by a single step in yeast recombination and are stably expressed by this cDNA clone. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Arenhart, S.; Gil, L. H. V. G.] Fundacao Oswaldo Cruz Fiocruz, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol & Terapia Expt, Lab Virol & Terapia Expt LaViTE, BR-50670420 Recife, PE, Brazil.
   [Arenhart, S.; Flores, E. F.; Weiblen, R.] Univ Fed Santa Maria, CCR, DMVP, SV, BR-97105900 Santa Maria, RS, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol & Terapia Expt, Lab Virol & Terapia Expt LaViTE, BR-50670420 Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Weiblen, Rudi/H-7003-2014; flores, eduardo furtado/H-5125-2016
OI Weiblen, Rudi/0000-0002-1737-9817; 
CR BAKER JC, 1995, VET CLIN N AM-FOOD A, V11, P425, DOI 10.1016/S0749-0720(15)30460-6
   Becher P, 2000, J VIROL, V74, P7884, DOI 10.1128/JVI.74.17.7884-7894.2000
   Behrens SE, 1998, J VIROL, V72, P2364, DOI 10.1128/JVI.72.3.2364-2372.1998
   Bolin SR, 2004, VET CLIN N AM-FOOD A, V20, P51, DOI 10.1016/j.cvfa.2003.11.009
   COLLETT MS, 1988, VIROLOGY, V165, P200, DOI 10.1016/0042-6822(88)90673-3
   CORAPI WV, 1989, J VIROL, V63, P3934, DOI 10.1128/JVI.63.9.3934-3943.1989
   Dehan P, 2005, VACCINE, V23, P4236, DOI 10.1016/j.vaccine.2005.03.026
   DONIS RO, 1995, VET CLIN N AM-FOOD A, V11, P393, DOI 10.1016/S0749-0720(15)30459-X
   Fan ZC, 2008, J VIROL METHODS, V151, P257, DOI 10.1016/j.jviromet.2008.04.008
   Fan ZC, 2008, J VIROL METHODS, V149, P309, DOI 10.1016/j.jviromet.2008.01.011
   Fan ZC, 2008, VIRUS RES, V138, P97, DOI 10.1016/j.virusres.2008.08.015
   FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   Gibson DG, 2008, P NATL ACAD SCI USA, V105, P20404, DOI 10.1073/pnas.0811011106
   Gil LHVG, 2006, J VIROL, V80, P900, DOI 10.1128/JVI.80.2.900-911.2006
   GILLESPIE JAMES H., 1960, CORNELL VET, V50, P73
   Harding MJ, 2002, AM J VET RES, V63, P1455, DOI 10.2460/ajvr.2002.63.1455
   Henningson JN, 2009, AM J VET RES, V70, P1117, DOI 10.2460/ajvr.70.9.1117
   Joska TM, 2014, J MICROBIOL METH, V100, P46, DOI 10.1016/j.mimet.2013.11.013
   Kummerer BM, 2000, J VIROL, V74, P390, DOI 10.1128/JVI.74.1.390-400.2000
   Linderbach BD, 2001, FIELDS VIROLOGY, P991
   MCCLURKIN AW, 1984, CAN J COMP MED, V48, P156
   Mendez E, 1998, J VIROL, V72, P4737, DOI 10.1128/JVI.72.6.4737-4745.1998
   Meyer C, 2002, J VIROL, V76, P8494, DOI 10.1128/JVI.76.16.8494-8503.2002
   Meyers G, 1996, J VIROL, V70, P8606, DOI 10.1128/JVI.70.12.8606-8613.1996
   Meyers G, 2007, J VIROL, V81, P3327, DOI 10.1128/JVI.02372-06
   Moormann RJM, 1996, J VIROL, V70, P763, DOI 10.1128/JVI.70.2.763-770.1996
   Myers TM, 2001, J VIROL, V75, P4226, DOI 10.1128/JVI.75.9.4226-4238.2001
   Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   Qu L, 2001, J VIROL, V75, P10651, DOI 10.1128/JVI.75.22.10651-10662.2001
   Rasmussen TB, 2010, VET MICROBIOL, V142, P13, DOI 10.1016/j.vetmic.2009.09.037
   Reimann I, 2004, VIROLOGY, V322, P143, DOI 10.1016/j.virol.2004.01.028
   Reimann I, 2003, VIROLOGY, V307, P213, DOI 10.1016/S0042-6822(02)00129-0
   RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987
   Ridpath JF, 2005, PREV VET MED, V72, P17, DOI 10.1016/j.prevetmed.2005.08.003
   Ridpath JF, 2010, VET CLIN N AM-FOOD A, V26, P105, DOI 10.1016/j.cvfa.2009.10.007
   Roda A, 2009, TRAC-TREND ANAL CHEM, V28, P307, DOI 10.1016/j.trac.2008.11.015
   RYAN MD, 1994, EMBO J, V13, P928, DOI 10.1002/j.1460-2075.1994.tb06337.x
   Sambrook J., 2001, MOL CLONING LAB MANU, V2
   Shanks RMQ, 2009, PLASMID, V62, P88, DOI 10.1016/j.plasmid.2009.05.002
   Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016
   TAUTZ N, 1994, J VIROL, V68, P3289, DOI 10.1128/JVI.68.5.3289-3297.1994
   VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902
   Vassilev VB, 1997, J VIROL, V71, P471, DOI 10.1128/JVI.71.1.471-478.1997
   Vassilev VB, 2001, VACCINE, V19, P2012, DOI 10.1016/S0264-410X(00)00438-2
NR 47
TC 4
Z9 4
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0034-5288
EI 1532-2661
J9 RES VET SCI
JI Res. Vet. Sci.
PD OCT
PY 2014
VL 97
IS 2
BP 439
EP 448
DI 10.1016/j.rvsc.2014.07.007
PG 10
WC Veterinary Sciences
SC Veterinary Sciences
GA AU7WN
UT WOS:000345809300046
PM 25108838
DA 2020-11-24
ER

PT J
AU Furbino, LE
   Godinho, VM
   Santiago, IF
   Pellizari, FM
   Alves, TMA
   Zani, CL
   Junior, PAS
   Romanha, AJ
   Carvalho, AGO
   Gil, LHVG
   Rosa, CA
   Minnis, AM
   Rosa, LH
AF Furbino, Laura E.
   Godinho, Valeria M.
   Santiago, Iara F.
   Pellizari, Franciane M.
   Alves, Tania M. A.
   Zani, Carlos L.
   Junior, Policarpo A. S.
   Romanha, Alvaro J.
   Carvalho, Amanda G. O.
   Gil, Laura H. V. G.
   Rosa, Carlos A.
   Minnis, Andrew M.
   Rosa, Luiz H.
TI Diversity Patterns, Ecology and Biological Activities of Fungal
   Communities Associated with the Endemic Macroalgae Across the Antarctic
   Peninsula
SO MICROBIAL ECOLOGY
LA English
DT Article
ID MARINE MACROALGAE; GEOMYCES; PENICILLIUM; ASCOMYCETE; DESV.; NOV.
AB We surveyed diversity patterns and engaged in bioprospecting for bioactive compounds of fungi associated with the endemic macroalgae, Monostroma hariotii and Pyropia endiviifolia, in Antarctica. A total of 239 fungal isolates were obtained, which were identified to represent 48 taxa and 18 genera using molecular methods. The fungal communities consisted of endemic, indigenous and cold-adapted cosmopolitan taxa, which displayed high diversity and richness, but low dominance indices. The extracts of endemic and cold-adapted fungi displayed biological activities and may represent sources of promising prototype molecules to develop drugs. Our results suggest that macroalgae along the marine Antarctic Peninsula provide additional niches where fungal taxa can survive and coexist with their host in the extreme conditions. We hypothesise that the dynamics of richness and dominance among endemic, indigenous and cold-adapted cosmopolitan fungal taxa might be used to understand and model the influence of climate change on the maritime Antarctic mycota.
C1 [Furbino, Laura E.; Godinho, Valeria M.; Santiago, Iara F.; Rosa, Carlos A.; Rosa, Luiz H.] Univ Fed Minas Gerais, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Pellizari, Franciane M.] Univ Estadual Parana, Lab Ficol & Qualidade Agua Mar, Paranagua, PR, Brazil.
   [Alves, Tania M. A.; Zani, Carlos L.] Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Quim Prod Nat, Belo Horizonte, MG, Brazil.
   [Junior, Policarpo A. S.; Romanha, Alvaro J.] Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Parasitol Celular & Mol, Belo Horizonte, MG, Brazil.
   [Romanha, Alvaro J.] Univ Fed Santa Catarina, BR-88040900 Florianopolis, SC, Brazil.
   [Carvalho, Amanda G. O.; Gil, Laura H. V. G.] Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Recife, PE, Brazil.
   [Carvalho, Amanda G. O.] Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil.
   [Minnis, Andrew M.] US Forest Serv, Ctr Forest Mycol Res, No Res Stn, Madison, WI USA.
RP Rosa, LH (corresponding author), Univ Fed Minas Gerais, Dept Microbiol, POB 486, BR-31270901 Belo Horizonte, MG, Brazil.
EM lhrosa@icb.ufmg.br
RI Zani, Carlos L/A-9658-2008; Alves, Tania Maria/B-4814-2009
OI Zani, Carlos L/0000-0003-1859-177X; Pellizzari,
   Franciane/0000-0003-1877-2570
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [Processes PROANTAR 557030/2009-9, Universal 471721/2013-1,
   PROANTAR 407230/2013-0]; Fundacao de Amparo a Pesquisa do Estado de
   Minas Gerais (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG)
   [Process Universal 0050-13]; Financiadora de Estudos e ProjetosCiencia
   Tecnologia e Inovacao (FINEP) [FINEP 2084/07]; Program for Technological
   Development of Tools for Health-PDTIS-FIOCRUZ; US Forest ServiceUnited
   States Department of Agriculture (USDA)United States Forest Service;
   Northern Research StationUnited States Department of Agriculture
   (USDA)United States Forest Service; Inter-Agency from the US Fish and
   Wildlife Service [F11RG00184]
FX We acknowledge the financial support from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Processes PROANTAR
   557030/2009-9, Universal 471721/2013-1 and PROANTAR 407230/2013-0,
   Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG),
   Process Universal 0050-13 and the Financiadora de Estudos e Projetos
   (FINEP 2084/07), the Program for Technological Development of Tools for
   Health-PDTIS-FIOCRUZ. A. M. Minnis received financial support from the
   US Forest Service, Northern Research Station and the Inter-Agency
   Agreement F11RG00184 grant from the US Fish and Wildlife Service. The
   results of this study are part of the Master Science degree of LE
   Furbino within the Programa of Pos-Graduacao in Biotecnologia of UFOP
   and the Pos-Doctoral of VM Godinho of CNPq under supervision of LH Rosa.
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Arenz BE, 2006, SOIL BIOL BIOCHEM, V38, P3057, DOI 10.1016/j.soilbio.2006.01.016
   Atalla MM, 2011, PENICILLIUM BREVICOM, V1, P1
   Bhadury P, 2011, PLOS ONE, V6e26445, P1
   Blanchette RA, 2010, MICROB ECOL, V60, P29, DOI 10.1007/s00248-010-9664-z
   Bridge PD, 2012, FUNGAL ECOL, V5, P381, DOI 10.1016/j.funeco.2012.01.007
   Carvalho CR, 2012, SYMBIOSIS, V57, P95, DOI 10.1007/s13199-012-0182-2
   CHARPY-ROUBAUD C, 1990, Marine Microbial Food Webs, V4, P31
   Clarke A, 2007, PHILOS T R SOC B, V362, P149, DOI 10.1098/rstb.2006.1958
   Donachie SP, 1998, AQUAT MICROB ECOL, V14, P129, DOI 10.3354/ame014129
   ESPINELINGROFF A, 1991, J CLIN MICROBIOL, V29, P393, DOI 10.1128/JCM.29.2.393-394.1991
   FELL JW, 1971, ANTON VAN LEE J M S, V37, P359, DOI 10.1007/BF02218506
   FELL JW, 1968, A VAN LEEUW J MICROB, V34, P365, DOI 10.1007/BF02046459
   FELL JW, 1973, CAN J MICROBIOL, V19, P643, DOI 10.1139/m73-106
   Frisvad JC, 2004, STUD MYCOL, P1
   Gazis R, 2011, MOL ECOL, V20, P3001, DOI 10.1111/j.1365-294X.2011.05110.x
   GLASS NL, 1995, APPL ENVIRON MICROB, V61, P1323, DOI 10.1128/AEM.61.4.1323-1330.1995
   Godinho VM, 2013, ISME J, V7, P1434, DOI 10.1038/ismej.2013.77
   Goncalves VN, 2012, FEMS MICROBIOL ECOL, V82, P459, DOI 10.1111/j.1574-6941.2012.01424.x
   Grasso S, 1997, MICROBIOLOGICA, V20, P371
   Guiry M. D., 2012, ALGAEBASE
   Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated
   Harrington TC, 2003, MYCOTAXON, V87, P141
   Hoog G.S., 2000, ATLAS CLIN FUNGI
   HYDE KD, 1995, HYDROBIOLOGIA, V295, P107, DOI 10.1007/BF00029117
   Iwamoto C, 2001, TETRAHEDRON, V57, P2997, DOI 10.1016/S0040-4020(01)00153-3
   Jones EBG, 2009, FUNGAL DIVERS, V35, P1
   Jones EBG, 2011, FUNGAL DIVERS, V50, P73, DOI 10.1007/s13225-011-0119-8
   Kirk PM, 2011, DICT FUNGI
   Kohlmeyer J, 1979, MARINE MYCOLOGY HIGH
   Kurtzman CP, 2011, YEASTS: A TAXONOMIC STUDY, VOLS 1-3, 5TH EDITION, P1
   Lachance MA, 1999, CAN J MICROBIOL, V45, P172, DOI 10.1139/cjm-45-2-172
   Li Y, 2008, J NAT PROD, V71, P1643, DOI 10.1021/np8003003
   Loque CP, 2010, POLAR BIOL, V33, P641, DOI 10.1007/s00300-009-0740-0
   Lorch JM, 2013, MYCOLOGIA, V105, P237, DOI 10.3852/12-207
   MERCANTINI R, 1989, MYCOPATHOLOGIA, V106, P47, DOI 10.1007/BF00436926
   Minnis AM, 2013, FUNGAL BIOL-UK, V117, P638, DOI 10.1016/j.funbio.2013.07.001
   National Committee for Clinical Laboratory Standards, 2003, M11A5 NCCLS
   Nedzarek A, 2004, POLAR BIOSCI, V17, P16
   Onofri S, 2007, CONTINENTAL ANTARCTI
   Parish CA, 2009, J NAT PROD, V72, P59, DOI 10.1021/np800528a
   Quartino ML, 2005, BOT MAR, V48, P187, DOI 10.1515/BOT.2005.029
   Romanha AJ, 2010, MEM I OSWALDO CRUZ, V105, P233, DOI 10.1590/S0074-02762010000200022
   Rosa LH, 2009, POLAR BIOL, V32, P161, DOI 10.1007/s00300-008-0515-z
   Rosa LH, 2010, FEMS MICROBIOL ECOL, V73, P178, DOI 10.1111/j.1574-6941.2010.00872.x
   Ruisi Serena, 2007, Reviews in Environmental Science and Bio/Technology, V6, P127, DOI 10.1007/s11157-006-9107-y
   Santiago IF, 2012, EXTREMOPHILES, V16, P95, DOI 10.1007/s00792-011-0409-9
   Stchigel AM, 2001, MYCOL RES, V105, P377, DOI 10.1017/S0953756201003379
   Suryanarayanan TS, 2010, BOT MAR, V53, P457, DOI 10.1515/BOT.2010.045
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Tosi S, 2002, POLAR BIOL, V25, P262, DOI 10.1007/s00300-001-0337-8
   Vaz ABM, 2011, BRAZ J MICROBIOL, V42, P937, DOI 10.1590/S1517-838220110003000012
   Vishniac HS, 2006, BIODIVERSITY AND ECOPHYSIOLOGY OF YEASTS, P419, DOI 10.1007/3-540-30985-3_16
   VISHNIAC HS, 1992, INT J SYST BACTERIOL, V42, P547, DOI 10.1099/00207713-42-4-547
   Wedge D. E., 1998, SAAS Bulletin of Biochemistry and Biotechnology, V11, P1
   White TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1
   Wiencke C., 2002, ANTARCTIC SEAWEEDS
   Zuccaro A., 2005, FUNGAL COMMUNITY ITS, P533, DOI DOI 10.1201/9781420027891.CH27
   Zucconi L, 2012, POLAR BIOL, V35, P749, DOI 10.1007/s00300-011-1119-6
NR 59
TC 52
Z9 55
U1 1
U2 29
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0095-3628
EI 1432-184X
J9 MICROB ECOL
JI Microb. Ecol.
PD MAY
PY 2014
VL 67
IS 4
BP 775
EP 787
DI 10.1007/s00248-014-0374-9
PG 13
WC Ecology; Marine & Freshwater Biology; Microbiology
SC Environmental Sciences & Ecology; Marine & Freshwater Biology;
   Microbiology
GA AF1SX
UT WOS:000334495000005
PM 24509705
DA 2020-11-24
ER

PT J
AU Santos, JJD
   Cordeiro, MT
   Bertani, GR
   Marques, ETD
   Gil, LHVG
AF da Silva Santos, Jefferson Jose
   Cordeiro, Marli Tenorio
   Bertani, Giovani Rota
   de Azevedo Marques, Ernesto Torres
   Vega Gonzales Gil, Laura Helena
TI Construction and characterisation of a complete reverse genetics system
   of dengue virus type 3
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE reverse genetics; dengue virus; molecular cloning
ID CDNA-CLONES; HEMORRHAGIC-FEVER; INFECTIOUS CLONE; VACCINE; YEAST;
   PATHOGENESIS; REPLICON; PROTEIN; STRAIN; DNA
AB Dengue virulence and fitness are important factors that determine disease outcome. However, dengue virus (DENV) molecular biology and pathogenesis are not completely elucidated. New insights on those mechanisms have been facilitated by the development of reverse genetic systems in the past decades. Unfortunately, instability of flavivirus genomes cloned in Escherichia coli has been a major problem in these systems. Here, we describe the development of a complete reverse genetics system, based on the construction of an infectious clone and replicon for a low passage DENV-3 genotype III of a clinical isolate. Both constructs were assembled into a newly designed yeast-E. coli shuttle vector by homologous recombination technique and propagated in yeast to prevent any possible genome instability in E. coli. RNA transcripts derived from the infectious clone are infectious upon transfection into BHK-21 cells even after repeated passages of the plasmid in yeast. Transcript-derived DENV-3 exhibited growth kinetics, focus formation size comparable to original DENV-3 in mosquito C6/36 cell culture. In vitro characterisation of DENV-3 replicon confirmed its identity and ability to replicate transiently in BHK-21 cells. The reverse genetics system reported here is a valuable tool that will facilitate further molecular studies in DENV replication, virus attenuation and pathogenesis.
C1 [da Silva Santos, Jefferson Jose; Cordeiro, Marli Tenorio; de Azevedo Marques, Ernesto Torres; Vega Gonzales Gil, Laura Helena] Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio] Dept Saude Estado Pernambuco, Lab Cent Saude Publ, Recife, PE, Brazil.
   [Bertani, Giovani Rota] Univ Fed Pernambuco, Dept Bioquim, Recife, PE, Brazil.
   [de Azevedo Marques, Ernesto Torres] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
RP Gil, LHVG (corresponding author), Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Recife, PE, Brazil.
EM laura@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Santos, Jefferson/W-9610-2019
OI Marques, Ernesto T. A/0000-0003-3826-9358; Santos,
   Jefferson/0000-0001-5895-4163
FU FIOCRUZ (Papes V); FACEPE [APQ-0519-2.12/06]; CNPqNational Council for
   Scientific and Technological Development (CNPq) [470892/2007-2];
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX Financial support: FIOCRUZ (Papes V), FACEPE (APQ-0519-2.12/06), CNPq
   (470892/2007-2); JJSS receives a graduate scholarship from the CNPq.
CR Alcaraz-Estrada SL, 2010, J GEN VIROL, V91, P2713, DOI 10.1099/vir.0.024083-0
   Alvarez DE, 2005, J VIROL, V79, P6631, DOI 10.1128/JVI.79.11.6631-6643.2005
   Ansari IH, 2004, J VIROL, V78, P9612, DOI 10.1128/JVI.78.18.9612-9623.2004
   Blaney JE, 2004, AM J TROP MED HYG, V71, P811, DOI 10.4269/ajtmh.2004.71.811
   Bouloy M, 2009, ANTIVIR RES, V84, P101, DOI 10.1016/j.antiviral.2009.08.002
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cox J, 2012, J VIROL, V86, P7637, DOI 10.1128/JVI.00534-12
   Das S, 2007, J VIS EXP, V2007, P220
   Fernandez-Garcia MD, 2009, CELL HOST MICROBE, V5, P318, DOI 10.1016/j.chom.2009.04.001
   FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   Gil LHVG, 2006, J VIROL, V80, P900, DOI 10.1128/JVI.80.2.900-911.2006
   Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019
   Hurrelbrink RJ, 1999, J GEN VIROL, V80, P3115, DOI 10.1099/0022-1317-80-12-3115
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   KAPOOR M, 1995, GENE, V162, P175, DOI 10.1016/0378-1119(95)00332-Z
   Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997
   Kurosu T, 2010, BIOCHEM BIOPH RES CO, V394, P398, DOI 10.1016/j.bbrc.2010.02.181
   LAI CJ, 1991, P NATL ACAD SCI USA, V88, P5139, DOI 10.1073/pnas.88.12.5139
   Lindenbach BD, 2007, FIELDS VIROLOGY, V1, P1102
   Liu WJ, 2006, J VIROL, V80, P2396, DOI 10.1128/JVI.80.5.2396-2404.2006
   MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223
   Messer WB, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001486
   MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395
   Pang X, 2001, BMC Microbiol, V1, P18, DOI 10.1186/1471-2180-1-18
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   Pu SY, 2011, J VIROL, V85, P2927, DOI 10.1128/JVI.01986-10
   Puig-Basagoiti F, 2005, ANTIMICROB AGENTS CH, V49, P4980, DOI 10.1128/AAC.49.12.4980-4988.2005
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   RICE C M, 1989, New Biologist, V1, P285
   Ruggli N, 1999, ADV VIRUS RES, V53, P183, DOI 10.1016/S0065-3527(08)60348-6
   Sambrook J, 2001, MOL CLONING LAB MANU
   Shanks RMQ, 2009, PLASMID, V62, P88, DOI 10.1016/j.plasmid.2009.05.002
   SIKORSKI RS, 1989, GENETICS, V122, P19
   Sriburi R, 2001, J VIROL METHODS, V92, P71, DOI 10.1016/S0166-0934(00)00277-9
   Suzuki R, 2007, VIROLOGY, V362, P374, DOI 10.1016/j.virol.2006.11.026
   Tuiskunen A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-398
   Ubol S, 2008, VIROLOGY, V376, P290, DOI 10.1016/j.virol.2008.03.030
   Widman DG, 2008, VACCINE, V26, P2762, DOI 10.1016/j.vaccine.2008.03.009
   Yamshchikov VF, 2001, VIROLOGY, V281, P294, DOI 10.1006/viro.2000.0795
NR 43
TC 9
Z9 11
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD DEC
PY 2013
VL 108
IS 8
BP 983
EP 991
DI 10.1590/0074-0276130298
PG 9
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 294HY
UT WOS:000330037300005
PM 24402142
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Nascimento, EJM
   Mailliard, RB
   Khan, AM
   Sidney, J
   Sette, A
   Guzman, N
   Paulaitis, M
   de Melo, AB
   Cordeiro, MT
   Gil, LVG
   Lemonnier, F
   Rinaldo, C
   August, JT
   Marques, ETA
AF Nascimento, Eduardo J. M.
   Mailliard, Robbie B.
   Khan, Asif M.
   Sidney, John
   Sette, Alessandro
   Guzman, Nicole
   Paulaitis, Michael
   de Melo, Andrea Barbosa
   Cordeiro, Marli T.
   Gil, Laura V. G.
   Lemonnier, Francoir
   Rinaldo, Charles
   August, J. Thomas
   Marques, Ernesto T. A., Jr.
TI Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID DENGUE HEMORRHAGIC-FEVER; ORIGINAL ANTIGENIC SIN; LYMPHOCYTE CLONES;
   VARIANT PEPTIDES; SUBTYPE-III; VIRUS; RESPONSES; VACCINE; BINDING; MICE
AB Anti-dengue T-cell responses have been implicated in both protection and immunopathology. However, most of the T-cell studies for dengue include few epitopes, with limited knowledge of their inter-serotype variation and the breadth of their human leukocyte antigen (HLA) affinity. In order to expand our knowledge of HLA-restricted dengue epitopes, we screened T-cell responses against 477 overlapping peptides derived from structural and non-structural proteins of the dengue virus serotype 3 (DENV3) by use of HLA class I and II transgenic mice (TgM): A2, A24, B7, DR2, DR3 and DR4. TgM were inoculated with peptides pools and the T-cell immunogenic peptides were identified by ELISPOT. Nine HLA class I and 97 HLA class II novel DENV3 epitopes were identified based on immunogenicity in TgM and their HLA affinity was further confirmed by binding assays analysis. A subset of these epitopes activated memory T-cells from DENV3 immune volunteers and was also capable of priming naive T-cells, ex vivo, from dengue IgG negative individuals. Analysis of inter-and intra-serotype variation of such an epitope (A02-restricted) allowed us to identify altered peptide ligands not only in DENV3 but also in other DENV serotypes. These studies also characterized the HLA promiscuity of 23 HLA class II epitopes bearing highly conserved sequences, six of which could bind to more than 10 different HLA molecules representing a large percentage of the global population. These epitope data are invaluable to investigate the role of T-cells in dengue immunity/pathogenesis and vaccine design.
C1 [Nascimento, Eduardo J. M.; Mailliard, Robbie B.; Rinaldo, Charles; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15213 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Khan, Asif M.; August, J. Thomas] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [Khan, Asif M.] Perdana Univ, Grad Sch Med, Serdang, Selangor Darul, Malaysia.
   [Sidney, John; Sette, Alessandro] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
   [Guzman, Nicole; Paulaitis, Michael] Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA.
   [de Melo, Andrea Barbosa; Cordeiro, Marli T.; Gil, Laura V. G.; Marques, Ernesto T. A., Jr.] Fiocruz MS, Dept Virol & Expt Therapy, CPqAM, Recife, PE, Brazil.
   [Lemonnier, Francoir] Inst Pasteur, Unite Immunite Cellulaire Antivirale, Paris, France.
RP Nascimento, EJM (corresponding author), Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15213 USA.
EM ejmn@pitt.edu; marques@pitt.edu
RI Nascimento, Eduardo/J-4590-2014; Khan, Mohammad Asif/F-4663-2010;
   Marques, Ernesto T. A/L-4967-2013; Mailiiard, Robbie/M-9723-2015
OI Nascimento, Eduardo/0000-0002-9851-2332; Khan, Mohammad
   Asif/0000-0001-9202-279X; Marques, Ernesto T. A/0000-0003-3826-9358;
   Mailliard, Robbie/0000-0001-5501-503X
FU NIH/NAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [HHSN272200900042C, U19 AI56541]
FX This work was supported by NIH/NAID contracts HHSN272200900042C (AS) and
   U19 AI56541. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ashour J, 2009, J VIROL, V83, P5408, DOI 10.1128/JVI.02188-08
   Bashyam HS, 2006, J IMMUNOL, V176, P2817, DOI 10.4049/jimmunol.176.5.2817
   Buchli R, 2004, BIOCHEMISTRY-US, V43, P14852, DOI 10.1021/bi048580q
   Capeding RZ, 2010, AM J TROP MED HYG, V82, P330, DOI 10.4269/ajtmh.2010.09-0542
   Chaturvedi UC, 2005, INDIAN J MED RES, V121, P639
   Chotiyarnwong P, 2007, ACTA CRYSTALLOGR F, V63, P386, DOI 10.1107/S1744309107013693
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Melo AB, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001938
   de Melo AB, 2011, AM J TROP MED HYG, V85, P739, DOI 10.4269/ajtmh.2011.10-0496
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   de Alencar LXE, 2013, J TROP MED-US, V2013, DOI 10.1155/2013/648475
   Fruci D, 2003, J IMMUNOL, V170, P2977, DOI 10.4049/jimmunol.170.6.2977
   Green S, 1997, VIROLOGY, V234, P383, DOI 10.1006/viro.1997.8648
   Green SL, 1997, VET CLIN N AM-EQUINE, V13, P1
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019
   Gwinn W, 2003, AM J TROP MED HYG, V69, P39, DOI 10.4269/ajtmh.2003.69.39
   Harenberg A, 2013, HUM VACC IMMUNOTHER, V9, P2317, DOI 10.4161/hv.25562
   Hertz T, 2011, J VIROL, V85, P1310, DOI 10.1128/JVI.01966-10
   Imrie A, 2007, J VIROL, V81, P10081, DOI 10.1128/JVI.00330-07
   Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635
   Jung KO, 2012, J VIROL, V86, P7616, DOI 10.1128/JVI.00166-12
   Kanakaratne N, 2009, EMERG INFECT DIS, V15, P192, DOI 10.3201/eid1502.080926
   Khan AM, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S5-S4
   Khan AM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000272
   KURANE I, 1993, J VIROL, V67, P6285, DOI 10.1128/JVI.67.10.6285-6288.1993
   Kurane I, 1998, VIROLOGY, V240, P169, DOI 10.1006/viro.1997.8925
   Lee KS, 2010, EMERG INFECT DIS, V16, P847, DOI 10.3201/eid1605.091006
   Li SF, 2011, VACCINE, V29, P3695, DOI 10.1016/j.vaccine.2011.03.002
   Lund O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026494
   Maciel M, 2008, VIROLOGY, V378, P105, DOI 10.1016/j.virol.2008.04.043
   Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338
   Mailliard RB, 2004, CANCER RES, V64, P5934, DOI 10.1158/0008-5472.CAN-04-1261
   Mailliard RB, 2013, J IMMUNOL, V191, P2570, DOI 10.4049/jimmunol.1300373
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mathew A, 1998, J VIROL, V72, P3999, DOI 10.1128/JVI.72.5.3999-4004.1998
   Mazzon M, 2009, J INFECT DIS, V200, P1261, DOI 10.1086/605847
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Morrison AC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000670
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296
   Okamoto Y, 1998, J GEN VIROL, V79, P697, DOI 10.1099/0022-1317-79-4-697
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Paramasivan R, 2010, INDIAN J MED RES, V132, P339
   Pascolo S, 2005, EXPERT OPIN BIOL TH, V5, P919, DOI 10.1517/14712598.5.7.919
   Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043
   Rodriguez-Madoz JR, 2010, J VIROL, V84, P4845, DOI 10.1128/JVI.02514-09
   Roederer M, 2003, J IMMUNOL METHODS, V274, P221, DOI 10.1016/S0022-1759(02)00423-4
   Rohrlich PS, 2003, INT IMMUNOL, V15, P765, DOI 10.1093/intimm/dxg073
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sanchez V, 2006, VACCINE, V24, P4914, DOI 10.1016/j.vaccine.2006.03.066
   Scharnagl NC, 2007, EXPERT REV VACCINES, V6, P605, DOI 10.1586/14760584.6.4.605
   Sette A, 2010, IMMUNITY, V33, P530, DOI 10.1016/j.immuni.2010.09.017
   Sidney J, 2001, Curr Protoc Immunol, VChapter 18, DOI 10.1002/0471142735.im1803s31
   Sidney J, 2010, J IMMUNOL, V185, P4189, DOI 10.4049/jimmunol.1001006
   Sidney J, 2010, J IMMUNOL, V184, P2492, DOI 10.4049/jimmunol.0903655
   Sidney John, 2008, Immunome Res, V4, P2, DOI 10.1186/1745-7580-4-2
   Simmons CP, 2005, J VIROL, V79, P5665, DOI 10.1128/JVI.79.9.5665-5675.2005
   Simon GG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008574
   STRAUSS G, 1994, IMMUNOGENETICS, V40, P104
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Sun JM, 2011, EMERG INFECT DIS, V17, P321, DOI 10.3201/eid1702.100396
   Tan PT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008754
   Thomas SJ, 2013, AM J TROP MED HYG, V88, P73, DOI 10.4269/ajtmh.2012.12-0361
   Toma A, 2009, DIABETES, V58, P394, DOI 10.2337/db08-0599
   Vandenbark AA, 2003, J IMMUNOL, V171, P127, DOI 10.4049/jimmunol.171.1.127
   Vaughan K, 2010, VIRAL IMMUNOL, V23, P259, DOI 10.1089/vim.2010.0006
   Weiskopf D, 2011, J IMMUNOL, V187, P4268, DOI 10.4049/jimmunol.1101970
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Zeng LL, 1996, J VIROL, V70, P3108, DOI 10.1128/JVI.70.5.3108-3117.1996
   Zivna I, 2002, J IMMUNOL, V168, P5959, DOI 10.4049/jimmunol.168.11.5959
   ZIVNY J, 1995, J EXP MED, V182, P853, DOI 10.1084/jem.182.3.853
NR 77
TC 23
Z9 23
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2013
VL 7
IS 10
AR e2497
DI 10.1371/journal.pntd.0002497
PG 16
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 299DW
UT WOS:000330376500034
PM 24130917
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU da Silva, MMC
   Gil, LHVG
   Marques, ETD
   Calzavara-Silva, CE
AF Carneiro da Silva, Mayara Marques
   Vega Gonzales Gil, Laura Helena
   de Azevedo Marques Junior, Ernesto Torres
   Calzavara-Silva, Carlos Eduardo
TI Potential biomarkers for the clinical prognosis of severe dengue
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue; biomarkers; apoptosis; innate immunity; quantitative real-time
   PCR
ID BLOOD MONONUCLEAR-CELLS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B;
   GENE-EXPRESSION; VIRUS-INFECTION; HEMORRHAGIC-FEVER; DENDRITIC CELLS;
   GAMMA RIII; DISEASE; RECEPTOR
AB Currently, several assays can confirm acute dengue infection at the point-of-care. However, none of these assays can predict the severity of the disease symptoms. A prognosis test that predicts the likelihood of a dengue patient to develop a severe form of the disease could permit more efficient patient triage and treatment. We hypothesise that mRNA expression of apoptosis and innate immune response-related genes will be differentially regulated during the early stages of dengue and might predict the clinical outcome. Aiming to identify biomarkers for dengue prognosis, we extracted mRNA from the peripheral blood mononuclear cells of mild and severe dengue patients during the febrile stage of the disease to measure the expression levels of selected genes by quantitative polymerase chain reaction. The selected candidate biomarkers were previously identified by our group as differentially expressed in microarray studies. We verified that the mRNA coding for CFD, MAGED1, PSMB9, PRDX4 and FCGR3B were differentially expressed between patients who developed clinical symptoms associated with the mild type of dengue and patients who showed clinical symptoms associated with severe dengue. We suggest that this gene expression panel could putatively serve as biomarkers for the clinical prognosis of dengue haemorrhagic fever.
C1 [Carneiro da Silva, Mayara Marques; Vega Gonzales Gil, Laura Helena; de Azevedo Marques Junior, Ernesto Torres] Fiocruz MS, Centro Pesquisas Aggeu Magalhaes, Dept Virol, Lab Virol & Terapia Expt, Recife, PE, Brazil.
   [de Azevedo Marques Junior, Ernesto Torres] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Calzavara-Silva, Carlos Eduardo] Fiocruz MS, Ctr Pesquisas Rene Rachou, Dept Imunol, Lab Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
RP Calzavara-Silva, CE (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Dept Imunol, Lab Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
EM calzavara@cpqrr.fiocruz.br
RI Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358; CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU FAPEMIGMinas Gerais State Research Foundation (FAPEMIG)
   [CBB-APQ-00741-11]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [550140/2010-7, 477569/2011-0]
FX FAPEMIG (CBB-APQ-00741-11), CNPq (550140/2010-7, 477569/2011-0)
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Aleyas AG, 2009, J IMMUNOL, V183, P2462, DOI 10.4049/jimmunol.0801952
   Applied Biosystems, 2012, AMPL EFF TAQMANR GEN
   Applied Biosystems, 2012, APPL BIOS US B
   Avirutnan P, 2008, VACCINE, V26, pI100, DOI 10.1016/j.vaccine.2008.11.061
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P287, DOI 10.1111/j.1574-695X.2008.00420.x
   Brown MG, 2009, J LEUKOCYTE BIOL, V85, P71, DOI 10.1189/jlb.0308167
   Calzavara-Silva CE, 2009, AN ACAD BRAS CIENC, V81, P671, DOI 10.1590/S0001-37652009000400006
   Chang K, 2009, J FORMOS MED ASSOC, V108, P879, DOI 10.1016/S0929-6646(09)60420-4
   Chaturvedi UC, 2006, FEMS IMMUNOL MED MIC, V47, P155, DOI 10.1111/j.1574-695X.2006.00058.x
   Cheng HJ, 2009, EXP BIOL MED, V234, P63, DOI 10.3181/0805-RM-147
   Coffey LL, 2009, MICROBES INFECT, V11, P143, DOI 10.1016/j.micinf.2008.12.006
   Conceicao TM, 2010, J INFECTION, V60, P65, DOI 10.1016/j.jinf.2009.10.003
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   delaSalle H, 1997, ADV EXP MED BIOL, V417, P345
   Durbin AP, 2008, VIROLOGY, V376, P429, DOI 10.1016/j.virol.2008.03.028
   Espina LM, 2003, AM J TROP MED HYG, V68, P48, DOI 10.4269/ajtmh.2003.68.48
   Fink J, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000086
   Galon J, 1996, J IMMUNOL, V157, P1184
   Gibbons RV, 2009, BMJ-BRIT MED J, V324, P1563
   Gil L, 2009, VIRAL IMMUNOL, V22, P23, DOI 10.1089/vim.2008.0063
   Gilfoy F, 2009, VIROLOGY, V385, P74, DOI 10.1016/j.virol.2008.11.034
   Gomes ALV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011267
   Gray KA, 2013, NUCLEIC ACIDS RES, V41, pD545, DOI 10.1093/nar/gks1066
   Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015
   Huerta-Zepeda A, 2008, THROMB HAEMOSTASIS, V99, P936, DOI [10.1160/TH07-08-0483, 10.1160/TH07-08-0438]
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952
   Kindzelskii AL, 2000, J IMMUNOL, V164, P953, DOI 10.4049/jimmunol.164.2.953
   Kwan WH, 2005, J VIROL, V79, P7291, DOI 10.1128/JVI.79.12.7291-7299.2005
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Levy A, 2010, T ROY SOC TROP MED H, V104, P16, DOI 10.1016/j.trstmh.2009.06.013
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102
   Long HT, 2009, J INFECT DIS, V199, P537, DOI 10.1086/596507
   Long TH, 2010, J VIROL, V84, P12982, DOI 10.1128/JVI.01224-10
   Mairuhu ATA, 2004, EUR J CLIN MICROBIOL, V23, P425, DOI 10.1007/s10096-004-1145-1
   Mandelboim O, 1999, P NATL ACAD SCI USA, V96, P5640, DOI 10.1073/pnas.96.10.5640
   Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007892
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Nasirudeen AMA, 2009, J MED VIROL, V81, P1069, DOI 10.1002/jmv.21486
   Nsakran S, 2008, EXP BIOL MED, V233, P401, DOI 10.3181/0707-MR-198
   Okado-Matsumoto A, 2000, J BIOCHEM, V127, P493, DOI 10.1093/oxfordjournals.jbchem.a022632
   Pold M, 1999, GENOMICS, V59, P161, DOI 10.1006/geno.1999.5870
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Screaton Gavin, 2006, Novartis Found Symp, V277, P164, DOI 10.1002/0470058005.ch12
   Senanayake Sanjaya, 2006, Aust Fam Physician, V35, P609
   Tsai TF, 1998, CURR OPIN INFECT DIS, V11, P547, DOI 10.1097/00001432-199810000-00006
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   WHO - World Health Organization, 2012, DENG DENG HAEM FEV
   Yen YT, 2008, J VIROL, V82, P12312, DOI 10.1128/JVI.00968-08
NR 55
TC 9
Z9 10
U1 0
U2 12
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD SEP
PY 2013
VL 108
IS 6
BP 755
EP 762
DI 10.1590/0074-0276108062013012
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 219HX
UT WOS:000324498000012
PM 24037198
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Pastor, AF
   Moura, LR
   Neto, JWD
   Nascimento, EJM
   Calzavara-Silva, CE
   Gomes, ALV
   da Silva, AM
   Cordeiro, MT
   Braga-Neto, U
   Crovella, S
   Gil, LHVG
   Marques, ETA
   Acioli-Santos, B
AF Pastor, Andre F.
   Moura, Lais Rodrigues
   Neto, Jose W. D.
   Nascimento, Eduardo J. M.
   Calzavara-Silva, Carlos E.
   Gomes, Ana Lisa V.
   da Silva, Ana Maria
   Cordeiro, Marli T.
   Braga-Neto, Ulisses
   Crovella, Sergio
   Gil, Laura H. V. G.
   Marques, Ernesto T. A., Jr.
   Acioli-Santos, Bartolomeu
TI Complement factor H gene (CFH) polymorphisms C-257T, G257A and
   haplotypes are associated with protection against severe dengue
   phenotype, possible related with high CFH expression
SO HUMAN IMMUNOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; HEMORRHAGIC-FEVER; VIRUS-INFECTIONS;
   INTERFERON-GAMMA; DISEASE SEVERITY; PROTEIN NS1; RISK-FACTOR; VIRAL
   LOAD; ACTIVATION; SURVEILLANCE
AB Four genetic polymorphisms located at the promoter (C-257T) and coding regions of CFH gene (exon 2 G257A, exon 14 A2089G and exon 19 G2881T) were investigated in 121 dengue patients (DENV-3) in order to assess the relationship between allele/haplotypes variants and clinical outcomes. A statistical value was found between the CFH-257T allele (TT/TC genotypes) and reduced susceptibility to severe dengue (SD). Statistical associations indicate that individuals bearing a T allele presented significantly higher protein levels in plasma. The -257T variant is located within a NF-kappa B binding site, suggesting that this variant might have effect on the ability of the CFH gene to respond to signals via the NF-kappa B pathway. The G257A allelic variant showed significant protection against severe dengue. When CFH haplotypes effect was considered, the ancestral CG/CG promoter-exon 2 SNP genotype showed significant risk to SD either in a general comparison (ancestral x all variant genotypes), as well as in individual genotypes comparison (ancestral x each variant genotype), where the most prevalent effect was observed in the CG/CG x CA/TG comparison. These findings support the involvement of -257T, 257A allele variants and haplotypes on severe dengue phenotype protection, related with high basal CFH expression. (C) 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Pastor, Andre F.; Moura, Lais Rodrigues; Neto, Jose W. D.; Calzavara-Silva, Carlos E.; Gomes, Ana Lisa V.; da Silva, Ana Maria; Cordeiro, Marli T.; Gil, Laura H. V. G.; Marques, Ernesto T. A., Jr.; Acioli-Santos, Bartolomeu] FIOCRUZ PE, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Braga-Neto, Ulisses] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX USA.
   [Pastor, Andre F.; Crovella, Sergio] Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Acioli-Santos, B (corresponding author), FIOCRUZ PE, Virol & Expt Therapy Lab, Av Prof Moraes Rego S-N Campus UFPE Cidade Univ, Recife, PE, Brazil.
EM bartacioli@yahoo.com
RI Nascimento, Eduardo/J-4590-2014; Neto, Jose Manoel Duarte/AAH-6963-2020;
   Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013;
   Crovella, Sergio/K-5050-2016
OI Nascimento, Eduardo/0000-0002-9851-2332; Neto, Jose Manoel
   Duarte/0000-0002-3588-2934; Marques, Ernesto T. A/0000-0003-3826-9358;
   Marques, Ernesto/0000-0003-3826-9358; Crovella,
   Sergio/0000-0001-8493-1168; CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU National Institute of Allergy and Infectious Diseases (NIAID/NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19 AI56541, N01 AI 40085]; Brazilian National
   Research Council (CNPq)National Council for Scientific and Technological
   Development (CNPq) [DCR 35.0382/2004.2]; FACEPE (Fundacao de Amparo
   Ciencia e Tecnologia do Estado de Pernambuco, Brazil); NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER; Division of Computing and Communication
   FoundationsNational Science Foundation (NSF)NSF - Directorate for
   Computer & Information Science & Engineering (CISE) [0845407] Funding
   Source: National Science Foundation
FX The author also acknowledge the support of the National Institute of
   Allergy and Infectious Diseases (NIAID/NIH), under Grants U19 AI56541
   and N01 AI 40085, the Brazilian National Research Council (CNPq), under
   Grant DCR 35.0382/2004.2 (to Dr. Braga-Neto), and the FACEPE (Fundacao
   de Amparo Ciencia e Tecnologia do Estado de Pernambuco, Brazil) for A.
   Pastor's fellowship.
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Alencar LXE, 2013, J TROPICAL MED, V2013, DOI DOI 10.1155/2013/648475
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Avirutnan P, 2007, PLOS PATHOG, V3, P1798, DOI 10.1371/journal.ppat.0030183
   Bokisch V A, 1973, Trans Assoc Am Physicians, V86, P102
   BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   CHIEWSILP P, 1981, AM J TROP MED HYG, V30, P1100, DOI 10.4269/ajtmh.1981.30.1100
   Chung KM, 2006, P NATL ACAD SCI USA, V103, P19111, DOI 10.1073/pnas.0605668103
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Sierra BDL, 2007, ARCH VIROL, V152, P533, DOI 10.1007/s00705-006-0869-x
   Fang X, 2012, FEMS IMMUNOL MED MIC, P1
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Furlan M, 2000, NEPHROL DIAL TRANSPL, V15, P1112, DOI 10.1093/ndt/15.8.1112
   Gubler D, 1997, DENGUE DENGUE HEMORR
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Halme J, 2009, MOL IMMUNOL, V46, P2284, DOI 10.1016/j.molimm.2009.04.005
   Krishna VD, 2009, J VIROL, V83, P4766, DOI 10.1128/JVI.01850-08
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102
   Loke H, 2001, J INFECT DIS, V184, P1369, DOI 10.1086/324320
   Luo W, 1999, SCAND J IMMUNOL, V49, P487
   Marques ETA, 2008, CAD SAUDE PUBLICA, V24, P547, DOI 10.1590/S0102-311X2008000300008
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Nishioka K, 1974, Allerg Immunol (Leipz), V20-21, P385
   Organization WH, 2004, DENGUE GUIDELINES DI
   PEREZ MLP, 1987, HAEMATOLOGIA, V20, P83
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Shresta S, 2012, MBIO, V3, DOI 10.1128/mBio.00003-12
   Soundravally R, 2007, HUM IMMUNOL, V68, P973, DOI 10.1016/j.humimm.2007.09.007
   Stephens HAF, 2002, TISSUE ANTIGENS, V60, P309, DOI 10.1034/j.1399-0039.2002.600405.x
   Tan GK, 2009, CURR OPIN INFECT DIS, V22, P302, DOI 10.1097/QCO.0b013e328329ae32
   Timar KK, 2006, MOL IMMUNOL, V43, P317, DOI 10.1016/j.molimm.2005.02.009
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
   Wang WK, 2003, VIROLOGY, V305, P330, DOI 10.1006/viro.2002.1704
   Warwicker P, 1997, IMMUNOGENETICS, V46, P437, DOI 10.1007/s002510050300
   Williams SA, 1997, SCAND J IMMUNOL, V45, P7, DOI 10.1046/j.1365-3083.1997.d01-364.x
NR 43
TC 12
Z9 12
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
J9 HUM IMMUNOL
JI Hum. Immunol.
PD SEP
PY 2013
VL 74
IS 9
BP 1225
EP 1230
DI 10.1016/j.humimm.2013.05.005
PG 6
WC Immunology
SC Immunology
GA 198RG
UT WOS:000322939400026
PM 23747994
OA Green Accepted
DA 2020-11-24
ER

PT J
AU Morais, ATS
   Terzian, ACB
   Duarte, DVB
   Bronzoni, RVM
   Madrid, MCFS
   Gavioli, AF
   Gil, LHVG
   Oliveira, AG
   Zanelli, CF
   Valentini, SR
   Rahal, P
   Nogueira, ML
AF Morais, Ana T. S.
   Terzian, Ana C. B.
   Duarte, Danilo V. B.
   Bronzoni, Roberta V. M.
   Madrid, Maria C. F. S.
   Gavioli, Arieli F.
   Gil, Laura H. V. G.
   Oliveira, Amanda G.
   Zanelli, Cleslei F.
   Valentini, Sandro R.
   Rahal, Paula
   Nogueira, Mauricio L.
TI The eukaryotic translation initiation factor 3 subunit L protein
   interacts with Flavivirus NS5 and may modulate yellow fever virus
   replication
SO VIROLOGY JOURNAL
LA English
DT Article
DE Eukaryotic translation initiation factor 3 subunit L; YFV protein
   nonstructural NS5; Protein-protein interaction
ID HEPATITIS-C VIRUS; ELONGATION FACTOR-I; RNA-POLYMERASE-I;
   GENE-EXPRESSION; HOST-CELL; PHOSPHORYLATION; PATHOGENESIS; INFECTIONS;
   COMPLEX; REGION
AB Background: Yellow fever virus (YFV) belongs to the Flavivirus genus and causes an important disease. An alarming resurgence of viral circulation and the expansion of YFV-endemic zones have been detected in Africa and South America in recent years. NS5 is a viral protein that contains methyltransferase and RNA-dependent RNA polymerase (RdRp) domains, which are essential for viral replication, and the interactions between NS5 and cellular proteins have been studied to better understand viral replication. The aim of this study was to characterize the interaction of the NS5 protein with eukaryotic translation initiation factor 3 subunit L (eIF3L) and to evaluate the role of eIF3L in yellow fever replication.
   Methods: To identify interactions of YFV NS5 with cellular proteins, we performed a two-hybrid screen using the YFV NS5 RdRp domain as bait with a human cDNA library, and RNApol deletion mutants were generated and analyzed using the two-hybrid system for mapping the interactions. The RNApol region involved was segmented into three fragments and analyzed using an eIF3L-expressing yeast strain. To map the NS5 residues that are critical for the interactions, we performed site-direct mutagenesis in segment 3 of the interaction domain (ID) and confirmed the interaction using in vitro assays and in vivo coimmunoprecipitation. The significance of eIF3L for YFV replication was investigated using eIF3L overexpression and RNA interference.
   Results: In this work, we describe and characterize the interaction of NS5 with the translation factor eIF3L. The interaction between NS5 and eIF3L was confirmed using in vitro binding and in vivo coimmunoprecipitation assays. This interaction occurs at a region (the interaction domain of the RNApol domain) that is conserved in several flaviviruses and that is, therefore, likely to be relevant to the genus. eIF3L overexpression and plaque reduction assays showed a slight effect on YFV replication, indicating that the interaction of eIF3L with YFV NS5 may play a role in YFV replication.
   Conclusions: Although the precise function of eIF3L on interactions with viral proteins is not entirely understood, these results indicate an interaction of eIF3L with YF NS5 and that eIF3L overexpression facilitates translation, which has potential implications for virus replication.
C1 [Morais, Ana T. S.; Terzian, Ana C. B.; Duarte, Danilo V. B.; Bronzoni, Roberta V. M.; Madrid, Maria C. F. S.; Gavioli, Arieli F.; Nogueira, Mauricio L.] Fac Med Sao Jose Rio do Preto FAMERP, Dept Doencas Dermatol Infecciosas & Parasitarias, Lab Pesquisas Virol, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
   [Morais, Ana T. S.; Rahal, Paula; Nogueira, Mauricio L.] Univ Estadual Paulista, Dept Biol, Programa Posgrad Microbiol, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.
   [Gil, Laura H. V. G.; Oliveira, Amanda G.] Ctr Pesquisas Aggeu Magalhaes CPqAM FIOCRUZ, Dept Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Zanelli, Cleslei F.; Valentini, Sandro R.] Univ Estadual Paulista, Fac Ciencias Farmaceut, Dept Ciencias Biol, BR-14801902 Araraquara, Brazil.
   [Nogueira, Mauricio L.] Univ Texas Med Branch, Ctr Trop Dis, Galveston, TX 77555 USA.
RP Nogueira, ML (corresponding author), Fac Med Sao Jose Rio do Preto FAMERP, Dept Doencas Dermatol Infecciosas & Parasitarias, Lab Pesquisas Virol, Av Brigadeiro Faria Lima 5416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM mauricio.nogueira@pq.cnpq.br
RI Rahal, Paula/D-3871-2012; Zanelli, Cleslei Fernando/AAE-1003-2019;
   Valentini, Sandro R/C-4353-2012; Nogueira, Mauricio L/B-7599-2012
OI Rahal, Paula/0000-0001-5693-6148; Zanelli, Cleslei
   Fernando/0000-0001-7831-1149; Nogueira, Mauricio L/0000-0003-1102-2419;
   Valentini, Sandro Roberto/0000-0003-4453-5413
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2010/05043-1, 2009/01400-7]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [566289/2008-3]
FX We thank Dr. Charles Rice (Rockefeller University, USA) for the
   pACNR/FLYF-17D vector used to construct the RdRp segments and for the
   NS5 antiserum supply. We also thank Dr. Pierre Jalinot (Laboratorie de
   Biologie Moleculaire de la Cellule, Lyon, France) for the pSGFlag-eIF3L
   plasmid used in the experiments. This work was supported by FAPESP
   (Grant # 2010/05043-1 and Grant # 2009/01400-7 to MLN) and by a CNPq
   Grant (Grant # 566289/2008-3 to MLN). MLN is supported by a CNPq
   Fellowship.
CR Badtke MP, 2006, BIOL PROCED ONLINE, V8, P77, DOI 10.1251/bpo121
   Bhattacharya D, 2008, VIROLOGY, V380, P276, DOI 10.1016/j.virol.2008.07.013
   Blackwell JL, 1997, J VIROL, V71, P6433, DOI 10.1128/JVI.71.9.6433-6444.1997
   Bollati M, 2010, ANTIVIR RES, V87, P125, DOI 10.1016/j.antiviral.2009.11.009
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   Bronzoni RVM, 2011, ARCH VIROL, V156, P931, DOI 10.1007/s00705-011-0927-x
   Cai Q, 2010, J MOL BIOL, V403, P185, DOI 10.1016/j.jmb.2010.07.054
   Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000
   Damoc E, 2007, MOL CELL PROTEOMICS, V6, P1135, DOI 10.1074/mcp.M600399-MCP200
   Davidson AD, 2009, ADV VIRUS RES, V74, P41, DOI 10.1016/S0065-3527(09)74002-3
   De Nova-Ocampo M, 2002, VIROLOGY, V295, P337, DOI 10.1006/viro.2002.1407
   Easton LE, 2009, NUCLEIC ACIDS RES, V37, P5537, DOI 10.1093/nar/gkp588
   Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101
   Fernandez-Garcia MD, 2009, CELL HOST MICROBE, V5, P318, DOI 10.1016/j.chom.2009.04.001
   Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001
   GOLEMIS EA, 2001, MOL CLONING LAB MANU
   Gould EA, 2008, LANCET, V371, P500, DOI 10.1016/S0140-6736(08)60238-X
   Houshmand H, 2003, BIOCHEM BIOPH RES CO, V309, P695, DOI 10.1016/j.bbrc.2003.08.054
   Johnson CM, 2001, J GEN VIROL, V82, P2935, DOI 10.1099/0022-1317-82-12-2935
   Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098
   Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001
   Masutani M, 2007, EMBO J, V26, P3373, DOI 10.1038/sj.emboj.7601765
   Morris-Desbois C, 2001, J BIOL CHEM, V276, P45988, DOI 10.1074/jbc.M104966200
   Pacca C, 2009, VIRUS GENES, V38, P224, DOI 10.1007/s11262-009-0328-3
   Pastorino B, 2010, ANTIVIR RES, V87, P281, DOI 10.1016/j.antiviral.2010.04.014
   Pijlman GP, 2008, CELL HOST MICROBE, V4, P579, DOI 10.1016/j.chom.2008.10.007
   Queiroz SR, 2013, AN ACAD BRAS CIENC, V1
   Scherer CA, 2007, VACCINE, V25, P6458, DOI 10.1016/j.vaccine.2007.06.035
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Seither P, 2001, BIOL CHEM, V382, P1163, DOI 10.1515/BC.2001.146
   Valente ST, 2009, P NATL ACAD SCI USA, V106, P4071, DOI 10.1073/pnas.0900557106
   Yuan XJ, 2002, EMBO REP, V3, P1082, DOI 10.1093/embo-reports/kvf212
NR 32
TC 12
Z9 14
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD JUN 22
PY 2013
VL 10
AR 205
DI 10.1186/1743-422X-10-205
PG 13
WC Virology
SC Virology
GA 174GR
UT WOS:000321143500001
PM 23800076
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Queiroz, SRA
   Silva, ANMR
   Santos, JJS
   Marques, ETA
   Bertani, GR
   Gil, LHVG
AF Queiroz, Sabrina R. A.
   Silva, Andrea N. M. R.
   Santos, Jefferson J. S.
   Marques, Ernesto T. A., Jr.
   Bertani, Giovani R.
   Gil, Laura H. V. G.
TI Construction of yellow fever virus subgenomic replicons by yeast-based
   homologous recombination cloning technique
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE cloning technique; homologous recombination; replicon; reporter gene;
   yellow fever virus
ID IN-VITRO; DNA FRAGMENTS; RNA; VACCINE; IMMUNIZATION; VECTORS; SYSTEM;
   TRANSCOMPLEMENTATION; REPLICATION; EXPRESSION
AB RNA replicon derived from Flavivirus genome is a valuable tool for studying viral replication independent of virion assembly and maturation, besides being a great potencial for heterologous gene expression. In this study we described the construction of subgenomic replicons of yellow fever virus by yeast-based homologous recombination technique. The plasmid containing the yellow fever 17D strain replicon (pBSC-repYFV-17D), previously characterized, was handled to heterologous expression of the green fluorescent protein (repYFV-17D-GFP) and firefly luciferase (repYFV-17D-Luc) reporter genes. Both replicons were constructed by homologous recombination between the linearized vector pBSC-repYFV-17D and the PCR product containing homologous 25 nucleotides ends incorporated into PCR primers. The genomic organization of these constructs is similar to repYFV-17D, but with insertion of the reporter gene between the remaining 63 N-terminal nucleotides of the capsid protein and 72 C-terminal nucleotides of the E protein. The replicons repYFV-17D-GFP and repYFV-17D-Luc showed efficient replication and expression of the reporter genes. The yeast-based homologous recombination technique used in this study proved to be applicable for manipulation of the yellow fever virus genome in order to construct subgenomic replicons.
C1 [Queiroz, Sabrina R. A.; Silva, Andrea N. M. R.; Santos, Jefferson J. S.; Marques, Ernesto T. A., Jr.; Gil, Laura H. V. G.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, BR-50760420 Recife, PE, Brazil.
   [Bertani, Giovani R.] Univ Fed Pernambuco, Dept Bioquim, BR-50760420 Recife, PE, Brazil.
RP Gil, LHVG (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Av Prof Moraes Rego,S-N,Cidade Univ,Campus Univ F, BR-50760420 Recife, PE, Brazil.
EM lgilfiocruz@gmail.com
RI Santos, Jefferson/W-9610-2019; ALMEIDA-QUEIROZ, SABRINA/I-5361-2013;
   Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013
OI Santos, Jefferson/0000-0001-5895-4163; Marques, Ernesto T.
   A/0000-0003-3826-9358; Marques, Ernesto/0000-0003-3826-9358
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R21AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085] Funding Source: NIH RePORTER
CR Aberle JH, 2005, J VIROL, V79, P15107, DOI 10.1128/JVI.79.24.15107-15113.2005
   Anraku I, 2002, J VIROL, V76, P3791, DOI 10.1128/JVI.76.8.3791-3799.2002
   Ansari IH, 2004, J VIROL, V78, P9612, DOI 10.1128/JVI.78.18.9612-9623.2004
   Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0
   Fayzulin R, 2006, VIROLOGY, V351, P196, DOI 10.1016/j.virol.2006.02.036
   Gehrke R, 2003, J VIROL, V77, P8924, DOI 10.1128/JVI.77.16.8924-8933.2003
   Gibson DG, 2009, NUCLEIC ACIDS RES, V37, P6984, DOI 10.1093/nar/gkp687
   Gibson DG, 2008, P NATL ACAD SCI USA, V105, P20404, DOI 10.1073/pnas.0811011106
   Gubler DJ, 2007, FIELDS VIROLOGY, P1153
   Imoto J, 2007, VACCINE, V25, P1076, DOI 10.1016/j.vaccine.2006.09.059
   Ishikawa T, 2008, VACCINE, V26, P2772, DOI 10.1016/j.vaccine.2008.03.010
   Jones CT, 2005, VIROLOGY, V331, P247, DOI 10.1016/j.virol.2004.10.034
   KAPOOR M, 1995, GENE, V162, P175, DOI 10.1016/0378-1119(95)00332-Z
   Khromykh AA, 2000, CURR OPIN MOL THER, V2, P555
   Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997
   KHROMYKH AA, 1994, J VIROL, V68, P4580, DOI 10.1128/JVI.68.7.4580-4588.1994
   Khromykh AA, 1998, J VIROL, V72, P7270, DOI 10.1128/JVI.72.9.7270-7279.1998
   Kofler RM, 2004, P NATL ACAD SCI USA, V101, P1951, DOI 10.1073/pnas.0307145101
   Kummerer BM., 2006, MOL BIOL FLAVIVIRUS, P1
   Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698
   Lai Ching-Juh, 2003, Adv Virus Res, V61, P469, DOI 10.1016/S0065-3527(03)61013-4
   Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997
   LINDENBACH BD, 2007, FIELDS VIROLOGY PHIL, P1100
   MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799
   Ng CY, 2007, ANTIVIR RES, V76, P222, DOI 10.1016/j.antiviral.2007.06.007
   Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451
   ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354
   Mosimann ALP, 2010, J VIROL METHODS, V163, P147, DOI 10.1016/j.jviromet.2009.09.004
   Pang X, 2001, BMC Microbiol, V1, P28, DOI 10.1186/1471-2180-1-28
   PANICALI D, 1982, P NATL ACAD SCI-BIOL, V79, P4927, DOI 10.1073/pnas.79.16.4927
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   POST LE, 1981, CELL, V25, P227, DOI 10.1016/0092-8674(81)90247-6
   Puri B, 2000, VIRUS GENES, V20, P57, DOI 10.1023/A:1008160123754
   Rossi SL, 2007, VIROLOGY, V364, P184, DOI 10.1016/j.virol.2007.02.009
   Rossi SL, 2005, VIROLOGY, V331, P457, DOI 10.1016/j.virol.2004.10.046
   Sambrook J, 2001, MOL CLONING LAB MANU
   Scholle F, 2004, J VIROL, V78, P11605, DOI 10.1128/JVI.78.21.11605-11614.2004
   Shanks RMQ, 2009, PLASMID, V62, P88, DOI 10.1016/j.plasmid.2009.05.002
   Shi PY, 2002, VIROLOGY, V296, P219, DOI 10.1006/viro.2002.1453
   Shustov AV, 2007, J VIROL, V81, P11737, DOI 10.1128/JVI.01112-07
   SUMIYOSHI H, 1992, J VIROL, V66, P5425, DOI 10.1128/JVI.66.9.5425-5431.1992
   Suzuki R, 2009, J VIROL, V83, P1870, DOI 10.1128/JVI.01891-08
   Varnavski AN, 2000, J VIROL, V74, P4394, DOI 10.1128/JVI.74.9.4394-4403.2000
   Varnavski AN, 1999, VIROLOGY, V255, P366, DOI 10.1006/viro.1998.9564
   Widman DG, 2008, VACCINE, V26, P2762, DOI 10.1016/j.vaccine.2008.03.009
   Yamshchikov G, 2005, VACCINE, V23, P4785, DOI 10.1016/j.vaccine.2005.04.036
NR 46
TC 6
Z9 6
U1 1
U2 10
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD MAR
PY 2013
VL 85
IS 1
BP 159
EP 168
DI 10.1590/S0001-37652013005000008
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 177RQ
UT WOS:000321393500012
PM 23460439
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Carvalho-Leandro, D
   Ayres, CFJ
   Guedes, DRD
   Suesdek, L
   Melo-Santos, MAV
   Oliveira, CF
   Cordeiro, MT
   Regis, LN
   Marques, ET
   Gil, LH
   Magalhaes, T
AF Carvalho-Leandro, D.
   Ayres, C. F. J.
   Guedes, D. R. D.
   Suesdek, L.
   Melo-Santos, M. A. V.
   Oliveira, C. F.
   Cordeiro, M. T.
   Regis, L. N.
   Marques, E. T.
   Gil, L. H.
   Magalhaes, T.
TI Immune transcript variations among Aedes aegypti populations with
   distinct susceptibility to dengue virus serotype 2
SO ACTA TROPICA
LA English
DT Article
DE Mosquito; Dengue virus; Immune response; Toll; JAK-STAT; RNAi
ID ORAL INFECTION; VECTOR COMPETENCE; SINDBIS VIRUS; PATHWAY; EXPRESSION;
   MIDGUT; RNAI; QUANTITATION; SUPPRESSORS; STRAINS
AB The innate immune response of insects is one of the factors that may dictate their susceptibility to viral infection. Two immune signaling pathways, Toll and JAK-STAT, and the RNA interference (RNAi) pathway are involved in Aedes aegypti responses against dengue virus (DENV), however natural differences in these antiviral defenses among mosquito populations have not been studied. Here, two field Ae. aegypti populations from distinct ecological environments, one from Recife and the other from Petrolina (Brazil), and a laboratory strain were studied for their ability to replicate a primary isolate of dengue virus serotype 2 (DENV-2). Virus infectivity and replication were determined in insect tissues collected after viral exposure through reverse-transcription real time PCR (RT-PCR). The expression of a transcript representing these defense mechanisms (Toll, JAK-STAT and RNAi) in the midgut and fat body was studied with RTPCR to evaluate variations in innate immune mechanisms possibly employed against DENV. Analyses of infection rates indicated that the field populations were more susceptible to DENV-2 infection than the lab strain. There were distinct expression patterns among mosquito populations, in both control and infected insects. Moreover, lower expression of immune molecules in DENV-2-infected insects compared to controls was observed in the two field populations. These results suggest that natural variations in vector competence against DENV may be partly due to differences in mosquito defense mechanisms, and that the down-regulation of immune transcripts after viral infection depends on the insect strain. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Carvalho-Leandro, D.; Ayres, C. F. J.; Guedes, D. R. D.; Melo-Santos, M. A. V.; Oliveira, C. F.; Regis, L. N.; Magalhaes, T.] Fiocruz Pernambuco, Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Entomol, Recife, PE, Brazil.
   [Ayres, C. F. J.; Guedes, D. R. D.; Melo-Santos, M. A. V.; Oliveira, C. F.; Regis, L. N.; Marques, E. T.; Gil, L. H.] Fiocruz Pernambuco, CPqAM, Programa Posgrad Saude Publ, Recife, PE, Brazil.
   [Carvalho-Leandro, D.; Ayres, C. F. J.] Univ Fed Pernambuco UFPE, Ctr Ciencias Biol, Dept Zool, Programa Posgrad Biol Anim, Recife, PE, Brazil.
   [Suesdek, L.] Inst Butantan Sao Paulo, Parasitol Lab, Sao Paulo, Brazil.
   [Suesdek, L.] Univ Sao Paulo, Inst Ciencias Biomed, Programa Posgrad Biol Relacao Patogeno Hospedeiro, BR-09500900 Sao Paulo, Brazil.
   [Cordeiro, M. T.; Marques, E. T.; Gil, L. H.] Fiocruz Pernambuco, CPqAM, Lab Virol & Terapia Expt LaViTE, Recife, PE, Brazil.
   [Cordeiro, M. T.] Secretaria Saude Pernambuco, Recife, PE, Brazil.
   [Marques, E. T.] Univ Pittsburg, Ctr Vaccine Res, Pittsburg, KS USA.
RP Magalhaes, T (corresponding author), Fiocruz Pernambuco, CPqAM, LaViTE, Recife, PE, Brazil.
EM danilo@cpqam.fiocruz.br; tans@cpqam.fiocruz.br;
   dguedes@cpqam.fiocruz.br; linrocha@butantan.gov.br;
   mavarjal@cpqam.fiocruz.br; claudia@cpqam.fiocruz.br;
   marli@cpqam.fiocruz.br; leda@cpqam.fiocruz.br; marques@pitt.edu;
   laura@cpqam.fiocruz.br; tecamagalhaes@hotmail.com
RI Suesdek, Lincoln/C-7943-2013; Ayres, Constancia/AAQ-3448-2020;
   Magalhaes, Tereza/V-6632-2019; Publica, Inct Saude/J-9544-2013; Marques,
   Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Suesdek, Lincoln/0000-0001-6829-738X; Marques,
   Ernesto/0000-0003-3826-9358; Marques, Ernesto T. A/0000-0003-3826-9358
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [Universal 479029/2010-5, Pronex Rede Dengue 550140/2010-7]; FACEPE
   [PPSUS/APQ-1361-4.00/08]; FIOCRUZ; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI056541, U19AI056541,
   U19AI056541, U19AI056541, U19AI056541] Funding Source: NIH RePORTER
FX We thank Dr. Brian D. Foy (CSU, USA) for providing the opportunity for
   the one-month training in the techniques used in this study, and Dr.
   Marcos H. F. Sorgine (UFRJ, Brazil) for his helpful comments on an early
   version of the manuscript. We also thank the staff of Recife and
   Petrolina City Halls for collaborating with mosquito egg collection, and
   the PDTIS program at FIOCRUZ for supplying reagents for real-time PCRs
   and for technical support with these assays. Financial support for this
   work was obtained from CNPq (Grants Universal 479029/2010-5 and Pronex
   Rede Dengue 550140/2010-7), FACEPE (Grant PPSUS/APQ-1361-4.00/08) and
   FIOCRUZ.
CR Bartholomay LC, 2010, SCIENCE, V330, P88, DOI 10.1126/science.1193162
   Behura SK, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001385
   Bennett KE, 2002, AM J TROP MED HYG, V67, P85, DOI 10.4269/ajtmh.2002.67.85
   Bivalkar-Mehla S, 2011, VIRUS RES, V155, P1, DOI 10.1016/j.virusres.2010.10.003
   Black WC, 2002, ARCH MED RES, V33, P379, DOI 10.1016/S0188-4409(02)00373-9
   Blair CD, 2011, FUTURE MICROBIOL, V6, P265, DOI [10.2217/FMB.11.11, 10.2217/fmb.11.11]
   Boissiere Anne, 2012, PLoS Pathog, V8, pe1002742, DOI 10.1371/journal.ppat.1002742
   Bonizzoni M, 2012, G3-GENES GENOM GENET, V2, P103, DOI 10.1534/g3.111.001107
   Colpitts TM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002189
   Diallo M, 2008, T ROY SOC TROP MED H, V102, P493, DOI 10.1016/j.trstmh.2008.02.010
   Dong YM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000423
   Fragkoudis R, 2008, INSECT MOL BIOL, V17, P647, DOI 10.1111/j.1365-2583.2008.00834.x
   GUBLER DJ, 1979, AM J TROP MED HYG, V28, P1045, DOI 10.4269/ajtmh.1979.28.1045
   Hess AM, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-45
   IBGE, 2010, CENS DEM 2010
   Keene KM, 2004, P NATL ACAD SCI USA, V101, P17240, DOI 10.1073/pnas.0406983101
   Ketting RF, 2011, DEV CELL, V20, P148, DOI 10.1016/j.devcel.2011.01.012
   Khoo CCH, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-130
   Kong YY, 2006, J VIROL METHODS, V138, P123, DOI 10.1016/j.jviromet.2006.08.003
   Lambrechts L, 2011, TRENDS PARASITOL, V27, P111, DOI 10.1016/j.pt.2010.12.001
   Lambrechts L, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-160
   Lan Q., 1992, Insect Molecular Biology, V1, P71, DOI 10.1111/j.1365-2583.1993.tb00107.x
   Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948
   Lin CC, 2004, J BIOL CHEM, V279, P3308, DOI 10.1074/jbc.M309749200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lourenco-De-Oliveira R, 2004, T ROY SOC TROP MED H, V98, P43, DOI 10.1016/S0035-9203(03)00006-3
   Magalhaes T, 2008, ARCH INSECT BIOCHEM, V68, P134, DOI 10.1002/arch.20238
   Magalhaes T, 2008, EXP PARASITOL, V120, P364, DOI 10.1016/j.exppara.2008.09.003
   [Ministerio da Sande Secretaria de Vigilancia em Sande], 2008, RED NAC MON RES AED
   Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100
   Payne AF, 2006, J VIROL METHODS, V134, P183, DOI 10.1016/j.jviromet.2006.01.003
   Ramirez JL, 2010, DEV COMP IMMUNOL, V34, P625, DOI 10.1016/j.dci.2010.01.006
   Ramirez JL, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001561
   Salazar MI, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-9
   Sanchez-Vargas I, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000299
   Sanders HR, 2005, INSECT BIOCHEM MOLEC, V35, P1293, DOI 10.1016/j.ibmb.2005.07.006
   Schneider JR, 2011, INFECT GENET EVOL, V11, P11, DOI 10.1016/j.meegid.2010.10.019
   Shin SW, 2005, J BIOL CHEM, V280, P16499, DOI 10.1074/jbc.M500711200
   Sim S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010678
   Souza-Neto JA, 2009, P NATL ACAD SCI USA, V106, P17841, DOI 10.1073/pnas.0905006106
   TABACHNICK WJ, 1985, AM J TROP MED HYG, V34, P1219, DOI 10.4269/ajtmh.1985.34.1219
   TARDIEUX I, 1990, AM J TROP MED HYG, V43, P308, DOI 10.4269/ajtmh.1990.43.308
   van Cleef KWR, 2011, METHODS MOL BIOL, V721, P201, DOI 10.1007/978-1-61779-037-9_12
   Vargas REM, 2010, INFECT GENET EVOL, V10, P580, DOI 10.1016/j.meegid.2010.01.004
   de Melo-Santos MAV, 2009, BIOL CONTROL, V49, P186, DOI 10.1016/j.biocontrol.2009.01.011
   Vazeille-Falcoz M, 1999, AM J TROP MED HYG, V60, P292, DOI 10.4269/ajtmh.1999.60.292
   Vidal P.O., 2011, INFECT GENETICS EVOL
   Xi ZY, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000098
   Zou Z, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002394
NR 49
TC 16
Z9 16
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD NOV
PY 2012
VL 124
IS 2
BP 113
EP 119
DI 10.1016/j.actatropica.2012.07.006
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 014JT
UT WOS:000309372600002
PM 22877626
DA 2020-11-24
ER

PT J
AU de Melo, AB
   da Silva, MDC
   Magalhaes, MCF
   Gil, LHVG
   de Carvalho, EMF
   Braga-Neto, UM
   Bertani, GR
   Marques, ETA
   Cordeiro, MT
AF de Melo, Andrea Barbosa
   da Silva, Maria da Paz C.
   Magalhaes, Maria Cecilia F.
   Vega Gonzales Gil, Laura Helena
   Freese de Carvalho, Eduardo M.
   Braga-Neto, Ulisses M.
   Bertani, Giovani Rota
   Marques, Ernesto T. A., Jr.
   Cordeiro, Marli Tenorio
TI Description of a Prospective 17DD Yellow Fever Vaccine Cohort in Recife,
   Brazil
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID SERIOUS ADVERSE EVENTS; HEMAGGLUTINATION-INHIBITION; IMMUNOFLUORESCENCE
   ASSAY; IGG ANTIBODIES; CLINICAL-TRIAL; UNITED-STATES; MAC-ELISA; VIRUS;
   DENGUE; NEUTRALIZATION
AB From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present in 70.6% (IgM) and 98.3% (IgG) of the vaccinated subjects. All vaccinees developed protective immunity, which was detected by the plaque reduction neutralization test (PRNT) with a geometric mean titer of 892. Of the 238 individuals, 86.6% had IgG antibodies to dengue virus; however, the presence of anti-dengue IgG did not interfere significantly with the development of anti-YF neutralizing antibodies. In a separate retrospective study of individuals immunized with the 17DD vaccine, the PRNT values at 5 and 10 years post-vaccination remained positive but showed a significant decrease in neutralization titer (25% with PRNT titers < 100 after 5 years and 35% after 10 years).
C1 [de Melo, Andrea Barbosa; Magalhaes, Maria Cecilia F.; Vega Gonzales Gil, Laura Helena; Marques, Ernesto T. A., Jr.; Cordeiro, Marli Tenorio] Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, BR-50670420 Recife, PE, Brazil.
   [da Silva, Maria da Paz C.; Bertani, Giovani Rota] Univ Fed Pernambuco, Dept Bioquim, Recife, PE, Brazil.
   [Braga-Neto, Ulisses M.] Texas A&M Univ, Dept Elect Engn, College Stn, TX 77843 USA.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   Secretaria Saude Estado Pernambuco, Cent Publ Hlth Lab, Recife, PE, Brazil.
   [Freese de Carvalho, Eduardo M.] Aggeu Magalhaes Res Ctr, Dept Saude Colet, Recife, PE, Brazil.
   [Cordeiro, Marli Tenorio] Secretaria Saude Estado Pernambuco, Telephone & Cent Lab Publ Hlth, Recife, PE, Brazil.
RP Marques, ETA (corresponding author), Fiocruz MS, Virol & Expt Therapy Lab, Aggeu Magalhaes Res Ctr, Av Moraes Rego S-N,Campus Univ Fed Pernambuco,Cid, BR-50670420 Recife, PE, Brazil.
EM abm@cpqam.fiocruz.br; mariadapazc@gmail.com; cecimag@cpqam.fiocruz.br;
   laura@cpqam.fiocruz.br; freese@cpqam.fiocruz.br; ulisses@ece.tamu.edu;
   gbertani@gmail.com; marques@pitt.edu; marli@cpqam.fiocruz.br
RI Marques, Ernesto/L-4514-2013; Publica, Inct Saude/J-9544-2013; Marques,
   Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU National Institute of Allergy and Infectious Diseases (NIAID/NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [N01-AI-40085]; Oswald Cruz Foundation [PDTIS-RVR9];
   National Science FoundationNational Science Foundation (NSF)
   [CCF-0845407]; Brazilian National Research Council (CAPES)National
   Council for Scientific and Technological Development (CNPq)CAPES;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R01AI040085, R01AI040085,
   R01AI040085, R01AI040085, R01AI040085, R21AI040085, R01AI040085,
   R01AI040085] Funding Source: NIH RePORTER
FX The authors would like to acknowledge the support of National Institute
   of Allergy and Infectious Diseases (NIAID/NIH) Grant N01-AI-40085,
   Oswald Cruz Foundation Grant PDTIS-RVR9, National Science Foundation
   Award CCF-0845407, and the Brazilian National Research Council (CAPES;
   doctoral scholarship for Andrea Melo).
CR Arya SC, 1999, EMERG INFECT DIS, V5, P487, DOI 10.3201/eid0503.990333
   Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2009, GUIA VIG EP
   CLARKE DH, 1958, AM J TROP MED HYG, V7, P561, DOI 10.4269/ajtmh.1958.7.561
   Codeco CT, 2004, T ROY SOC TROP MED H, V98, P702, DOI 10.1016/j.trstmh.2003.12.019
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Oliveira RL, 2003, AM J TROP MED HYG, V69, P105, DOI 10.4269/ajtmh.2003.69.105
   DOSSANTOS CND, 1995, VIRUS RES, V35, P35
   Galler R, 1998, VACCINE, V16, P1024, DOI 10.1016/S0264-410X(97)00278-8
   Galler R, 2001, VIROLOGY, V290, P309, DOI 10.1006/viro.2001.1168
   Gómez Sergio Y, 2008, Rev. salud pública, V10, P796
   Guimard T, 2009, AM J TROP MED HYG, V81, P1141, DOI 10.4269/ajtmh.2009.09-0295
   Houghton-Triviño Natalia, 2008, Rev. salud pública, V10, P299
   Izurieta RO, 2009, J GLOB INFECT DIS, V1, P111, DOI 10.4103/0974-777X.56257
   KUNO G, 1991, J VIROL METHODS, V33, P101, DOI 10.1016/0166-0934(91)90011-N
   KUNO G, 1987, AM J TROP MED HYG, V36, P153, DOI 10.4269/ajtmh.1987.36.153
   Kuno Goro, 2003, Adv Virus Res, V61, P3, DOI 10.1016/S0065-3527(03)61001-8
   LHUILLIER M, 1986, B WORLD HEALTH ORGAN, V64, P415
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101
   Lourenco-De-Oliveira R, 2004, T ROY SOC TROP MED H, V98, P43, DOI 10.1016/S0035-9203(03)00006-3
   Makela A, 2002, PEDIATRICS, V110, P957, DOI 10.1542/peds.110.5.957
   Marchevsky RS, 2006, BIOLOGICALS, V34, P191, DOI 10.1016/j.biologicals.2005.09.005
   Marques ETA, 2008, CAD SAUDE PUBLICA, V24, P547, DOI 10.1590/S0102-311X2008000300008
   Martin M, 2001, EMERG INFECT DIS, V7, P945, DOI 10.3201/eid0706.010605
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP, 2002, AM J TROP MED HYG, V66, P533, DOI 10.4269/ajtmh.2002.66.533
   MONATH TPC, 1971, AM J EPIDEMIOL, V93, P122, DOI 10.1093/oxfordjournals.aje.a121232
   Figueiredo LTM, 2007, REV SOC BRAS MED TRO, V40, P224, DOI 10.1590/S0037-86822007000200016
   MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985
   Niedrig M, 2007, J VIROL METHODS, V139, P103, DOI 10.1016/j.jviromet.2006.09.009
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   Niedrig M, 2008, CLIN VACCINE IMMUNOL, V15, P177, DOI 10.1128/CVI.00078-07
   NOGUEIRA RMR, 1992, REV I MED TROP, V34, P447, DOI 10.1590/S0036-46651992000500012
   Pfister M, 2005, AM J TROP MED HYG, V72, P339, DOI 10.4269/ajtmh.2005.72.339
   Pugachev KV, 2005, CURR OPIN INFECT DIS, V18, P387, DOI 10.1097/01.qco.0000178823.28585.ad
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Silva ML, 2010, CLIN VACCINE IMMUNOL, V17, P118, DOI 10.1128/CVI.00369-09
   STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568
   Suzano CES, 2006, VACCINE, V24, P1421, DOI 10.1016/j.vaccine.2005.09.033
   Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS7, DOI 10.1590/S0102-311X2009001300002
   Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0
   Vazquez S, 2003, J VIROL METHODS, V110, P179, DOI 10.1016/S0166-0934(03)00128-9
NR 45
TC 26
Z9 26
U1 0
U2 6
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2011
VL 85
IS 4
BP 739
EP 747
DI 10.4269/ajtmh.2011.10-0496
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 833QB
UT WOS:000295898900029
PM 21976581
OA Green Published, Bronze
DA 2020-11-24
ER

PT J
AU Gomes, ALV
   Wee, LJK
   Khan, AM
   Gil, LHVG
   Marques, ETA
   Calzavara-Silva, CE
   Tan, TW
AF Gomes, Ana Lisa V.
   Wee, Lawrence J. K.
   Khan, Asif M.
   Gil, Laura H. V. G.
   Marques, Ernesto T. A., Jr.
   Calzavara-Silva, Carlos E.
   Tan, Tin Wee
TI Classification of Dengue Fever Patients Based on Gene Expression Data
   Using Support Vector Machines
SO PLOS ONE
LA English
DT Article
ID PLASMACYTOID DENDRITIC CELLS; INTERFERON; INFECTION; ALGORITHMS;
   PREDICT; INNATE
AB Background: Symptomatic infection by dengue virus (DENV) can range from dengue fever (DF) to dengue haemorrhagic fever (DHF), however, the determinants of DF or DHF progression are not completely understood. It is hypothesised that host innate immune response factors are involved in modulating the disease outcome and the expression levels of genes involved in this response could be used as early prognostic markers for disease severity.
   Methodology/Principal Findings: mRNA expression levels of genes involved in DENV innate immune responses were measured using quantitative real time PCR (qPCR). Here, we present a novel application of the support vector machines (SVM) algorithm to analyze the expression pattern of 12 genes in peripheral blood mononuclear cells (PBMCs) of 28 dengue patients (13 DHF and 15 DF) during acute viral infection. The SVM model was trained using gene expression data of these genes and achieved the highest accuracy of similar to 85% with leave-one-out cross-validation. Through selective removal of gene expression data from the SVM model, we have identified seven genes (MYD88, TLR7, TLR3, MDA5, IRF3, IFN-alpha and CLEC5A) that may be central in differentiating DF patients from DHF, with MYD88 and TLR7 observed to be the most important. Though the individual removal of expression data of five other genes had no impact on the overall accuracy, a significant combined role was observed when the SVM model of the two main genes (MYD88 and TLR7) was re-trained to include the five genes, increasing the overall accuracy to similar to 96%.
   Conclusions/Significance: Here, we present a novel use of the SVM algorithm to classify DF and DHF patients, as well as to elucidate the significance of the various genes involved. It was observed that seven genes are critical in classifying DF and DHF patients: TLR3, MDA5, IRF3, IFN-alpha, CLEC5A, and the two most important MYD88 and TLR7. While these preliminary results are promising, further experimental investigation is necessary to validate their specific roles in dengue disease.
C1 [Gomes, Ana Lisa V.; Gil, Laura H. V. G.; Marques, Ernesto T. A., Jr.] Fiocruz MS, Aggeu Magalhaes Res Ctr, CPqAM, Dept Virol & Expt Therapy, Recife, PE, Brazil.
   [Wee, Lawrence J. K.; Khan, Asif M.; Tan, Tin Wee] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Marques, Ernesto T. A., Jr.] Univ Pittsburgh, Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Calzavara-Silva, Carlos E.] Fiocruz MS, Dept Cellular & Mol Immunol, Rene Rachou Res Ctr, CPqRR, Belo Horizonte, MG, Brazil.
RP Gomes, ALV (corresponding author), Fiocruz MS, Aggeu Magalhaes Res Ctr, CPqAM, Dept Virol & Expt Therapy, Recife, PE, Brazil.
EM tinwee@bic.nus.edu.sg
RI Marques, Ernesto T. A/L-4967-2013; Publica, Inct Saude/J-9544-2013;
   Marques, Ernesto/L-4514-2013; Tan, Tin Wee/B-8963-2009; Khan, Mohammad
   Asif/F-4663-2010
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; Tan, Tin Wee/0000-0002-4062-2854; Khan,
   Mohammad Asif/0000-0001-9202-279X; CALZAVARA-SILVA,
   CARLOS/0000-0002-1406-6401
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Ciencia e Tecnologia do Estado de
   (FACEPE), Brazil; National Institutes of Health (NIH), USAUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA
FX This work was supported by the Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES), Fundacao de Amparo a Ciencia e Tecnologia do
   Estado de (FACEPE), Brazil, the National Institutes of Health (NIH),
   USA. The first author ALVG was a visiting scientist with the Department
   of Biochemistry, National University of Singapore (NUS). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555
   CHANG CC, 2009, LIBSVM LIB SUPPORT V
   Chen PC, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-44
   Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013
   Coffey LL, 2009, MICROBES INFECT, V11, P143, DOI 10.1016/j.micinf.2008.12.006
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   Diamond MS, 2009, FRONT BIOSCI-LANDMRK, V14, P3024, DOI 10.2741/3432
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Holmes EC, 2000, TRENDS MICROBIOL, V8, P74, DOI 10.1016/S0966-842X(99)01669-8
   Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464
   Jones M, 2005, J VIROL, V79, P5414, DOI 10.1128/JVI.79.9.5414-5420.2005
   Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020
   KNIPE DP, 2007, FIELDS VIROLOGY, P250
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McKenna K, 2005, J VIROL, V79, P17, DOI 10.1128/JVI.79.1.17-27.2005
   Munoz-Jordan JL, 2010, CURR TOP MICROBIOL, V338, P35, DOI 10.1007/978-3-642-02215-9_3
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007892
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Sun PF, 2009, VIROLOGY, V383, P207, DOI 10.1016/j.virol.2008.10.022
   Tang EK, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-95
   Tang YC, 2007, IEEE ACM T COMPUT BI, V4, P365, DOI 10.1109/TCBB.2007.1028
   Tanner L, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000196
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   Wee LJK, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S5-S14
   *WHO, 1997, HAEM FEV DIAGN TREAT
   Yoneyama M, 2009, IMMUNOL REV, V227, P54, DOI 10.1111/j.1600-065X.2008.00727.x
NR 29
TC 16
Z9 16
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 23
PY 2010
VL 5
IS 6
AR e11267
DI 10.1371/journal.pone.0011267
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 615KY
UT WOS:000279135400013
PM 20585645
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU Calzavara-Silva, CE
   Gomes, ALV
   Maia, RCC
   Acioli-Santos, B
   Gil, LHVG
   Marques, ETA
AF Calzavara-Silva, Carlos E.
   Gomes, Ana L. V.
   Maia, Rita C. C.
   Acioli-Santos, Bartolomeu
   Gil, Laura H. V. G.
   Marques, Ernesto T. A., Jr.
TI Early molecular markers predictive of dengue hemorrhagic fever
SO ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
LA English
DT Article
DE real-time PCR; dengue hemorrhagic fever; molecular markers
ID ORIGINAL ANTIGENIC SIN; GENE-EXPRESSION; PERIPHERAL-BLOOD;
   VIRUS-INFECTION; APOPTOSIS
AB The management of acute dengue patients during outbreaks is a challenging problem. Most of the dengue fever cases are benign, but some cases develop into a severe and possibly lethal vasculopathy, known as dengue hemorrhagic fever. Early symptoms of dengue and hemorrhagic fever are very similar. An early differential diagnosis is needed to predict which of these two clinical presentations is crucial to proper patient care and public health management. This study evaluates the predictive potential of specific mRNA expression markers of dengue hemorrhagic fever using quantitative real-time PCR assays. Six candidate "dengue hemorrhagic fever specific signature genes" were evaluated and all showed good correlation among their transcription levels at early days of infection and the later development of severe vasculopathy. The markers selected were able to indicate, at early stages of infection, the evolution of a dengue-infected patient to the severe form of the illness. Despite the fact that these results grant further validation studies, the panel of candidate prognostic markers obtained demonstrated the potential to be useful for clinical use in the form of a fast assay based in blood samples.
C1 [Calzavara-Silva, Carlos E.; Gomes, Ana L. V.; Acioli-Santos, Bartolomeu; Gil, Laura H. V. G.] Fiocruz MS, Ctr Pesquisa Aggeu Magalhaes, Lab Virol & Terapia Expt, BR-50670420 Recife, PE, Brazil.
   [Marques, Ernesto T. A., Jr.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Div Infect Dis, Dept Med, Baltimore, MD 21205 USA.
   [Maia, Rita C. C.] Univ Fed Rural Pernambuco, Dept Vet Med, BR-50741150 Recife, PE, Brazil.
RP Calzavara-Silva, CE (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Imunol Celular & Mol, Av Augusto Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
EM calzavara@cpqam.fiocruz.br
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U19
   AI56541] Funding Source: Medline
CR *APPL BIOS, 2006, 127AP0502 APPL BIOS
   *APPL BIOS, 2008, 75007500 APPL BIOS
   Bente Dennis A, 2006, Drug Discov Today Dis Models, V3, P97, DOI 10.1016/j.ddmod.2006.03.014
   Brown MG, 2009, J LEUKOCYTE BIOL, V85, P71, DOI 10.1189/jlb.0308167
   Chaturvedi UC, 2006, FEMS IMMUNOL MED MIC, V47, P155, DOI 10.1111/j.1574-695X.2006.00058.x
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   Espina LM, 2003, AM J TROP MED HYG, V68, P48, DOI 10.4269/ajtmh.2003.68.48
   Fink J, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000086
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mosquera JA, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-26
   Myint KS, 2006, J INFECT DIS, V194, P600, DOI 10.1086/506451
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Shu PY, 2004, CLIN DIAGN LAB IMMUN, V11, P642, DOI 10.1128/CDLI.11.4.642-650.2004
   Simmons CP, 2007, J INFECT DIS, V195, P1097, DOI 10.1086/512162
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
NR 20
TC 4
Z9 5
U1 0
U2 2
PU ACAD BRASILEIRA DE CIENCIAS
PI RIO JANEIRO
PA RUA ANFILOFIO DE CARVALHO, 29, 3 ANDAR, 20030-060 RIO JANEIRO, BRAZIL
SN 0001-3765
EI 1678-2690
J9 AN ACAD BRAS CIENC
JI An. Acad. Bras. Cienc.
PD DEC
PY 2009
VL 81
IS 4
BP 671
EP 677
DI 10.1590/S0001-37652009000400006
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 516VD
UT WOS:000271570500006
PM 19893893
OA DOAJ Gold
DA 2020-11-24
ER

PT J
AU Nascimento, EJM
   Braga-Neto, U
   Calzavara-Silva, CE
   Gomes, ALV
   Abath, FGC
   Brito, CAA
   Cordeiro, MT
   Silva, AM
   Magalhaes, C
   Andrade, R
   Gil, LHVG
   Marques, ETA
AF Nascimento, Eduardo J. M.
   Braga-Neto, Ulisses
   Calzavara-Silva, Carlos E.
   Gomes, Ana L. V.
   Abath, Frederico G. C.
   Brito, Carlos A. A.
   Cordeiro, Marli T.
   Silva, Ana M.
   Magalhaes, Cecilia
   Andrade, Raoni
   Gil, Laura H. V. G.
   Marques, Ernesto T. A., Jr.
TI Gene Expression Profiling during Early Acute Febrile Stage of Dengue
   Infection Can Predict the Disease Outcome
SO PLOS ONE
LA English
DT Article
ID BOLSTERED ERROR ESTIMATION; T-CELL RESPONSES; HEMORRHAGIC-FEVER;
   PERIPHERAL-BLOOD; VIRUS-INFECTIONS; SHOCK-SYNDROME; ELEVATED LEVELS;
   SEVERITY; ACTIVATION; APOPTOSIS
AB Background: We report the detailed development of biomarkers to predict the clinical outcome under dengue infection. Transcriptional signatures from purified peripheral blood mononuclear cells were derived from whole-genome gene-expression microarray data, validated by quantitative PCR and tested in independent samples.
   Methodology/Principal Findings: The study was performed on patients of a well-characterized dengue cohort from Recife, Brazil. The samples analyzed were collected prospectively from acute febrile dengue patients who evolved with different degrees of disease severity: classic dengue fever or dengue hemorrhagic fever (DHF) samples were compared with similar samples from other non-dengue febrile illnesses. The DHF samples were collected 2-3 days before the presentation of the plasma leakage symptoms. Differentially-expressed genes were selected by univariate statistical tests as well as multivariate classification techniques. The results showed that at early stages of dengue infection, the genes involved in effector mechanisms of innate immune response presented a weaker activation on patients who later developed hemorrhagic fever, whereas the genes involved in apoptosis were expressed in higher levels.
   Conclusions/Significance: Some of the gene expression signatures displayed estimated accuracy rates of more than 95%, indicating that expression profiling with these signatures may provide a useful means of DHF prognosis at early stages of infection.
RP Nascimento, EJM (corresponding author), Fiocruz MS, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol & Terapia Expt, Recife, PE, Brazil.
EM marques@pitt.edu
RI Nascimento, Eduardo/J-4590-2014; Publica, Inct Saude/J-9544-2013;
   Marques, Ernesto/L-4514-2013; Marques, Ernesto T. A/L-4967-2013
OI Nascimento, Eduardo/0000-0002-9851-2332; Marques,
   Ernesto/0000-0003-3826-9358; Marques, Ernesto T. A/0000-0003-3826-9358;
   CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI056541, U19AI056541, U19AI056541, U19AI056541, U19AI056541]
   Funding Source: NIH RePORTER; Direct For Computer & Info Scie &
   EnginrNational Science Foundation (NSF)NSF - Directorate for Computer &
   Information Science & Engineering (CISE) [0845407] Funding Source:
   National Science Foundation; NIAID NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U19
   AI056541, U19 AI56541] Funding Source: Medline
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Azeredo EL, 2006, CLIN EXP IMMUNOL, V143, P345, DOI 10.1111/j.1365-2249.2006.02996.x
   Bandyopadhyay S, 2006, TROP MED INT HEALTH, V11, P1238, DOI 10.1111/j.1365-3156.2006.01678.x
   BRAGA UMD, 2005, EURASIP BOOK SERIES
   Braga-Neto U, 2004, PATTERN RECOGN, V37, P1267, DOI 10.1016/j.patcog.2003.08.017
   Cardier JE, 2005, CYTOKINE, V30, P359, DOI 10.1016/j.cyto.2005.01.021
   Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096
   Clementi M, 2006, REPROD TOXICOL, V21, P345, DOI 10.1016/j.reprotox.2005.08.006
   Cordeiro MT, 2007, REV SOC BRAS MED TRO, V40, P605, DOI 10.1590/S0037-86822007000600001
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;329::AID-JMV12&gt;3.0.CO;2-G
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713
   Juffrie M, 2000, INFECT IMMUN, V68, P702, DOI 10.1128/IAI.68.2.702-707.2000
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mangada MM, 2002, J INFECT DIS, V185, P1697, DOI 10.1086/340822
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Mustafa AS, 2001, FEMS IMMUNOL MED MIC, V30, P229, DOI 10.1111/j.1574-695X.2001.tb01575.x
   Myint KS, 2006, J INFECT DIS, V194, P600, DOI 10.1086/506451
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   *OPAS, 1995, DENG DENG HEM AM GUI
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Pettiford JN, 2002, CLIN EXP IMMUNOL, V128, P110, DOI 10.1046/j.1365-2249.2002.01813.x
   Ramilo O, 2007, BLOOD, V109, P2066, DOI 10.1182/blood-2006-02-002477
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   SCHERER CA, 2007, VACCINE
   Sierra B, 2007, HUM IMMUNOL, V68, P531, DOI 10.1016/j.humimm.2007.03.001
   Sima C, 2005, PATTERN RECOGN, V38, P2472, DOI 10.1016/j.patcog.2005.03.026
   Sima C, 2005, BIOINFORMATICS, V21, P1046, DOI 10.1093/bioinformatics/bti081
   Simmons CP, 2007, J INFECT DIS, V195, P1097, DOI 10.1086/512162
   Soundravally R, 2007, HUM IMMUNOL, V68, P973, DOI 10.1016/j.humimm.2007.09.007
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Tan GK, 2009, CURR OPIN INFECT DIS, V22, P302, DOI 10.1097/QCO.0b013e328329ae32
   Tseng CS, 2005, FEMS IMMUNOL MED MIC, V43, P99, DOI 10.1016/j.femsim.2004.10.004
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   *WHO, 1999, TREATM DENG FEV DENG
   Yunta M, 2003, ONCOGENE, V22, P1219, DOI 10.1038/sj.onc.1206183
NR 49
TC 48
Z9 48
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 19
PY 2009
VL 4
IS 11
AR e7892
DI 10.1371/journal.pone.0007892
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 522NJ
UT WOS:000272004600001
PM 19936257
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-24
ER

PT J
AU da Silva, ANMR
   Nascimento, EJM
   Cordeiro, MT
   Gil, LHVG
   Abath, FGC
   Montenegro, SML
   Marques, ETA
AF Rangel da Silva, Andrea N. M.
   Nascimento, Eduardo J. M.
   Cordeiro, Marli Tenorio
   Gil, Laura H. V. G.
   Abath, Frederico G. C.
   Montenegro, Silvia M. L.
   Marques, Ernesto T. A., Jr.
TI Identification of Continuous Human B-Cell Epitopes in the Envelope
   Glycoprotein of Dengue Virus Type 3 (DENV-3)
SO PLOS ONE
LA English
DT Article
ID MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDE; NEUTRALIZING ANTIBODY;
   REACTIVE EPITOPES; SWISS-MODEL; DOMAIN-III; PROTEIN; DETERMINANTS;
   RECOGNITION; PREDICTION
AB Background: Dengue virus infection is a growing global public health concern in tropical and subtropical regions of the world. Dengue vaccine development has been hampered by concerns that cross-reactive immunological memory elicited by a candidate vaccine could increase the risk of development of more severe clinical forms. One possible strategy to reduce risks associated with a dengue vaccine is the development of a vaccine composed of selected critical epitopes of each of the serotypes.
   Methodology/Principal Findings: Synthetic peptides were used to identify B-cell epitopes in the envelope (E) glycoprotein of dengue virus type 3 (DENV-3). Eleven linear, immunodominant epitopes distributed in five regions at amino acid (aa) positions: 51-65, 71-90, 131-170, 196-210 and 246-260 were identified by employing an enzyme-linked immunosorbent assay (ELISA), using a pool of human sera from dengue type 3 infected individuals. Peptides 11 (aa51-65), 27 and 28 (aa131-150) also reacted with dengue 1 (DENV-1) and dengue 2 (DENV-2) patient sera as analyzed through the ROC curves generated for each peptide by ELISA and might have serotype specific diagnostic potential. Mice immunized against each one of the five immunogenic regions showed epitopes 51-65, 131-170, 196-210 and 246-260 elicited the highest antibody response and epitopes 131-170, 196-210 and 246-260, elicited IFN-gamma production and T CD4+ cell response, as evaluated by ELISA and ELISPOT assays respectively.
   Conclusions/Significance: Our study identified several useful immunodominant IgG-specific epitopes on the envelope of DENV-3. They are important tools for understanding the mechanisms involved in antibody dependent enhancement and immunity. If proven protective and safe, in conjunction with others well-documented epitopes, they might be included into a candidate epitope-based vaccine.
RP da Silva, ANMR (corresponding author), Fiocruz MS, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
EM marques@pitt.edu
RI montenegro, silvia/AAD-9090-2020; Nascimento, Eduardo/J-4590-2014;
   Marques, Ernesto T. A/L-4967-2013; Publica, Inct Saude/J-9544-2013;
   Marques, Ernesto/L-4514-2013
OI Nascimento, Eduardo/0000-0002-9851-2332; Marques, Ernesto T.
   A/0000-0003-3826-9358; Marques, Ernesto/0000-0003-3826-9358
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI05641] Funding Source: Medline
CR AnandaRao R, 2005, VIRUS RES, V112, P60, DOI 10.1016/j.virusres.2005.03.022
   Apt D, 2006, VACCINE, V24, P335, DOI 10.1016/j.vaccine.2005.07.100
   Beasley DWC, 2001, VIROLOGY, V279, P447, DOI 10.1006/viro.2000.0721
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   Crill WD, 2004, J VIROL, V78, P13975, DOI 10.1128/JVI.78.24.13975-13986.2004
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Guirakhoo F, 2004, J VIROL, V78, P4761, DOI 10.1128/JVI.78.9.4761-4775.2004
   Guzman MG, 2004, INT J INFECT DIS, V8, P69, DOI 10.1016/j.ijid.2003.03.003
   HECHAVARRIA A, 2002, MANUAL PROCEDIMIENTO
   Hombach J, 2005, VACCINE, V23, P5205, DOI [10.1016/j.vaccine.2005.07.002, 10.1016/j.vaccine.2004.11.040]
   Huang JH, 1999, J MED VIROL, V57, P1, DOI 10.1002/(SICI)1096-9071(199901)57:1&lt;1::AID-JMV1&gt;3.0.CO;2-T
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   MATHEWS JH, 1991, J VIROL, V65, P5141, DOI 10.1128/JVI.65.10.5141-5148.1991
   Matsui K, 2009, VIROLOGY, V384, P16, DOI 10.1016/j.virol.2008.11.013
   Miagostovich MP, 2002, BRAZ J MED BIOL RES, V35, P869, DOI 10.1590/S0100-879X2002000800002
   Modis Y, 2005, J VIROL, V79, P1223, DOI 10.1128/JVI.79.2.1223-1231.2005
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   Oliphant T, 2006, J VIROL, V80, P12149, DOI 10.1128/JVI.01732-06
   Reynolds J, 2009, CLIN EXP IMMUNOL, V155, P311, DOI 10.1111/j.1365-2249.2008.03833.x
   Roehrig JT, 1998, VIROLOGY, V246, P317, DOI 10.1006/viro.1998.9200
   ROEHRIG JT, 1992, J VIROL, V66, P3385, DOI 10.1128/JVI.66.6.3385-3390.1992
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Serafin IL, 2001, ARCH VIROL, V146, P2469, DOI 10.1007/s007050170017
   SINGH B, 1980, J IMMUNOL, V124, P1336
   Thullier P, 2001, J GEN VIROL, V82, P1885, DOI 10.1099/0022-1317-82-8-1885
   Wu HC, 2003, J GEN VIROL, V84, P2771, DOI 10.1099/vir.0.19228-0
   Wu HC, 2001, J CLIN MICROBIOL, V39, P977, DOI 10.1128/JCM.39.3.977-982.2001
   Yamada KI, 2002, J CLIN VIROL, V24, P203, DOI 10.1016/S1386-6532(01)00250-5
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW172, DOI 10.1093/nar/gki452
   Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990
   Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019
NR 37
TC 20
Z9 21
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 13
PY 2009
VL 4
IS 10
AR e7425
DI 10.1371/journal.pone.0007425
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 506WQ
UT WOS:000270808300008
PM 19826631
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Henningson, JN
   Topliff, CL
   Gil, LHV
   Donis, RO
   Steffen, DJ
   Charleston, B
   Eskridge, KM
   Kelling, CL
AF Henningson, Jamie N.
   Topliff, Christina L.
   Gil, Laura H. V.
   Donis, Ruben O.
   Steffen, David J.
   Charleston, Bryan
   Eskridge, Kent M.
   Kelling, Clayton L.
TI Effect of the viral protein N-pro on virulence of bovine viral diarrhea
   virus and induction of interferon type I in calves
SO AMERICAN JOURNAL OF VETERINARY RESEARCH
LA English
DT Article; Proceedings Paper
CT 86th Conference of Research Workers in Animal Diseases
CY DEC, 2005
CL St Louis, MO
ID CLASSICAL SWINE-FEVER; REGULATORY FACTOR-3; PROTEASOMAL DEGRADATION;
   SYSTEMIC INFECTION; INDUCED APOPTOSIS; PESTIVIRUS; PRODUCT; CELLS;
   REPLICATION; 6-MONTH-OLD
AB Objective-To characterize the influence of the viral protein N-pro on virulence of bovine viral diarrhea virus (BVDV) and on type I interferon responses in calves.
   Animals-10 calves, 4 to 6 months of age. Procedures-BVDV virulence and type I interferon responses of calves (n = 5) infected with a noncytopathic BVDV with a deleted N-pro were compared with those of calves (5) infected with a noncytopathic BVDV with a functional N-pro. Rectal temperatures, clinical signs, platelet counts, and total and differential WBC counts were evaluted daily. Histologic examinations and immunohistochemical analyses of tissues were conducted to assess lesions and distribution of viral antigens, respectively. Serum type I interferon concentrations were determined.
   Results-Calves infected with N-pro-deleted BVDV developed leukopenia and lymphopenia, without developing increased rectal temperatures or lymphoid depletion of target lymphoid organs. There was minimal antigen deposition in lymphoid organs. Calves infected with N-pro BVDV developed increased rectal temperatures, leukopenia, lymphopenia, and lymphoid depletion with marked BVDV antigen deposition in lymphatic tissues. Interferon type I responses were detected in both groups of calves.
   Conclusions and Clinical Relevance-Deletion of N-pro resulted in attenuation of BVDV as evidenced by reduced virulence in calves, compared with BVDV with a functional N-pro. Deletion of N-pro did not affect induction of type I interferon. The N-pro-deleted BVDV mutant may represent a safe noncytopathic virus candidate for vaccine development. (Am J Vet Res 2009;70:1117-1123)
C1 [Henningson, Jamie N.; Topliff, Christina L.; Steffen, David J.; Kelling, Clayton L.] Univ Nebraska, Coll Agr Sci & Nat Resources, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA.
   [Eskridge, Kent M.] Univ Nebraska, Coll Arts & Sci, Dept Stat, Lincoln, NE 68583 USA.
   [Gil, Laura H. V.] Fundacao Osvaldo Cruz, Ctr Aggeu Magalhaes, BR-50670420 Recife, PE, Brazil.
   [Donis, Ruben O.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Coordinating Ctr Infect Dis, Atlanta, GA 30333 USA.
   [Charleston, Bryan] AFRC, Inst Anim Hlth, Pirbright Lab, Woking GU24 0NF, Surrey, England.
RP Kelling, CL (corresponding author), Univ Nebraska, Coll Agr Sci & Nat Resources, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA.
RI Driemeier, David/H-3461-2012
OI Driemeier, David/0000-0003-3766-0654; Charleston,
   Bryan/0000-0002-6952-9338
FU Biotechnology and Biological Sciences Research CouncilBiotechnology and
   Biological Sciences Research Council (BBSRC) [BBS/E/I/00001432] Funding
   Source: Medline
CR BIELEFELDTOHMANN H, 1995, VET CLIN N AM-FOOD A, V11, P447, DOI 10.1016/S0749-0720(15)30461-8
   Brodersen BW, 1998, AM J VET RES, V59, P1423
   Chen ZH, 2007, VIROLOGY, V366, P277, DOI 10.1016/j.virol.2007.04.023
   COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1
   COLLETT MS, 1988, VIROLOGY, V165, P200, DOI 10.1016/0042-6822(88)90673-3
   COLLETT MS, 1991, ARCH VIROL, P19
   DONIS RO, 1988, J GEN VIROL, V69, P77, DOI 10.1099/0022-1317-69-1-77
   Fray MD, 2001, J IMMUNOL METHODS, V249, P235, DOI 10.1016/S0022-1759(00)00359-8
   Gil LHVG, 2006, J VIROL, V80, P900, DOI 10.1128/JVI.80.2.900-911.2006
   Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341
   Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024
   Hilton L, 2006, J VIROL, V80, P11723, DOI 10.1128/JVI.01145-06
   Hoff HS, 1997, VIRUS RES, V49, P101, DOI 10.1016/S0168-1702(97)01460-3
   Houe H, 2003, BIOLOGICALS, V31, P137, DOI 10.1016/S1045-1056(03)00030-7
   JOHNSON HM, 1976, CRC CR REV BIOCH MOL, V4, P203, DOI 10.3109/10409237609105459
   Kelling CL, 2005, AM J VET RES, V66, P1785, DOI 10.2460/ajvr.2005.66.1785
   Kelling CL, 2002, AM J VET RES, V63, P1379, DOI 10.2460/ajvr.2002.63.1379
   Kelling CL, 2007, AM J VET RES, V68, P788, DOI 10.2460/ajvr.68.7.788
   Knoetig SM, 2002, ANTIVIR RES, V53, P75, DOI 10.1016/S0166-3542(01)00193-0
   Liebler-Tenorio EM, 2004, J VET DIAGN INVEST, V16, P388, DOI 10.1177/104063870401600504
   Marshall DJ, 1996, VET PATHOL, V33, P311, DOI 10.1177/030098589603300308
   Meyers G, 2007, J VIROL, V81, P3327, DOI 10.1128/JVI.02372-06
   NUTTALL PA, 1980, RES VET SCI, V28, P91, DOI 10.1016/S0034-5288(18)32779-6
   Robek MD, 2005, J VIROL, V79, P3851, DOI 10.1128/JVI.79.6.3851-3854.2005
   Ruggli N, 2003, J VIROL, V77, P7645, DOI 10.1128/JVI.77.13.7645-7654.2003
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Schweizer M, 2001, J VIROL, V75, P4692, DOI 10.1128/JVI.75.10.4692-4698.2001
   Seago J, 2007, J GEN VIROL, V88, P3002, DOI 10.1099/vir.0.82934-0
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   STRANDEN AM, 1993, VIROLOGY, V197, P642, DOI 10.1006/viro.1993.1639
   Summerfield A, 2006, J INTERF CYTOK RES, V26, P248, DOI 10.1089/jir.2006.26.248
   Tratschin JD, 1998, J VIROL, V72, P7681, DOI 10.1128/JVI.72.9.7681-7684.1998
   Vassilev VB, 1997, J VIROL, V71, P471, DOI 10.1128/JVI.71.1.471-478.1997
   Vassilev VB, 2000, VIRUS RES, V69, P95, DOI 10.1016/S0168-1702(00)00176-3
   Wengler G., 1991, CLASSIFICATION NOMEN, P223
   WILHELMSEN CL, 1990, VET PATHOL, V27, P235, DOI 10.1177/030098589002700404
   WISKERCHEN M, 1991, J VIROL, V65, P4508, DOI 10.1128/JVI.65.8.4508-4514.1991
   Zhang G, 1996, J GEN VIROL, V77, P1677, DOI 10.1099/0022-1317-77-8-1677
NR 38
TC 4
Z9 4
U1 0
U2 3
PU AMER VETERINARY MEDICAL ASSOC
PI SCHAUMBURG
PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA
SN 0002-9645
EI 1943-5681
J9 AM J VET RES
JI Am. J. Vet. Res.
PD SEP
PY 2009
VL 70
IS 9
BP 1117
EP 1123
DI 10.2460/ajvr.70.9.1117
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA 489WP
UT WOS:000269456800008
PM 19719427
DA 2020-11-24
ER

PT J
AU Nascimento, EJM
   Silva, AM
   Cordeiro, MT
   Brito, CA
   Gil, LHVG
   Braga-Neto, U
   Marques, ETA
AF Nascimento, Eduardo J. M.
   Silva, Ana M.
   Cordeiro, Marli T.
   Brito, Carlos A.
   Gil, Laura H. V. G.
   Braga-Neto, Ulisses
   Marques, Ernesto T. A.
TI Alternative Complement Pathway Deregulation Is Correlated with Dengue
   Severity
SO PLOS ONE
LA English
DT Article
AB Background: The complement system, a key component that links the innate and adaptive immune responses, has three pathways: the classical, lectin, and alternative pathways. In the present study, we have analyzed the levels of various complement components in blood samples from dengue fever (DF) and dengue hemorrhagic fever (DHF) patients and found that the level of complement activation is associated with disease severity.
   Methods and Results: Patients with DHF had lower levels of complement factor 3 (C3; p = 0.002) and increased levels of C3a, C4a and C5a (p<0.0001) when compared to those with the less severe form, DF. There were no significant differences between DF and DHF patients in the levels of C1q, immunocomplexes (CIC-CIq) and CRP. However, small but statistically significant differences were detected in the levels of MBL. In contrast, the levels of two regulatory proteins of the alternative pathway varied widely between DF and DHF patients: DHF patients had higher levels of factor D (p = 0.01), which cleaves factor B to yield the active (C3bBb) C3 convertase, and lower levels of factor H (p = 0.03), which inactivates the (C3bBb) C3 convertase, than did DF patients. When we considered the levels of factors D and H together as an indicator of (C3bBb) C3 convertase regulation, we found that the plasma levels of these regulatory proteins in DHF patients favored the formation of the (C3bBb) C3 convertase, whereas its formation was inhibited in DF patients (p<0.0001).
   Conclusion: The data suggest that an imbalance in the levels of regulatory factors D and H is associated with an abnormal regulation of complement activity in DHF patients.
RP Nascimento, EJM (corresponding author), Johns Hopkins Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21218 USA.
EM emarques@jhmi.edu
RI Publica, Inct Saude/J-9544-2013; Marques, Ernesto/L-4514-2013;
   Nascimento, Eduardo/J-4590-2014; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Nascimento,
   Eduardo/0000-0002-9851-2332; Marques, Ernesto T. A/0000-0003-3826-9358
FU Division of Computing and Communication FoundationsNational Science
   Foundation (NSF)NSF - Directorate for Computer & Information Science &
   Engineering (CISE) [0845407] Funding Source: National Science
   Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19AI056541, U19AI056541, U19AI056541, U19AI056541,
   U19AI056541] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U19 AI56541, U19 AI056541] Funding Source: Medline
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   ACIOLISANTOS B, PNAS UNPUB
   Ault BH, 2000, PEDIATR NEPHROL, V14, P1045, DOI 10.1007/s004670050069
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Bokisch V A, 1973, Trans Assoc Am Physicians, V86, P102
   BOONPUCKNAVIG S, 1979, AM J TROP MED HYG, V28, P881, DOI 10.4269/ajtmh.1979.28.881
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chung KM, 2006, P NATL ACAD SCI USA, V103, P19111, DOI 10.1073/pnas.0605668103
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Coppo Paul, 2009, Cardiovascular & Hematological Disorders - Drug Targets, V9, P36
   Cordeiro MT, 2007, AM J TROP MED HYG, V77, P1128, DOI 10.4269/ajtmh.2007.77.1128
   Cordeiro MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004945
   Cummings DAT, 2005, P NATL ACAD SCI USA, V102, P15259, DOI 10.1073/pnas.0507320102
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   Fakhouri F, 2008, BLOOD, V112, P4542, DOI 10.1182/blood-2008-03-144691
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   HARBOE M, 2008, J CELL MOL MED
   Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   Karpman D, 2006, SEMIN THROMB HEMOST, V32, P128, DOI 10.1055/s-2006-939769
   Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110
   Kittigul L, 2007, J CLIN VIROL, V39, P76, DOI 10.1016/j.jcv.2007.04.006
   Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   LARUSSA VF, 1995, BAILLIERE CLIN HAEM, V8, P249, DOI 10.1016/S0950-3536(05)80240-9
   Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   Lutz HU, 2007, MOL IMMUNOL, V44, P3862, DOI 10.1016/j.molimm.2007.06.146
   Mehlhop E, 2007, CELL HOST MICROBE, V2, P417, DOI 10.1016/j.chom.2007.09.015
   Meri S, 2007, ANN NY ACAD SCI, V1109, P93, DOI 10.1196/annals.1398.011
   MITRAKUL C, 1977, AM J TROP MED HYG, V26, P975, DOI 10.4269/ajtmh.1977.26.975
   Morrison TE, 2008, CURR DRUG TARGETS, V9, P165
   NASCIMENTO EJM, J CLIN INVESTI UNPUB
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nishioka K, 1974, Allerg Immunol (Leipz), V20-21, P385
   Pierson Theodore C., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000665
   Saito M, 2004, CLIN EXP IMMUNOL, V138, P299, DOI 10.1111/j.1365-2249.2004.02626.x
   SOBEL AT, 1975, J EXP MED, V142, P139, DOI 10.1084/jem.142.1.139
   Srichaikul T, 2000, BEST PRACT RES CL HA, V13, P261, DOI 10.1053/beha.2000.0073
   Stahl AL, 2008, BLOOD, V111, P5307, DOI 10.1182/blood-2007-08-106153
   Su DHW, 2007, OPHTHALMOLOGY, V114, P1743, DOI 10.1016/j.ophtha.2007.03.054
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   Villar-Centeno LA, 2008, AM J TROP MED HYG, V78, P370, DOI 10.4269/ajtmh.2008.78.370
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
   Wiersinga WJ, 2006, CLIN INFECT DIS, V43, P800, DOI 10.1086/507111
   Yamanaka A, 2008, J VIROL, V82, P927, DOI 10.1128/JVI.00992-07
NR 51
TC 80
Z9 80
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2009
VL 4
IS 8
AR e6782
DI 10.1371/journal.pone.0006782
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 488FQ
UT WOS:000269335000025
PM 19707565
OA DOAJ Gold, Green Published
DA 2020-11-24
ER

PT J
AU Liang, DL
   Chen, LM
   Ansari, IH
   Gil, LHVG
   Topliff, CL
   Kelling, CL
   Donis, RO
AF Liang, Delin
   Chen, Limei
   Ansari, Israrul H.
   Gil, Laura H. V. G.
   Topliff, Christina L.
   Kelling, Clayton L.
   Donis, Ruben O.
TI A replicon trans-packaging system reveals the requirement of
   nonstructural proteins for the assembly of bovine viral diarrhea virus
   (BVDV) virion
SO VIROLOGY
LA English
DT Article
DE BVDV; Pseudo-particles; Trans-packaging; Complementation; NS2-3-4A
   precursor; Replication; Virion assembly
ID SWINE-FEVER VIRUS; SERINE-PROTEASE; CLEAVAGE SITES; RNA-POLYMERASE;
   IN-VITRO; PESTIVIRUS; REPLICATION; NS3; CYTOPATHOGENICITY; POLYPROTEIN
AB A selective trans-packaging system was developed to produce and isolate bovine viral diarrhea Virus (BVDV) pseudo-particles with complementing reporter replicons and their packaging proteins expressed in trans with recombinant vaccinia Virus. The encapsidation Of replicon rNS3-5B was dependent not only on the in trans expression of structural proteins C, E-rns, El and E2, but also the nonstructural proteins, p7 and contiguous precursor NS2-3-4A. Nonstructural p7, NS4B. NS5A or NS5B Could be expressed in cis and in trans with precursor NS2-3-4A without significantly affecting virion assembly efficiency. NS2-3-4A was identified as an in trans functional precursor in virion assembly. BVDV genomes with mutant NS5B, which did not undergo active replication, were packaged 5-fold less efficiently than the intact genomes demonstrating the importance of replication in virion packaging. These results suggest that genome replication and assembly are closely associated, consistent with a model in which these two steps are Coupled for maximum efficiency. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Liang, Delin; Chen, Limei; Ansari, Israrul H.; Gil, Laura H. V. G.; Topliff, Christina L.; Kelling, Clayton L.; Donis, Ruben O.] Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA.
RP Donis, RO (corresponding author), Ctr Dis Control & Prevent, Influenza Div, NCIRD, CCID, 1600 Clifton Rd,Mail Stop G-16, Atlanta, GA 30333 USA.
EM ckelling1@unl.edu; rdonis@cdc.gov
RI Publica, Inct Saude/J-9544-2013
OI ANSARI, Israrul/0000-0003-0326-0329
FU USDA/NRIUnited States Department of Agriculture (USDA)
   [2002-35204-11619]
FX A contribution of the University of Nebraska Agricultural Research
   Division, supported by funds provided through USDA/NRI grant
   2002-35204-11619 to R.O.D. is acknowledged. We thank Dr. E. J. Dubovi
   for antibodies and bovine cell lines. We also thank the UNL genome
   research facility for all the DNA sequencing. The members of the Donis
   lab are acknowledged for their help and valuable Suggestions.
CR Agapov EV, 2004, J VIROL, V78, P2414, DOI 10.1128/JVI.78.5.2414-2425.2004
   Ansari IH, 2004, J VIROL, V78, P9612, DOI 10.1128/JVI.78.18.9612-9623.2004
   Ausubel F. M., 1989, CURRENT PROTOCOLS MO
   Behrens SE, 1998, J VIROL, V72, P2364, DOI 10.1128/JVI.72.3.2364-2372.1998
   COLLETT MS, 1988, J GEN VIROL, V69, P2637, DOI 10.1099/0022-1317-69-10-2637
   DONIS RO, 1987, VIROLOGY, V158, P168, DOI 10.1016/0042-6822(87)90250-9
   Elbers K, 1996, J VIROL, V70, P4131, DOI 10.1128/JVI.70.6.4131-4135.1996
   FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994
   FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538
   GILLESPIE JAMES H., 1960, CORNELL VET, V50, P73
   Grassmann CW, 1999, J VIROL, V73, P9196, DOI 10.1128/JVI.73.11.9196-9205.1999
   Grassmann CW, 2001, J VIROL, V75, P7791, DOI 10.1128/JVI.75.17.7791-7802.2001
   Harada T, 2000, J VIROL, V74, P9498, DOI 10.1128/JVI.74.20.9498-9506.2000
   Horscroft N, 2005, J VIROL, V79, P2788, DOI 10.1128/JVI.79.5.2788-2796.2005
   Lackner T, 2006, P NATL ACAD SCI USA, V103, P1510, DOI 10.1073/PNAS.0508247103
   Lackner T, 2004, J VIROL, V78, P10765, DOI 10.1128/JVI.78.19.10765-10775.2004
   Lai VCH, 1999, J VIROL, V73, P10129, DOI 10.1128/JVI.73.12.10129-10136.1999
   LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356
   MEYERS G, 1995, J VIROL, V69, P3683, DOI 10.1128/JVI.69.6.3683-3689.1995
   Meyers G, 1996, J VIROL, V70, P8606, DOI 10.1128/JVI.70.12.8606-8613.1996
   Moser C, 1999, J VIROL, V73, P7787, DOI 10.1128/JVI.73.9.7787-7794.1999
   Ohmann H B, 1990, Rev Sci Tech, V9, P61
   POOLE TL, 1995, VIROLOGY, V206, P750, DOI 10.1016/S0042-6822(95)80003-4
   Qu L, 2001, J VIROL, V75, P10651, DOI 10.1128/JVI.75.22.10651-10662.2001
   Rinck G, 2001, J VIROL, V75, P9470, DOI 10.1128/JVI.75.19.9470-9482.2001
   Rumenapf T, 1998, J VIROL, V72, P2544
   RUMENAPF T, 1993, J VIROL, V67, P3288
   Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Tautz N, 1999, J VIROL, V73, P9422, DOI 10.1128/JVI.73.11.9422-9432.1999
   Tautz N, 1997, J VIROL, V71, P5415, DOI 10.1128/JVI.71.7.5415-5422.1997
   Tautz N, 2000, VIROLOGY, V273, P351, DOI 10.1006/viro.2000.0425
   Van Regenmortel MHV, 1999, ARCH VIROL, V144, P1041, DOI 10.1007/s007050050567
   Vassilev VB, 1997, J VIROL, V71, P471, DOI 10.1128/JVI.71.1.471-478.1997
   Vassilev VB, 2000, VIRUS RES, V69, P95, DOI 10.1016/S0168-1702(00)00176-3
   Xu JA, 1997, J VIROL, V71, P5312, DOI 10.1128/JVI.71.7.5312-5322.1997
NR 36
TC 5
Z9 5
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAY 10
PY 2009
VL 387
IS 2
BP 331
EP 340
DI 10.1016/j.virol.2009.02.019
PG 10
WC Virology
SC Virology
GA 439YF
UT WOS:000265663100011
PM 19327808
OA Green Published
DA 2020-11-24
ER

PT J
AU Gil, LHVG
   van Olphen, AL
   Mittal, SK
   Donis, RO
AF Gil, LHVG
   van Olphen, AL
   Mittal, SK
   Donis, RO
TI Modulation of PKR activity in cells infected by bovine viral diarrhea
   virus
SO VIRUS RESEARCH
LA English
DT Article
DE bovine viral diarrhea virus; persistent infection; innate immunity;
   double stranded RNA-dependent protein kinase; PKR; NF-kappa B
ID DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; HEPATITIS-C
   VIRUS; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; POLIOVIRUS
   INFECTION; PERSISTENT INFECTION; ANTIVIRAL ACTIONS; MUCOSAL DISEASE
AB Bovine viral diarrhea Virus is all important animal pathogen. The cytopathic and noncytopathic biotypes of the virus are associated with distinct pathologic entities. A striking difference between the two biotypes is viral RNA accumulation in infected cells. Viral dsRNA is thought to activate protein kinase PKR; an important mediator of innate immunity. In this Study, we investigated PKR activation and its consequences in BVDV-infected cells. Infection with cp BVDV was found to induce PKR activation, eIF2 alpha phosphorylation, translation inhibition and NF-kappa B activation. In contrast, PKR activity and eIF2 alpha phosphorylation were not induced during infection with the ncp BVDV. In addition, cells infected with ncp BVDV showed no PKR phosphorylation in response to infection with the unrelated poliovirus Whereas uninfected ncp BVDV cells when infected with poliovirus showed high levels of phosphorylated PKR. Cells infected with ncp BVDV failed to respond to synthetic dsRNA (poly I:C) treatment with NF-kappa B activation. However, the NF-kappa B response to bacterial lipopolysaccarides (LPS) was normal in these cells, suggesting a specific Suppression of antiviral response signaling in ncp BVDV infected cells. These results indicate that ncp BVDV has evolved specific mechanisims to prevent activation of PKR and its antiviral effectors, most likely to facilitate the establishment and maintenance of persistent infection. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68583 USA.
   Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA.
   Purdue Univ, Sch Vet Med, Dept Vet Pathobiol, W Lafayette, IN 47907 USA.
RP Donis, RO (corresponding author), Ctr Dis Control & Prevent, Influenza Branch, DVRD, NCID, Mail Stop G-16,1600 Clifton Rd, Atlanta, GA 30333 USA.
EM laura@cpqam.fiocruz.br; rdonis@cdc.gov
CR Adler B, 1997, J VIROL, V71, P3255, DOI 10.1128/JVI.71.4.3255-3258.1997
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Baigent SJ, 2004, VET IMMUNOL IMMUNOP, V100, P135, DOI 10.1016/j.vetimm.2004.04.003
   Baigent SJ, 2002, J VIROL, V76, P8979, DOI 10.1128/JVI.76.18.8979-8988.2002
   Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000
   Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888
   Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5
   Baldocchi D, 2001, AGR FOREST METEOROL, V107, P1, DOI 10.1016/S0168-1923(00)00228-8
   Bendfeldt S, 2003, VET MICROBIOL, V96, P313, DOI 10.1016/j.vetmic.2003.09.003
   BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989
   BROWNLIE J, 1990, VET MICROBIOL, V23, P371, DOI 10.1016/0378-1135(90)90169-V
   Buckwold VE, 2003, ANTIVIR RES, V60, P1, DOI 10.1016/S0166-3542(03)00174-8
   Charleston B, 2001, J GEN VIROL, V82, P1893, DOI 10.1099/0022-1317-82-8-1893
   CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x
   Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503
   CORAPI WV, 1990, AM J VET RES, V51, P1388
   Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475
   Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279
   DONIS RO, 1987, J GEN VIROL, V68, P1607, DOI 10.1099/0022-1317-68-6-1607
   GALANG CK, 1994, ONCOGENE, V9, P2913
   Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4
   Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448
   Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241
   Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109
   Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710
   GILLESPIE JAMES H., 1960, CORNELL VET, V50, P73
   Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341
   HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441
   Hoffer B, 1997, J NEURAL TRANSM-SUPP, P1
   Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405
   Hui DJ, 2003, J BIOL CHEM, V278, P39477, DOI 10.1074/jbc.M305038200
   Ieki K, 2004, CLIN EXP ALLERGY, V34, P745, DOI 10.1111/j.1365-2222.2004.1941.x
   Iqbal M, 2004, J VIROL, V78, P136, DOI 10.1128/JVI.78.1.136-145.2004
   Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267
   Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002
   Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888
   Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0
   Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693
   Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1
   KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315
   Lackner T, 2004, J VIROL, V78, P10765, DOI 10.1128/JVI.78.19.10765-10775.2004
   Lai VCH, 2000, J VIROL, V74, P6339, DOI 10.1128/JVI.74.14.6339-6347.2000
   Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697
   Liang DL, 2003, J GEN VIROL, V84, P1269, DOI 10.1099/vir.0.18557-0
   Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630
   Mahalingam S, 2002, J LEUKOCYTE BIOL, V72, P429
   MAISONNAVE J, 1982, ARCH VIROL, V72, P279, DOI 10.1007/BF01315224
   MCCLURKIN AW, 1984, CAN J COMP MED, V48, P156
   MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232
   O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833
   Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1
   Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200
   RANSONE LJ, 1987, J VIROL, V61, P1781, DOI 10.1128/JVI.61.6.1781-1787.1987
   ROSSI CR, 1980, AM J VET RES, V41, P552
   Ruggli N, 2003, J VIROL, V77, P7645, DOI 10.1128/JVI.77.13.7645-7654.2003
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1
   SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O
   Schweizer M, 1999, J GEN VIROL, V80, P1147, DOI 10.1099/0022-1317-80-5-1147
   Schweizer M, 2001, J VIROL, V75, P4692, DOI 10.1128/JVI.75.10.4692-4698.2001
   Sherf B A, 1996, PROMEGA NOTES, V57, P2
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995
   van Olphen AL, 2002, J VIROL, V76, P5882, DOI 10.1128/JVI.76.12.5882-5892.2002
   Van Regenmortel M.H.V., 2000, 7 INT COMM TAX VIR, P1167
   VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902
   Vassilev VB, 2000, VIRUS RES, V69, P95, DOI 10.1016/S0168-1702(00)00176-3
   Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761
   Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Wu SY, 1996, BIOCHEMISTRY-US, V35, P8275, DOI 10.1021/bi953028+
   Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860
   Zhang G, 1996, J GEN VIROL, V77, P1677, DOI 10.1099/0022-1317-77-8-1677
NR 73
TC 23
Z9 23
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD MAR
PY 2006
VL 116
IS 1-2
BP 69
EP 77
DI 10.1016/j.virusres.2005.08.011
PG 9
WC Virology
SC Virology
GA 019VI
UT WOS:000235864400008
PM 16194578
DA 2020-11-24
ER

PT J
AU ORELLANA, M
   CAPDEVILA, J
   GIL, L
AF ORELLANA, M
   CAPDEVILA, J
   GIL, L
TI MODULATION OF ARACHIDONIC-ACID METABOLISM BY ALTERATION IN THE
   COMPOSITION OF CYTOCHROME-P-450 ISOZYMES
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED,DEPT BIOQUIM,SANTIAGO,CHILE.
   VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37240.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PD NOV
PY 1987
VL 20
IS 2
BP R232
EP R232
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA L1512
UT WOS:A1987L151200325
DA 2020-11-24
ER

PT J
AU GIL, L
   ORELLANA, M
   VALDES, E
AF GIL, L
   ORELLANA, M
   VALDES, E
TI REGIO AND STEREOSELECTIVITY OF STEROID HYDROXYLATIONS CATALYZED BY
   CYTOCHROME-P-450 MONOOXYGENASES
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA English
DT Meeting Abstract
C1 UNIV CHILE,FAC MED,DEPT BIOQUIM,SANTIAGO,CHILE.
CR GIL L, 1984, ANAL LETT, V17, P883
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PD NOV
PY 1986
VL 19
IS 2
BP R144
EP R144
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA F0931
UT WOS:A1986F093100015
DA 2020-11-24
ER

PT J
AU ORELLANA, M
   GIL, L
AF ORELLANA, M
   GIL, L
TI INFLUENCE OF NUTRITIONAL-STATUS AND INDUCERS ON TESTOSTERONE-METABOLISM
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,DIV CIENCIAS MED SUR,DEPT MED EXPTL,SANTIAGO,CHILE.
   UNIV CHILE,FAC MED,DIV CIENCIAS MED NORTE,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1985
VL 18
IS 2
BP R155
EP R155
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA AVC75
UT WOS:A1985AVC7500211
DA 2020-11-24
ER

PT J
AU GIL, L
   VASQUEZ, H
   SALAZAR, I
AF GIL, L
   VASQUEZ, H
   SALAZAR, I
TI NUTRITIONAL-STATUS AN IMPORTANT FACTOR IN THE METABOLIC-ACTIVATION OF
   BENZO(A)PYRENE
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED NORTE,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1984
VL 17
IS 2
BP R107
EP R107
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA TS304
UT WOS:A1984TS30400081
DA 2020-11-24
ER

PT J
AU ORELLANA, M
   MANCILLA, J
   GIL, L
AF ORELLANA, M
   MANCILLA, J
   GIL, L
TI HYDROXYLATION OF TESTOSTERONE IN NORMAL AND PROTEIN-ENERGY MALNOURISHED
   RATS PRETREATED WITH BETA-NAPHTHOFLAVONE
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1984
VL 17
IS 1
BP R61
EP R61
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA TM792
UT WOS:A1984TM79200042
DA 2020-11-24
ER

PT J
AU FERREIRA, J
   GIL, L
AF FERREIRA, J
   GIL, L
TI STOICHIOMETRY OF H+ RELEASE AND CA-+2 UPTAKE COUPLED TO
   ELECTRON-TRANSPORT IN LIVER-MITOCHONDRIA FROM MALNOURISHED RATS
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED NORTE,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1983
VL 16
IS 2
BP R152
EP R152
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA RS731
UT WOS:A1983RS73100112
DA 2020-11-24
ER

PT J
AU MANCILLA, J
   GIL, L
AF MANCILLA, J
   GIL, L
TI A SIMPLE, RELIABLE AND RAPID ISOCRATIC METHOD TO STUDY
   TESTOSTERONE-METABOLISM BY HPLC
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1983
VL 16
IS 1
BP R88
EP R88
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA RG771
UT WOS:A1983RG77100053
DA 2020-11-24
ER

PT J
AU ORELLANA, M
   MANCILLA, J
   GIL, L
AF ORELLANA, M
   MANCILLA, J
   GIL, L
TI OXIDATION OF TESTOSTERONE BY RAT-LIVER MICROSOMES - METABOLITES
   SEPARATION BY HPLC
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,DIV CS MED S,DEPT MED EXPTL,SANTIAGO,CHILE.
   UNIV CHILE,FAC MED,DIV CS MED N,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1983
VL 16
IS 2
BP R204
EP R204
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA RS731
UT WOS:A1983RS73100312
DA 2020-11-24
ER

PT J
AU FERREIRA, J
   GIL, L
AF FERREIRA, J
   GIL, L
TI NUTRITIONAL EFFECTS ON THE F1-ATPASE ACTIVITY OF RAT-LIVER MITOCHONDRIA
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED,DEPT BIOQUIM,DIV CIENCIAS MED NORTE,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1982
VL 15
IS 2
BP R123
EP R123
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA PR418
UT WOS:A1982PR41800096
DA 2020-11-24
ER

PT J
AU SALAZAR, I
   TARRAGOLITVAK, L
   GIL, L
   LITVAK, S
AF SALAZAR, I
   TARRAGOLITVAK, L
   GIL, L
   LITVAK, S
TI EFFECT OF BP ON MITOCHONDRIAL DNA-SYNTHESIS AND DNA-POLYMERASE
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1982
VL 15
IS 1
BP R69
EP R69
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA PK308
UT WOS:A1982PK30800044
DA 2020-11-24
ER

PT J
AU CERVANTES, P
   FERREIRA, J
   GIL, L
   OLATE, J
   PEDEMONTE, J
   SALAZAR, I
AF CERVANTES, P
   FERREIRA, J
   GIL, L
   OLATE, J
   PEDEMONTE, J
   SALAZAR, I
TI NUTRITIONAL EFFECTS ON THE RAT-LIVER ELECTRO TRANSPORT CHAINS
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1981
VL 14
IS 3
BP 257
EP 257
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA MU816
UT WOS:A1981MU81600077
DA 2020-11-24
ER

PT J
AU GIL, L
   PEDEMONTE, J
AF GIL, L
   PEDEMONTE, J
TI RELATION BETWEEN ACUTE PROTEIN-MALNUTRITION AND MICROSOMAL OXIDATION OF
   DRUGS
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED NORTE,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1980
VL 13
IS 1
BP 28
EP 28
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA KS995
UT WOS:A1980KS99500019
DA 2020-11-24
ER

PT J
AU FERREIRA, J
   GIL, L
   STUTZIN, A
   ORREGO, F
AF FERREIRA, J
   GIL, L
   STUTZIN, A
   ORREGO, F
TI GUANETHIDINE INHIBITS ELECTRON-TRANSPORT IN RAT-HEART, BRAIN AND
   LIVER-MITOCHONDRIA
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED NORTE,DEPT FISIOL & BIOFIS,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1980
VL 13
IS 1
BP 65
EP 65
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA KS995
UT WOS:A1980KS99500136
DA 2020-11-24
ER

PT J
AU FERREIRA, J
   GIL, L
AF FERREIRA, J
   GIL, L
TI ALTERATIONS IN THE MITOCHONDRIAL OXIDATIVE SYSTEM AND IN CA++ TRANSPORT
   IN RAT-LIVER MITOCHONDRIA BY SEVERE PROTEIN-CALORIE MALNUTRITION
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED NORTE,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1980
VL 13
IS 1
BP 65
EP 65
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA KS995
UT WOS:A1980KS99500135
DA 2020-11-24
ER

PT J
AU SALAZAR, I
   GIL, L
AF SALAZAR, I
   GIL, L
TI NUTRITIONAL EFFECTS IN THE ACTIVITY OF RAT-LIVER BENZPYRENE HYDROXYLASE
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1980
VL 13
IS 1
BP 108
EP 108
PG 1
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA KS995
UT WOS:A1980KS99500308
DA 2020-11-24
ER

PT J
AU GIL, L
   PEDEMONTE, J
AF GIL, L
   PEDEMONTE, J
TI ALTERATIONS IN DRUG-METABOLISM FOR NUTRITIONAL EFFECTS
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
C1 UNIV CHILE,FAC MED NORTE,DEPT BIOQUIM,SANTIAGO,CHILE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC BIOL CHILE
PI SANTIAGO
PA CASILLA 14164 CORREO, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1980
VL 13
IS 4
BP 458
EP 459
PG 2
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA MH542
UT WOS:A1980MH54200023
DA 2020-11-24
ER

PT J
AU DELVILLA.EM
   GIL, LH
AF DELVILLA.EM
   GIL, LH
TI IN-VIVO METABOLISM OF DDT AND ROLE OF INSECTICIDE SYNERGISTS IN
   HOUSEFLIES
SO ARCHIVOS DE BIOLOGIA Y MEDICINA EXPERIMENTALES
LA Spanish
DT Meeting Abstract
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOCIEDAD BIOLGIA CHILE
PI SANTIAGO
PA CASILLA 16164, SANTIAGO 9, CHILE
SN 0004-0533
J9 ARCH BIOL MED EXP
PY 1970
VL 7
IS 1-3
BP R12
EP &
PG 0
WC Biology; Medicine, General & Internal; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; General & Internal Medicine;
   Research & Experimental Medicine
GA J0158
UT WOS:A1970J015800050
DA 2020-11-24
ER

EF